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Abstract 
GABAA receptors are an integral part of regulating neuronal transmission. Through the 
action of their endogenous agonist, γ-aminobutyric acid, they control most neuronal 
signal inhibition. GABAA receptors constantly move through the membrane, readily 
adapting to different stimuli, aided by transient interactions with scaffolding proteins. 
This thesis attempts to design and synthesise small, novel chemical tracking devices in 
order to gain insight into the driving forces of GABAA receptor diffusion.  
To this aim, photoaffinity labelled probe 1, based on a GABAA receptor antagonist 
gabazine, was synthesised. A benzophenone photoaffinity label was prepared, and 
installed onto a pyridazinyl-phenol core. A Sonogashira reaction, to install a carboxylic 
acid handle for the biotinylated linker, initially proved unsuccessful until the replacement 
of aryl bromide with an aryl iodide (Figure 1). Biotinylated probe 1 was associated with 
a quantum dot coated in streptavidin, and placed in live neurons. Real-time recording of 
the quantum dot trajectories show receptors moving in synaptic and extrasynaptic sites. 
 
Figure 1: Photoaffinity probe 1 for tracking GABAA receptors in cells. 
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This thesis also describes a modular synthetic strategy to build additional chemical tools. 
A “clickable” alkyne gabazine fragment 2 was synthesised and underwent copper 
catalysed alkyne-azide couplings to give probes 3 and 4. These covalently bind to the 
receptor through an acrylamide electrophilic moiety, and cleavage of the directing 
gabazine fragment after UV light leaves a silently-tagged receptor. Further generations 
of these probes could be used to track unblocked, native receptors in order to compare the 
effects of antagonism on receptor movement (Figure 2). 
 
Figure 2: Photocleavable affinity antagonists 3 and 4 
In addition, this thesis discusses a novel photoswitchable antagonist, azo-gabazine 5, 
which uses the cis-trans photoisomerisation of azobenzene to tune its potency under 
different wavelengths of light. It is synthesised and used to confer a photoswitching 
ability onto a native neuronal GABAA receptors in a biological setting (Figure 3). 
 
Figure 3: Development of a photoswitchable antagonist to the GABAA receptor, azo-gabazine 5. 
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Nothing can be more certain than this: we are just beginning to learn something of 
the wonders of the world on which we live and move and have our being. 
WILLIAM RAMSAY, Essays Biographical and Chemical, 1908 
 
 
 
 
Still I had a lurking question. Would it not be better if one could really ‘see’ whether 
molecules as complicated as the sterols, or strychnine were just as experiment 
suggested? 
DOROTHY HODGKIN, Nobel Prize Lecture, 1964 
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MTSES sodium 2-(sulfonatoethyl)methanethiosulfonate 
nAChR nicotinic acetylcholine receptors 
NHS  N-hydroxysuccinimide 
NBS  N-bromosuccinimide 
nd  product not detected 
NMDA N-methyl-D-aspartate 
NMP N-methylpyrrolidinone 
OEG  oligoethylene glycol 
PEG  polyethylene glycol 
petrol  petroleum ether 
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Chapter 1 
Introduction 
1.1 Introduction to GABAA receptors 
GABAA receptors are ligand-gated chloride ion channels found mainly at postsynaptic 
membranes in the brain. Their principal agonist, the neurotransmitter γ-aminobutyric 
acid (GABA, 1, Figure 1) mediates most neural synaptic and extrasynaptic inhibition.1 
This means that GABA receptors are responsible for preventing signals being 
transferred between neurons by preventing the postsynaptic membrane becoming 
depolarised and firing an action potential. As GABA binds to the receptor it induces a 
conformation change in the complex, making the membrane permeable to chloride 
ions. The resulting chloride ion influx hyperpolarises the membrane, reducing its 
excitability by sending the membrane potential further below the threshold required to 
fire an action potential.2,3 
In order to mediate this fast synaptic inhibition, the receptors need to accumulate in 
synapses opposite GABA-releasing neuron terminals. The concentration of GABAA 
receptors in these synapses directly influences the strength of synaptic inhibition.1 
GABAA receptors move into and out of the synapse, aided by complex interactions 
with scaffold proteins in the membrane. This localisation and dispersal is key for 
modulating neuronal transmission, as well as for enabling learning and memory 
(Figure 1 (ii)).4 The precise signals, timings and mechanisms by which GABAA 
receptors are localised or dispersed from clusters remain unknown.5 
Heterogeneity in receptor structure means there are variations in the transport and 
localisation of GABAA receptors.
6 GABAA receptors have a pentameric structure, and 
are assembled from a wide range of subunits, of which 19 have been identified [α(1-
Chapter 1: Introduction 
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6), β(1-3), γ(1-3), δ, ε, θ, ρ(1-3) and π] (Figure 1 (i)). Most GABAA receptors 
expressed in the brain consist of two α subunits, two β subunits and one γ subunit. A 
binding site for GABA is formed at the interface of an α and β subunits. GABA 
receptors composed of different subunits accumulate at different regions of the 
synapse, have different membrane dynamics and different physiological and 
pharmacological properties.6 
 
Figure 1: (i) Structure of a GABAA receptor, showing subunit composition and location of the GABA 
binding sites between β and α subunits. (ii) Movement of GABA receptors between synaptic and 
extra-synaptic sites. 
GABAA receptors are assembled within the neuron and are then inserted into the 
plasma membrane at extrasynaptic sites, where they exhibit free Brownian diffusion. 
Once they diffuse into the synaptic cleft they are constrained by transient interactions 
with scaffolding molecules.7 There is continual exchange between diffuse receptor 
populations and clusters in synaptic and extrasynaptic sites (Figure 1 (ii)).3 
There are several different classes of ligands for the GABAA receptor, including 
agonists, antagonists and both positive and negative allosteric modulators. Agonists, 
such as muscimol 2 and isoguvacine 3 bind at the GABA binding site, along with 
competitive antagonists gabazine 4 and bicuculline 5 (Figure 2). 
Chapter 1: Introduction 
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Figure 2: Ligands which bind at the α and β subunit interface on the GABAA receptor. 
A major class of drugs which bind to the GABAA receptor at the interface of α and γ 
subunits are the benzodiazepines, of which there are currently fifty drugs on the 
market, including diazepam (Valium®, 6) and chlordiazepoxide (Librium®, 7, Figure 
3).8 Through their positive allosteric modulation of GABAA receptors they are used 
clinically to treat pain, anxiety, insomnia, epileptic seizures, alcohol-withdrawal and 
amnesia. GABA receptor ligands sometimes have varying affinities for particular 
receptor subtypes and this has an impact on their pharmacological properties, 
including unwanted side effects. Benzodiazepines which have additional selectivity 
for α2 over α1 subunit-containing receptors, for example, would be effective anti-
anxiety drugs with low sedative effects. Zolpidem 8, in contrast, an allosteric 
modulator for GABAA receptors, interacts preferentially with α1-containing receptors 
and is used as a sedative drug to treat insomnia (Figure 3). Agonists which act on α3 
subunit-containing receptors mediate pain relief, whilst there is investigation into α5-
selective inverse agonists as learning and memory enhancers.9 GABAA receptors 
containing α4 or α6 subunits, mainly found extrasynaptically, are insensitive to 
benzodiazepines. 
Chapter 1: Introduction 
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Figure 3: Ligands which bind at the α and γ subunit interface on the GABAA receptor. 
It has been shown that not only do GABAA receptor ligands modulate the opening of 
the chloride ion channel, they have implications for the lateral diffusion of the 
receptors. The GABAA agonist muscimol 2 has been shown to decrease the presence 
of GABAA receptors at synapses, whilst the antagonist gabazine 4 increased this 
number.10 Benzodiazepines providing positive allosteric modulation, however, also 
increased the number of receptors at the synapse, and this gives rise to the hypothesis 
that the movement of the GABAA receptor is dependent upon its conformation rather 
than just its occupancy.10 
1.2 Introduction to photoaffinity labels 
Photoaffinity labelling was pioneered in 196211 and is now a highly respected 
technique for studying the relationships between ligands and their target biomolecules 
in vitro. A ligand with high specificity to a receptor is modified to include a 
photoreactive group, which forms a highly reactive species upon UV/Vis irradiation 
at a requisite wavelength. This reactive species then generates a covalent bond 
between the probe and the receptor, irreversibly tagging it. In biological systems, it is 
important to be able to use irradiation of a wavelength higher than 350 nm, as this 
causes less protein degradation in the sample. The most popular photoaffinity labels 
include diazirines, aryl azides, and benzophenones. 
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Trifluoromethyldiazirine species 9, which are the most stable of the commonly used 
diazirines, undergo photolysis very efficiently at 350-380 nm wavelength irradiation, 
losing nitrogen to form carbene 10 which reacts with nearby molecules (Scheme 1). 
Occasionally synthetically challenging, their preference for O-H bonds over C-H 
bonds means that their use is limited when there are water molecules in the binding 
pocket.12 
 
Scheme 1: The photoreactivity of 3-phenyl-3-(trifluoromethyl)diazirines. 
Aryl azides 11 are small and easily incorporated into ligand molecules with minimal 
structural disturbance. The loss of nitrogen upon excitation creates a highly reactive 
nitrene species 12 (Scheme 2).13 Their activation wavelength of 300 nm is more 
harmful to biological samples and they also have a tendency to form side products via 
rearrangement of the reactive nitrene species 12.  
 
Scheme 2: The photoreactivity of aryl azides. 
Benzophenones 13 are chemically the most stable and they are inert to solvent effects, 
reacting with C-H bonds in preference to other bonds. Upon irradiation a 
benzophenone is excited via an n,π* electron transition and reacts via H-abstraction 
and radical recombination (Scheme 3). The excitation occurs upon irradiation at 350-
360 nm wavelengths, which is less damaging to cells. In addition the excited state 
relaxes back to the ground state if it does not react, which means repeated rounds of 
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17 
 
excitation are possible. The disadvantages of using a benzophenone photoaffinity label 
in an aqueous biological system include its hydrophobicity and bulk.14 
 
Scheme 3: The photoreactivity of benzophenones. 
Photoaffinity labelling can be used to irreversibly block one specific protein 
component in a system, and it can also be used to establish the precise site of ligand-
receptor binding. The receptor is tagged covalently and, after enzymatic or chemical 
degradation, a particular subunit or protein fragment can be identified by mass 
spectrometry, or an alternate spectroscopic technique, as the binding site. 
Photoaffinity labelling is particularly powerful when studying receptors which are 
embedded in membranes and otherwise difficult to visualise.15 
1.3 Photoaffinity labels for GABA receptors 
Photoaffinity labelling has been crucial to mapping the myriad binding sites of the 
GABAA receptor. The progression of recombinant receptor technology over the last 
twenty years has allowed the expression of GABAA receptors of known subunit 
composition in cells, and this has gradually diminished the idea of there being a 
handful of distinct binding sites on receptors.16 Instead, focus has shifted onto the 
actions of ligands towards receptors of different subunit composition. This strongly 
suggests that proposed sites on receptors overlap and interact, and are therefore 
difficult to quantify.16 
Photoaffinity labelling studies have shown, however, likely positions for the binding 
of many classes of ligands on particular GABAA receptors. General anaesthetic  
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(R)-etomidate (R)-14 was the basis for the photoafffinity labelled analogue, (R)-
azietomidate (R)-15, which helped construct a coherent and consistent model of 
general anaesthetic binding at the GABA site of the GABAA receptor.
17,18,19 The 
‘convulsant’ binding site of GABAA receptors, which interacts with the 
benzodiazepine site,20 was first probed with the photoaffinity labelled agonist, the 
diazo derivative 16 of convulsant TBOB 17 (Figure 4).21 
 
Figure 4: Photoaffinity analogues of GABAA receptor ligands. 
Photoaffinity labels based on non-competitive antagonists have also emerged, for 
example, NMB 18,22 and diazirine fipronil 19 (which bind similarly to DBCPP 20 and 
fipronil 21 respectively) have both been used in binding site analysis (Figure 5).23,24 
 
Figure 5: Photoaffinity analogues of non-competitive GABAA receptor ligands. 
Propofol 22, an allosteric modulator of the GABAA receptor and a commonly used 
sedative drug, has also been manipulated in order to ascertain where it binds on the 
receptor. A diazirine analogue of propofol (AziPm, 23) was synthesised in 11 steps 
and 18% yield from Cumene 24 (Figure 6). It was irradiated in the presence of GABAA 
receptors, which then underwent trypsin-mediated digestion. LC/MS/MS analysis of 
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the resulting peptides and residues highlighted the position at which AziPm 23 was 
covalently bound, and reinforced the location of the known propofol modulatory 
binding cavity, distinct from both the GABA and benzodiazpeine binding sites.25 
 
Figure 6: Propofol 22 and diazirine analogue AziPm, 23. 
Furthermore, muscimol 2 has been shown to act as both a competitive agonist and a 
photoaffinity label for the GABAA receptor.
26 The reactive species 25 and 26 formed 
upon irradiation (Scheme 4) form covalent bonds with the binding site in the receptor. 
However, the requisite wavelength of below 210 nm would degrade the biological 
sample, so this technique could only be used for basic studies. Thiomuscimol 27 (with 
a UV maximum absorption peak slightly higher at 262 nm) has also been used as a 
photoaffinity label to the GABAA receptor (Scheme 4).
27 
 
Scheme 4: Photoreactivity of muscimol 2. Thiomuscimol 27 has an analogous reactivity. 
1.4 Previous work on photoaffinity-labelled antagonists for the GABAA receptor 
Previous work in the Baker and Smart groups has included the synthesis and 
evaluation of potent GABAA receptor antagonists based on gabazine 4.
28 Gabazine 4, 
first synthesised in 1987,29 is one of many synthetic antagonists which arose from the 
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knowledge that adding hydrophobic ring systems to a γ-aminobutyric acid core yields 
GABAA receptor antagonists (Figure 7).
29 Gabazine 4 is also susceptible to certain 
modifications without loss of potency; indeed the replacement of the methoxy group 
with a benzoxy group leads to antagonist 28 which has an increased potency against 
GABAA receptors, as do substituted benzoxy analogues in compounds 29 and 30 
(Figure 7).30 
A useful measure of the effectiveness of antagonism of compounds is the half-
maximal inhibitory concentration (IC50), that is, the concentration of compound 
required to halve the maximum known response of the receptor. In the case of GABAA 
receptors the response is quantified by the measurement of the current across the 
membrane of a cell. This is measured using whole-cell voltage-clamp 
electrophysiology where a glass electrode containing internal solution is sealed into 
the membrane of a cell expressing GABAA receptors. An equal concentration of 
internal and external chloride ions and a negative holding potential ensure that 
observed changes in membrane potential arise from chloride ions driven through 
GABAA receptors. This response is measured in the presence of varying 
concentrations of antagonist and a dose-response curve is plotted and interpreted to 
give the IC50 value. The IC50 values given in Figure 7 are derived from GABA-
activated responses in HEK293 cells, which are human embryonic kidney cells which 
have been transfected to express GABAA receptors with a particular subunit 
composition. 
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Figure 7: Gabazine 4, antagonist to the GABAA receptor, and analogues with increased potency in 
α1β2γ2S GABAA receptors transiently expressed in HEK293 cells.30 
The synthesis of three photoaffinity labelled antagonists based upon gabazine 4 has 
been reported, making use of diazirine, azide and benzophenone photoaffinity labels.30 
The pyridazine skeleton 31, common to all syntheses was formed in a microwave-
assisted Suzuki coupling reaction between commercially available starting materials 
4-hydroxyphenylboronic acid 32 and 3-amino-6-chloropyridazine 33 in 72% yield 
(Scheme 5). 
 
Scheme 5: Microwave-assisted Suzuki coupling reaction conditions. 
In the synthesis of the azide analogue, 4-aminotoluene underwent oxidation to the 
diazonium salt, which then underwent displacement with sodium azide to give azide 
34 in 86% yield (Scheme 6). Radical bromination with N-bromosuccinimide in the 
presence of AIBN led to formation of brominated azide 35 in 44% yield. A Williamson 
ether synthesis with potassium tert butoxide and pyridazine skeleton 31 furnished 
pyridazine 36 in 38% yield. N-Alkylation was achieved on heating with allyl 4-
bromobutyrate in 37% yield, and subsequent deprotection of allyl ester 37 was 
achieved with tetrakis(triphenylphosphine)palladium and morpholine in 94% yield, 
giving azide analogue 38 in a total of 5 steps and 5% overall yield (Scheme 6). 
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Scheme 6: Synthesis of azide photoaffinity label based upon gabazine 4. 
The benzophenone analogue 39 was synthesised relatively easily in three steps in 12% 
overall yield. The requisite benzophenone bromide 40 is commercially available, and 
the ether synthesis was achieved with potassium tert butoxide and 31 in 31% yield. 
The N-alkylation of pyridazine 41 and subsequent ester deprotection were 
accomplished in 60 and 65% yield respectively to give benzophenone 39 (Scheme 7). 
 
Scheme 7: Synthesis of benzophenone photoaffinity label based upon gabazine 4. 
The trifluorodiazirine analogue 42 was synthetically more challenging; the brominated 
species 43 itself requiring a six step synthesis. 4-Bromotoluene was reacted with n-
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butyllithium and quenched with ethyl trifluoroacetate to give ketone 44 in 38% yield. 
Oxime 45 was synthesised in 99% yield as a mixture of isomers upon reaction of 
ketone 44 with hydroxylamine hydrochloride. Tosylation of the oxime was 
accomplished in 75% yield upon reaction with p-toluenesulfonyl chloride giving tosyl 
oxime 45, which was when reacted with ammonia condensed in a sealed vessel at −78 
°C to give diaziridine 46 in 88% yield. The subsequent oxidation to diazirine 47 was 
achieved upon reaction with iodine and triethylamine in dichloromethane in 61% 
yield. Diazirine 47 then underwent radical bromination with N-bromosuccinimde and 
AIBN to furnish bromide 43 in 65% yield. A Williamson ether synthesis was achieved 
in 62% yield, and the N-alkylation and ester deprotection in 41 and 59% respectively, 
which afforded diazirine analogue 42 in nine steps and 2% overall yield (Scheme 8). 
  
Scheme 8: Synthesis of diazirine photoaffinity label based upon gabazine 4. 
The potency and photoactivity of these compounds was measured by calculation of 
the IC50 value, and measurement of the photolytic block. Whole-cell patch clamp 
electrophysiology was used to record the membrane current from multiple ion 
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channels on a cell. GABA was applied and the postsynaptic membrane current was 
measured. The photoactive antagonist was then applied and exposed to UV radiation 
in brief ten second flashes. The cells were washed to remove any non-covalently 
bound antagonist, then GABA was reapplied and the membrane current recorded 
again. The difference in the transmembrane current before and after the UV irradiation 
is called the photolytic block, and denotes the percentage of GABA receptors which 
have been inactivated. 
The IC50 value of gabazine 4 in recombinant α1β2γ2S receptors in HEK293 cells was 
349 nM. Photoaffinity compounds 38, 39 and 42 all had lower IC50 values than 
gabazine 4, denoting that they were all more potent antagonists. In addition, the 
benzophenone analogue 39 gave a 49% photolytic block in these recombinant 
α1β2γ2S receptors. Azide 38 and diazirine 42 gave 29 and 21% photolytic block 
respectively (Figure 8). 
  
Figure 8: Photoaffinity labelled antagonists for the GABAA receptor. 
Once the receptor is blocked irreversibly in a recombinant cell system, there is no 
effective mechanism by which receptors could be replaced. In a primary culture of 
hippocampal neurons however, the biological structure is in place for the receptors to 
be replenished. The timescale and mechanisms of this receptor trafficking are an 
ongoing and important area of research, and further experiments using benzophenone 
Chapter 1: Introduction 
25 
 
39 on a primary culture would be highly beneficial. Chapter 2 of this thesis describes 
new routes in a scale-up synthesis of this photoaffinity labelled antagonist 38 in order 
for additional biological experiments in primary neuronal cultures to be carried out. 
1.5 Photoaffinity-fluorescent probes and GABA receptors 
The strength of inhibitory synaptic transmission is dependent upon the local 
concentration of GABA receptors on the postsynaptic membrane. It is known that 
GABAA receptors are mobile on the membrane, and that this mobility occurs not just 
when they are being inserted into the membrane after synthesis.31 To study this, 
photoaffinity labels have been tagged with fluorescent probes to visualise the 
movement of a labelled protein (Figure 9). The ligand would bind to the receptor, and 
irradiation of the photoaffinity label will tag the receptor covalently, whilst the 
fluorescent reporter can be tracked under a microscope. 
 
Figure 9: Photoaffinity-fluorescent probe for a membrane bound receptor. 
Li et al. successfully synthesised a fluorescent probe 48 for photoaffinity labelling 
GABAB receptors in living cells (Figure 10). Based on a high-affinity, GABAB-
specific antagonist 49, probe 48 incorporates a photolabile diazirine group, as well as 
a fluorescent tag derived from BODIPY. Following irradiation, probe 48 was 
successful in significantly preventing GABAB receptors (transfected into HEK293 
cells) being activated by GABA, which shows that it is a potential technique for 
providing, via fluorescence imaging, important information about the localisation of 
GABAB receptors expressed in live cells. 
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Figure 10: Antagonist to the GABAB receptor 49 and the photoaffinity probe for the GABAB receptor 
48, showing the receptor ligand group (blue), the photoaffinity label (red) and the BODIPY-derived 
fluorophore tag (gold).32 
1.6 Introduction to quantum dot tracking of GABA receptors 
In many cases, this tracking of receptors in membranes is carried out using quantum 
dots, which are particularly well suited for visualising and tracking molecular 
processes in cells by standard fluorescence microscopy.33 Quantum dots are 
nanometre-sized fluorescent probes, generally composed of a heavy metal core (for 
example CdSe) responsible for the fluorescence; a non-emissive stabilising shell (for 
example ZnS); and a coating which provides binding sites for organic molecules. They 
surpass other organic fluorophores and fluorescent protein tags as they are stable to 
photobleaching, and, as they are highly tuneable in terms of colour, different quantum 
dots can be used to study more different proteins in the same experiment.34 
There are various ways to incorporate a quantum dot onto a molecule. The quantum 
dot can be coated in a polyacrylamide, and covalently bound via linkers to the ligands. 
Quantum dots can also be coated in proteins such as streptavidin, meaning they can be 
strongly but non-covalently bound to nearly any compound containing a biotin 50 
moiety (Figure 11).35 In addition there are quantum dots which have a surface coating 
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with reactive chemical functional groups, including primary amines, thiols, 
maleimides and carboxylic acids. These provide a variety of conjugation strategies to 
ensure selective binding of the quantum dot in a biological system. There are relatively 
few reported uses of small molecule-quantum dot conjugates, despite their ready 
synthesis and their potential to target proteins which do not have target-specific 
antibodies or peptides available.36 
 
Figure 11: D-Biotin 50 is used to recognise a streptavidin-coated quantum dot. 
Quantum dots have opened new perspectives for the study of GABA receptor 
trafficking, as they enable measurements at a single molecule level and can give 
information about the organisation and mobility of receptors in the membrane.34 For 
example, the presence of GABA receptors in tobacco plants was reportedly first 
detected by the use of GABA directly linked via an amide bond to a quantum dot 
coated in mercaptoacetic acid (Scheme 9).37 
 
Scheme 9: GABA-quantum dot conjugate 
Gussin et al. have achieved the conjugation of a quantum dot to GABAC receptors 
using the specificity of the agonist, muscimol 2.36 GABAC receptors have pentameric 
structures and are assembled from ρ1-3 subunits. Here, GABAC receptors were 
expressed in a model cell system as homopentamers of ρ1 subunits. GABA receptor 
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agonist muscimol 2 was bound to a quantum dot which was coated in polyacrylamide 
via a polyethylene glycol (PEG) linker chain, in a test to study the biological activity 
of such a compound (Figure 12). The long PEG linker of 3400 units was used to 
achieve sufficient distance between the quantum dot and the GABAC − muscimol 
binding site, and enabled several (150-200) muscimol ligands to be joined to one 
quantum dot. The positive and specific biological activity of this conjugate 51 is 
encouraging for future investigations into neurotransmitter membrane receptors. 
 
Figure 12: Muscimol − quantum dot conjugate 51, where n = 150-200. 
Another approach, using antibodies and protein recognition to tag the target protein or 
biomolecule, has been used successfully to show how the distribution of GABAA 
receptors on the postsynaptic membrane changes upon application of a GABA 
gradient.38 Bouzigues et al. saw asymmetric redistribution of GABAA receptors when 
they followed single receptors with quantum dots. The γ2 subunits of GABAA 
receptors on the membrane of rat spinal neurons were labelled with a γ2-specific 
antibody. This antibody was then labelled with a secondary, biotinylated antibody, 
which was associated with a streptavidin-coated quantum dot (Figure 13 (i)). It was 
found that on membranes with no GABA, the average position of the 10-30 tagged 
receptors had a statistically random motion. In a uniform GABA concentration, the 
receptors still maintained a statistically random motion (Figure 13 (ii), grey), but on 
the application of a GABA gradient, the GABAA receptors had a directed motion 
towards the higher GABA concentration (Figure 13 (ii), black). Upon removal of the 
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GABA concentration gradient, the spread of GABA receptors returned to a symmetric 
distribution. This is important in showing how GABAA receptors adapt to stimuli and 
influence the propagation of synaptic inhibition.38 
 
Figure 13: (i) schematic of quantum dot tagged GABAA Receptors; (ii) Displacement of the centre of 
mass of receptors in the presence of no GABA gradient (grey) and GABA gradient (black).38 
Muir et al. used quantum dots bound to single, non-native receptors to investigate the 
effect that the activation of glutamate receptors in excitatory synapses have on the 
lateral mobility of GABAA receptors in inhibitory synapses. The pH-sensitive 
superecliptic pHluorin (SEP) fluorescent protein was used to visualise only receptors 
at the surface of cells (the pH inside the cell is unfavourable to SEP fluorescence). 
α2SEP-GABAA receptors (assembled from SEP-tagged α2 subunits alongside 
endogenous GABAA receptor subunits) could be seen on the cell surface in live 
hippocampal neurons. Imaging revealed the initial intensities and location of α2SEP-
GABAA receptor clusters (groups of 20-30 receptors). It was shown that glutamate 
receptor activation led to a decrease in the fluorescence at these clusters, but no 
decrease in the overall fluorescence. This suggested that there must be a redistribution, 
rather than removal, of GABAA receptors. This technique could not, however, resolve 
the behaviour of a single GABAA receptor. In order to do this, a quantum dot (anti-
(i) (ii) 
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mouse) antibody conjugate was attached to a receptor via an antibody that recognised 
the SEP tag (Figure 14 (i)). The trajectory of a single quantum dot-α2SEP-GABAA 
receptor into and out of a cluster was then tracked under a microscope, and its diffusion 
rate increased on glutamate receptor activation (Figure 14 (iii)). It was concluded that 
glutamate receptor activation led to the dispersal of GABAA receptor clusters by 
increasing GABAA receptor mobility.39 
 
Figure 14: (i) Schematic of a quantum dot-tagged α2SEP GABAA receptor; (ii) α2SEP GABAA receptors 
expressed in a hippocampal neuron;39 (iii) trajectory of a quantum dot-tagged α2SEP GABAA receptor 
shown (black) into and out of a GABAA receptor cluster (green).39 
One of the advantages of this research is that it enabled the simultaneous visualisation 
of single GABAA receptors movement alongside the real location of receptor clusters 
(Figure 14, (ii)). One disadvantage is the size and bulk of the SEP-tagged receptors, 
which could be showing a different dynamic behaviour than unmodified GABAA 
receptors in the brain. A second limitation is the fact that the receptors here are not 
native, and this may also affect the way they diffuse through the membrane. The 
combination of a photoaffinity labelled antagonist and a fluorescent probe could be 
very powerful in investigating the movement of native receptors in the plasma 
membrane. 
(i) (ii) (iii) 
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1.7 Limitations of quantum dot tracking 
There are many questions to be considered about the efficacy of using quantum dots 
to study membrane receptor diffusion.40 It is important, firstly, to consider whether the 
presence of a quantum dot influences the surface diffusion. It is generally thought that 
the diffusion of the receptor is not hindered by the presence of a quantum dot, instead 
the rate limiting factor is the viscosity of the membrane itself, reported to be 100-1000 
times more viscous than the extracellular medium.41 A comparison between the 
diffusion rates of AMPA receptors tagged with a variety of sized quantum dot 
conjugates were deemed to not be significantly different.41 [AMPA receptors are 
ligand-gated cation channels, activated by glutamate, and are excitatory synaptic 
receptors].41 However, when discussing receptors inside the synaptic cleft, there seems 
to be more doubt on the issue. Dahan et al. tracked synaptic glycine receptors, and 
showed that the quantum dots were small enough to penetrate into the synaptic cleft.42 
On the other hand, the diffusion rates of a quantum dot coated in a large protein were 
different to that of a quantum dot coated in a relatively small Fab fragment, which 
supports the rationale that the smaller the probe the more accurate the tracking of 
synaptic receptors.41 
A second point to consider is whether an endogenous receptor and mutated 
recombinant receptors have the same surface diffusion. This is a limitation in many of 
the methods outlined above, and it is not possible to form pertinent controls for many 
of these experiments. 
The ideal tool for studying lateral mobility of GABAA receptors would be one which 
could track individual native receptors. This could be mediated by a small GABAA-
specific ligand covalently bound to the receptor. This covalent bond could come from 
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an electrophilic moiety in the molecule, or from the excitation of a photoaffinity label, 
the latter also allowing additional spatial control (Figure 15). 
 
Figure 15: A photoaffinity labelled fluorescent probe to track the lateral mobility of GABAA 
receptors. 
A better picture would be gained if the modification of the GABAA receptors remained 
as small as possible. The fluorescent probe should be small enough to fit inside the 
synaptic cleft, as well as being far enough away from the receptor-ligand binding site 
to not cause steric interference. A quantum dot has many advantages over fluorescent 
proteins and organic fluorophores. Furthermore, in general it is more effective to 
measure the effect of an antagonist as opposed to an agonist, as the block of ion current 
over the membrane is easier to quantify than an incremental increase, which is highly 
dependent on agonist concentration. The development of a chemical tool upon this 
basis, such as that shown in Figure 15, is attempted in Chapter 2 of this thesis.  
1.8 Introduction to photocleavable probes for receptors 
The movement of receptors in the membrane has been shown to be highly dependent 
upon the conformation of the receptor.43,4 It has already been mentioned that in the 
presence of a GABA gradient, the GABAA receptors move non-randomly. In addition, 
recent work has highlighted that GABAA receptors disperse in the presence of 
agonists, but in the presence of antagonists they remain more stationary in the synapse. 
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This is due to changes in the interaction of GABAA with large proteins on the 
cytoskeleton. More widely, neuronal activity modifies the diffusion properties of 
GABAA receptors. Most tracking methods described above reveal the location and 
movement of their targets, but seldom reveal information about the activation state of 
the channel.44 A probe based upon a photoaffinity labelled antagonist will necessarily 
only give information about the movement of a blocked receptor. A receptor with a 
free binding site may well move differently, and in probes which rely upon ligand 
specificity to direct fluorescent attachment, this calls for a photocaging strategy, 
whereby the ligand is cleaved once the fluorescent probe is installed. 
An example of this technique is the nanoprobe 52, which was designed as a ligand-
targeted and photocleavable probe for delivering a fluorophore to native AMPA 
receptors in order to carry out studies on receptor trafficking. Nanoprobe 52 is 
comprised of a polyamine receptor-specific ligand [gold] attached, via a nitroindoline 
photocage [red], to an acrylamide electrophile [black] and a Cy3 fluorescent dye [blue] 
(Figure 16). The electrophilic acrylamide would form a covalent bond with a residue 
near the binding site in the ion channel, and photolysis of the photocage would cause 
ligand release, leaving a covalently tagged receptor in a non-antagonised state.44,45 
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Figure 16: Nanoprobe 52 for ‘silent’ fluorescent labelling of neuronal receptors, showing the ligand 
group (gold), the photocleavable group (red) and the Cy3 fluorophore tag (blue). 
There are many different electrophilic moieties which have been used to facilitate 
protein-ligand covalent attachment, including epoxides, aryl halides, haloacetamides, 
maleimides and carbonates.46 The benzodiazepine ligand Ro15-4513 53, as well as 
diazepam 6, were modified to include an electrophilic isothiocyanate group, giving 54 
and 55 respectively (Figure 17). These compounds were incubated with GABAA 
receptors of different subunit compositions, which had been mutated to include 
cysteine residues at various points in the benzodiazepine binding site. The cases in 
which irreversible binding was observed were used to generate an experimental 
picture of how each ligand sits in the binding pocket.47,48 
 
Figure 17: Isothiocyanate electrophilic analogues 54 and 55, of allosteric modulators 53 and 6 to 
probe the benzodiazepine binding site. 
The photorelease of a compound can be facilitated by many different photocleavable 
groups, allowing the compound to leave as a variety of molecular functionalities 
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including phosphates, carboxylates, phenols, thiols, amines and amides.49 Several of 
these photocaged ligands, which are inactive until uncaged, have been used effectively 
in neuronal cultures, in the form of photocaged neurotransmitters.50 Of these, various 
nitroindolinyl- and nitrobenzyl-based photocages, for example DPNI-GABA 56 and 
CNB-L-glutamate 57, are commercially available and widely used (Figure 18). 
 
Figure 18: Commercially available photocaged neurotransmitters. 
A nanoprobe with the functionality described above and based on gabazine, could 
release its ligand from the GABA binding site of a GABAA receptor upon irradiation, 
leaving a fluorescent probe covalently tethered. With further development and 
optimisation, it could track unblocked GABAA receptors in a live neuronal system. 
Research into a system such as this is described in Chapter 3 of this thesis. 
1.9 Introduction to photoswitching ligands 
Photoaffinity labelling, and the above photocleavable ligands are irreversible 
optopharmacological tools.51 Chemical photoswitches, in contrast, are bistable 
photochromic compounds which can be activated and deactivated in cycles. These 
could be used to reversibly control the function of a biological system, using a mode 
of reactivity which is orthogonal to most cellular processes, light. Synthetic bistable 
molecules include azobenzenes 58, stilbenes 59, and hemithioindigos 60, which form 
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photostationary states consisting of different ratios of cis and trans photoisomers 
under different wavelengths of light or thermal conditions (Figure 19). 
 
Figure 19: Compounds which undergo cis-trans photoisomerisation. 
In addition, spiropyrans 61, diarylethenes 62 and thiophenefulgides 63, are synthetic 
photoswitches which reversibly switch between open and closed forms (Figure 20). 
 
Figure 20: Ring opening and closing photochromic compounds. 
By far the most well-known and well-used photoswitch is azobenzene 58, first 
reported in 1937,52 which upon irradiation with UV light forms a cis-enriched 
photostationary state. This can be relaxed to a majority trans equilibrium thermally or 
upon visible light irradiation.53 In order to be of use in a biological system, a synthetic 
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photoswitch would need to undergo rapid switching, and have a high extinction co-
efficient with a high quantum yield at wavelengths that are not harmful to living 
cells.54 
Substituents on the phenyl rings greatly affect the photoisomerism of the azobenzene, 
including the wavelength at which isomerisation is optimised. The use of UV 
irradiation in a working biological system has the great disadvantage of causing cell 
damage, and for this reason substituted azobenzenes with red-shifted absorbance have 
been synthesised.55 Many of these either have ortho- or para-amino-, para-amido- 
groups, or invoke a push-pull electron effect by having acceptor and donor groups in 
opposing para- positions.56 
1.10 Introduction to photoswitchable ligands for receptors 
In biological systems, photochromic ligands to a protein can provide precise spatial 
and temporal control of function. Photodynamic properties can be conferred onto a 
receptor via an untethered ligand with active and inactive photoswitchable states.57 
Another method would be a tethering approach, through which a photoswitch is bound 
via a covalent bond between a genetically introduced nucleophilic residue and a 
complementary electrophilic moiety on the ligand. Once bound, application of the 
light stimulus will cause the photoswitchable tethered ligand (PTL) to change 
conformation and retract its binding motif from the binding pocket (Figure 21). This 
is then reversed upon application of a light stimulus of a different wavelength. In this 
way the receptor is reversibly activated/deactivated upon UV exposure. 
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Figure 21: General mechanism of use for a tethered photoswitchable ligand. 
Photoswitchable ligands and PTLs in the literature mostly contain azobenzenes, 
although some others have been used. For example, the spiropyran iodoacetate 64 has 
been successfully used to regulate the opening and closing of a mechanosensitive 
channel of large conductance (MscL). Cysteine residues, genetically introduced in the 
channel pore, covalently bind to 64, and irradiation of the system causes ring-opening 
formation of the dipolar merocyanine structural isomer 65, the dipolar nature of which 
forces the channel open. This releases liposomal material which can be quantified 
using fluorescence readings (Scheme 10).58 In fact, spiropyrans can undergo structural 
isomerisation under a number of different stimuli including light, temperature, redox 
potentials, presence of metal ions and mechanical stress, and the vastly different 
polarity of the two isomers can be used to refine solvation and chelation properties.59 
Scheme 10: Light induced photoisomerisation of a spiropyran derivative. 
In 1971 Erlanger et al. synthesised two photoswitchable activators of acetylcholine 
receptors (AChRs), having previously demonstrated the use of azobenzenes in 
regulating the activities of chymotrypsin and acetylcholinesterase enzymes. BisQ 66, 
synthesised in two steps from 1,2-di-p-tolyldiazene (Scheme 11), has two quaternary 
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methyl ammonium salts, which block the receptor’s binding site. It was found that a 
trans-BisQ is over 500-fold more potent than BisQ in a majority cis- photostationary 
state. In addition, following reduction with dithiothreitol (DTT), the receptor binds 
covalently to the second antagonist, QBr 67, and to some extent still confers 
photoswitchable activity to the receptor (Scheme 11).60 
 
Scheme 11: Synthesis and of non-tethered BisQ 66 and tethered QBr 67 photoswitchable ligands to 
the acetylcholine receptor. 
The photo control of ion channels in particular was substantially extended by Trauner 
and colleagues during the 2000s.56 They developed maleimide-azobenzene-glutamate 
(MAG) compounds, for example 68, which were able to demonstrate receptor 
conjugation and light activation of an ionotropic glutamate receptor (iGluR6), itself 
mutated to include a strategically placed single cysteine residue (Figure 22). 
 
Figure 22: Example of MAG photoswitch 68 for an AChR. 
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Furthermore, Trauner et al. built a range of photoswitchable tethered ligands, which 
used the affinity and selectivity of the ligand to accelerate covalent attachment, this 
time onto native nucleophilic residues near the binding site. A variety of electrophilic 
moieties were used in the investigation of wild-type Shaker channels expressed in 
HEK293 cells.61 Of these, acrylamide 69, chloroacetamide 70 and epoxide 71 
imparted photosensitivity to the endogenous channels. In cultured hippocampal 
neurons, acrylamide 69 and chloroacetamide 70 were again successful, essentially 
yielding a photoswitchable ion channel (Figure 23). 
 
Figure 23: Photosensitive affinity ligands for endogenous K+ ion channels. 
More recently, the same group have enabled optical control of α7 nicotinic 
acetylcholine receptors (nAChRs) with a freely diffusible ligand. AzoCholine 72 was 
similar to BisQ 66 and resembles α7 nAChR antagonist MG624 73.62 2-Chloro-N,N-
dimethylethylamine hydrochloride underwent nucleophilic substitution with 4-
hydroxyazobenzene 74 to form 4-(dimethylaminoethyl)oxyazobenzene 75, which 
then underwent quarternisation with iodomethane to give AzoCholine 72 in two steps 
and 64% overall yield (Scheme 12). 
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Scheme 12: Synthesis of AzoCholine 72. 
Upon the comparison of AzoCholine 72 with BisQ 66, it was found that, whilst 
AzoCholine 72 was a potent agonist in its trans state and could be used as a 
photoswitchable ligand on a chimeric model of neuronal α7 nAChRs in HEK293T 
cells, BisQ 66 showed no activation. However, when subunits for muscle nAChRs 
were expressed in these cells, BisQ 66 proved to be a photoswitchable agonist where 
AzoCholine 72 did not. Upon application of AzoCholine 72, extracellular 
electrophysiology of mouse hippocampal slices showed that activity of the receptors 
could be modulated by alternating between 360 and 460 nm wavelengths of light. 
1.11 Photoswitchable ligands and GABAA Receptors 
Alongside success with neuronal voltage-gated potassium ion channels and nicotinic 
acetylcholine receptors, Trauner et al. also worked on developing photoswitchable 
ligands for GABAA receptors. Propofol 22, an allosteric modulator to the GABA 
receptor, is known to tolerate modification at the para- position of the phenol, and 
sixteen azo-propofols were designed and synthesised. The most promising of these, 
the para-amino compound 74, was found to have the most favourable characteristics 
for a photochromic potentiator of GABAA receptors (Figure 24).
63 It has a red-shifted 
absorption spectrum, with a majority cis photostationary state under 404 nm light. This 
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compound also quickly reverts thermally to the trans isomer once the light is switched 
off. Application of azo-propofol 74 alongside GABA to Xenopus ooctyes resulted in 
an increased GABA response through positive allosteric modulation. Irradiation using 
390-450 nm light during this time prevented this potentiation, which then returned 
when the light was turned off. This photoswitching ability was also shown in α1β2γ2 
GABAA receptors expressed in HEK cells. The use of this compound as a light-
dependent anaesthetic was then investigated by looking at righting reflexes in 
tadpoles, which was significantly potentiated in the presence of photoswitchable azo-
propofol 74. 
 
Figure 24: Photoswitchable analogue of allosteric modulator for GABAA receptors. 
In the same year Pepperberg et al. made a propofol analogue 75 for photoregulation 
of GABAA receptors (Figure 25).
64 The trans isomer of this compound potentiates the 
GABA response and, at high concentrations, directly activates the receptor. The cis 
isomer produces little receptor potentiation both in α1β2γ2 GABAA receptors 
expressed in Xenopus laevis oocytes and in native GABAA receptors in retinal 
ganglion cells. 
 
Figure 25: Tethered 75 and non-tethered photoswitchable ligand 76 for GABAA receptors. 
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Further to this, a tethered analogue 76 was synthesised, which incorporated a 
maleimide-terminated PEG linker, and was tested on oocytes expressing α1β2γ2 
GABAA receptors which had a cysteine substituted into the 79-position of the γ 
subunit. This cysteine covalently anchored the ligand to the receptor. In the presence 
of GABA, and with picrotoxin, the tethered ligand also showed analogous potentiation 
and depotentiation of the receptors controlled by UV and visible light irradiation. 
Another optogenetic strategy towards engineering a light-regulated GABAA receptor 
was recently developed by Lin et al., and involved the synthesis initially of a 
photoswitchable tethered ligand 77, comprising a maleimide, azobenzene and 
muscimol moiety and synthesised in three steps from maleimidoacetic acid in 29% 
yield (Scheme 13).65 Despite muscimol 2 being an agonist for the GABAA receptor, 
compound 77 acted as a photoswitchable antagonist, and replacement of the muscimol 
moiety with a hydroxybenzylamine group 78 in fact increased the distinction between 
the cis and trans isomers in terms of inhibition. This inhibition was measured in 
α1T125Cβ2γ2S receptors in HEK293T cells, as well as in cultured hippocampal 
neurons, showing direct photocontrol and the formation of light regulated GABAA 
receptors. 
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Scheme 13: Synthesis of tethered photoswitchable ligands for the GABAA receptor. 
A recent dissertation from the Krönig group describes the synthesis of a water soluble 
photoswitchable benzodiazepine derivative 79, which utilises the photoisomerisation 
of dithienylethenes. Dithienylethene 79, despite its limited use as a photoswitchable 
allosteric modulator for GABAA receptors in cells, is a further sign that optical control 
of receptors continues to interest and excite the scientific community.66 
  
Figure 26: Water soluble photoswitchable benzodiazepine ligands for the GABAA receptor. 
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It was hypothesised that a non-tethered photoswitchable antagonist for the GABAA 
receptor could be designed and, through a short burst of UV or visible light, produce 
reversible antagonism of the receptors on cells. A compound of this type could give 
spatial and temporal control of receptors, giving valuable information on the effect of 
antagonism in different areas of a neuron. 
1.12 Thesis aims 
Light is an important tool when it comes to orthogonal control of biological systems. 
On systems which are not inherently light sensitive, this requires the use of light-
activatable compounds. This thesis describes the organic synthesis of different light-
activatable antagonists for the GABAA receptor. These include a photoaffinity probe, 
which would direct the attachment of a tracking device, in this case a quantum dot, to 
the receptors in order to help understand their movement at different locations on the 
neuronal membrane. The synthesis of a second photoactivatable antagonist, was 
designed so that once covalently bound to the receptor, UV light would release the 
binding moiety, leaving a silently-tagged receptor. The tracking of this would provide 
a comparison between the movement of a blocked and un-blocked receptor. A third 
antagonist, which could change its potency towards the receptor upon application of 
different wavelengths of light, would also be synthesised and shown to be a powerful 
tool in locating GABAA receptors as well as in spatial and temporal control of neuronal 
inhibition.  
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Chapter 2 
Photoaffinity antagonists for the GABAA receptor 
2.1 Synthesis of a photoaffinity labelled antagonist based on gabazine 
A photoaffinity labelled antagonist has two main components: a binding moiety and a 
photoactive group. Previous work in the Baker and Smart groups has shown highly 
promising biological *activity of photoaffinity labelled antagonist 39, based on 
gabazine 4. To further explore the biological applications of this analogue, and to carry 
out biological testing on GABAA receptors in a primary neuronal culture, the first goal 
of this project was to scale up the synthesis of 39 to obtain sufficient material 
(Figure 27). 
 
Figure 27: Photoaffinity labelled antagonist for the GABAA receptor 39. 
Firstly, 3-arylpyridazine 31 was synthesised via a Suzuki-type palladium coupling 
reaction between 4-hydroxyphenylboronic acid 32 and 3-amino-6-chloropyridazine 
33. After initial reactions using the previously reported microwave irradiation30 gave 
the product 31 in 58% yield, it became apparent that it would be useful if larger scale 
reactions were not hindered by the small scale limit of the microwave. Various 
reaction conditions were then attempted.67,68,69 Attempts to increase the product 
formation by using a more reactive palladium (0) species, Pd(PPh3)4, were 
unsuccessful, with no product being detected by TLC, potentially due to rapid 
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oxidation of the catalyst before the reaction. Another palladium (0) catalyst, Pd2(dba)3 
along with tributylphosphine ligand, gave only slightly more success, with the low 
yield of 37% partially ascribed to degradation the oxygen-sensitive phosphine ligand. 
It was found that the optimal conditions involved the use of Pd(PPh3)2Cl2 catalyst, 
with aqueous Na2CO3 in 1,4-dioxane. Though none of the yields were excellent, they 
enabled reaction to be performed on a gram scale in 56% yield and on a ten gram scale 
in 47% yield. 
 
Palladium source Reaction conditions Yield 
Pd(PPh3)2Cl2 (5 mol%) 
K2CO3, MeCN:H2O (1:1), 
μW 120 °C, 10 min 
58% 
Pd(PPh3)4 (5 mol%) 
2M aq Na2CO3 (2.2 eq), 
PhMe: EtOH (10:1), 82 °C, 42 h 
nd 
Pd2(dba)3 (2 mol%), 
tBu3P (4 mol%) 
K2CO3 (2.0 eq), 
1,4-dioxane, 101 °C, 24 h 
37% 
Pd(PPh3)2Cl2 (5 mol%) 
1M aq Na2CO3 (3.0 eq), 
1,4-dioxane, 101 °C, 16 h 
56% 
Pd(PPh3)2Cl2 (5 mol%) 
1M aq K2CO3 (3.0 eq), 
1,4-dioxane, 101 °C, 16 h 
53% 
 
Table 1: Optimisation of reaction conditions in the formation of 31. nd: not detected. 
Benzophenone derivative 41 was then synthesised in a 44% yield via deprotonation of 
alcohol 31 at 0 °C with KOtBu, followed by addition of commercially available 
bromomethyl benzophenone 40 (Scheme 14). The reaction was carried out in DMF, 
as the starting materials are relatively insoluble in other solvents. 
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Scheme 14: Ether synthesis reaction conditions. 
The pyridazine nitrogen then underwent N-alkylation in the presence of allyl 4-
bromobutyrate in DMF at 80°C giving pyridazinyl ester 80 in 85% yield (Scheme 15). 
N-Alkylation occurs at the N(2) nitrogen when there is an aromatic group in the 6-
position of the pyridazine skeleton, thought to be due to deactivation of the N(1) 
position, alongside steric factors.29 Hydrolysis of allyl ester 80 was achieved upon 
reaction with Pd(PPh3)4 in the presence of the allyl group scavenger DMBA, yielding 
photoaffinity-labelled antagonist 39, in an overall 9% yield over four steps 
(Scheme 15). 
 
Scheme 15: N-Alkylation and subsequent allyl-ester hydrolysis reaction conditions. 
This material 39 was then used by Dr Martin Mortensen in the Smart group, for further 
biological testing including its application onto live cerebellar granule cells. In a live 
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system it is possible for inhibitory signals to be regained after a time, as new, 
unblocked endogenous receptors are inserted into the membrane by the cell, or as 
unblocked receptors make their way through the membrane to the blocked site. 
However, by measuring the response of neuron, via whole-cell patch clamping, to 
1 mM of applied GABA at different times after 20 s irradiation at 365 nm, it was 
shown that even after forty minutes, the time course of the experiment, GABA signals 
remained suppressed (Figure 28, (i)). In addition, recording spontaneous inhibitory 
post synaptic currents (sIPSCs) from a single cell, [spikes in current due to endogenous 
release of GABA from neighbouring pre-synaptic terminals] thirty minutes after 
irradiation in the presence of 39, showed no discernible recovery of inhibitory signals, 
suggesting that the arrival of new receptors via membrane insertion must be a slow 
process. (Figure 28, (ii)). 
 
Figure 28: (i) Time profile for 1 mM GABA-activated currents before and after treatment with 10 µM 
39 and 20 s UV; (ii) sIPSCs from a single cerebellar granule cell 3 minutes before, and 29 minutes 
after treatment with 39 and UV. 
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2.2 Synthesis of a photoaffinity probe for quantum dot tracking of the GABAA 
receptor 
This section concerns the design and synthesis of a chemical tool which can 
photocrosslink to the receptor and is also able to relay information about the lateral 
movement of GABAA receptors. The photocrosslinking, as before, would be directed 
by the binding of a gabazine core and facilitated by a benzophenone photoaffinity 
label. The incorporation of a biotin via a solubilising ethylene glycol linker would 
enable connection to a streptavidin-coated quantum dot (Figure 29). Once irreversibly 
bound to receptors on cells, the quantum dot movement can be recorded, showing the 
precise routes of these receptor-quantum dot constructs over time. The site of 
attachment for the linker on benzophenone was devised from computational docking 
studies, which suggested that, once in the binding site, there would be space in the 3-
position for a straight linker segment.70 
 
Figure 29: Photoaffinity labelled probe for the GABAA Receptor. 
In a retrosynthetic analysis, the biotin and linker fragments were installed via amide 
bond couplings, and a Sonogashira-type reaction installed a linear alkyne section in 
the most tolerated position (Scheme 16). The intermediate 81 was synthesised by the 
strategy similar to one described in Schemes 5 and 6, starting with 4-(6-
aminopyridazin-3-yl)phenol 31 (Scheme 16). A previous, unoptimised attempt at this 
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route yielded insufficient material,28 and in order to generate biological data and 
quantum dot tracking of receptors, an optimised route and scale up production of the 
probe was required. 
  
Scheme 16: Retrosynthetic analysis of photoaffinity labelled probe for the GABAA receptor. 
Benzylic bromide 82 was synthesised in two steps from 3-bromo-4-methylbenzoic 
acid 83. Acid 83 was refluxed in thionyl chloride to give the acid chloride 
intermediate, and then heated in benzene with AlCl3 to yield (3-bromo-4-
methylphenyl)(phenyl)methanone 84 in 53% yield. Upon treatment with N-
bromosuccinimide in the presence of AIBN, mono bromination at the benzylic 
position to give 82 was accomplished in 70% yield. In this reaction the doubly 
brominated species 85 was also isolated in 4% yield, whilst 16% of starting material 
84 was returned (Scheme 17). 
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Scheme 17: Construction of benzophenone fragment. 
The displacement reaction was then accomplished upon treatment of arylpyridazine 
31 with KOtBu and 18-crown-6, followed by addition of bromomethylbenzophenone 
82. This gave benzophenone derivative 86 in 63% yield (Scheme 18). 
 
Scheme 18: Introduction of pyridazine core. 
The next step in the synthesis was the Sonogashira-type coupling71 between 
arylbromide 86 and 5-hexynoic acid to give acid 87. The Songogashira conditions 
shown in Scheme 19 had previously been applied in the group, but only with limited 
success.28 Application of these conditions to bromide 86 proved unsuccessful so 
further optimisation was undertaken. 
 
Scheme 19: Unsuccessful Sonogashira reaction conditions. 
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It was thought that a copper catalysed alkyne-alkyne homocoupling could be 
competing in this reaction, as the carboxylic acid could not be recovered. Accordingly 
all solvent was degassed with argon and the hexynoic acid was added to the reaction 
mixture slowly.72 However, no desired product, nor homocoupled product were 
detected. 
Sonogashira reaction conditions in the literature are quite varied, and the reaction is 
very substrate dependant. The main components include a palladium (0) source, which 
is either added to the reaction or formed in situ. A copper source and a base are 
required to activate the alkyne to undergo carbometallation onto the palladium. 
Varying sources of palladium, including Pd(PPh3)2Cl2 and Pd(PhCN)2Cl2, were used 
alongside amine bases, for example diethylamine and DIPEA, and CuI, at room 
temperature, according to literature conditions but with no success.73,74 An attempt 
using Pd/C and CuI with Cs2CO3 at 80 ºC was also unsuccessful.
 
One problem with the reaction could be the presence of the carboxylate anion formed 
by salt formation of 5-hexynoic acid and the base, as there are few reported cases of 
Sonogashira reactions involving a carboxylic acid.75 Accordingly 5-hexynoic acid 
methyl ester 88 was synthesised from 5-hexynoic acid in 87% yield (Scheme 20). 
 
Scheme 20: Hexynoic acid methyl ester formation. 
However, after subsequent application of 5-hexynoic acid methyl ester 88 to various 
reaction conditions, including with Pd(PPh3)2Cl2 and Pd(PhCN)2Cl2 catalyst at room 
temperature with CuI and a requisite base, no desired product 89 was detected 
(Scheme 21). 
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Scheme 21: Unsuccessful Sonogashira reaction conditions. 
A second reason for the failure of the required Sonogashira reaction could have been 
the co-ordination of the amine group in 86 to the palladium catalyst. To avoid this, the 
synthesis of a Boc-protected analogue of 86 was attempted (Scheme 22). However, 
unreacted starting material was isolated in 16% yield along with an inseparable 1.6:1 
mixture of Boc-isomers, which was not taken on to the Sonogashira reaction. These 
Boc-isomers were tentatively assigned via 1H NMR spectroscopy and known 
regioisomer chemical shifts to be 90 and 91, in 48 and 30% yields respectively. 
 
Scheme 22: Attempted Boc-protection of pyridazine. 
As a model system, 5-hexyn-1-ol was reacted with benzophenone derivative 84 under 
literature conditions in order to pinpoint the reactivity problem.76 The reagents were 
treated with Pd(PPh3)4 and CuI at a lower catalyst loading in triethylamine, but at a 
higher temperature of 80 °C for 16 h. Encouragingly the desired product 92 in this 
reaction was isolated in 69% yield (Scheme 23). 
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Scheme 23: Sonogashira reaction conditions - increased temperature. 
Concurrently, a reaction between model benzophenone 84 with 5-hexynoic acid 
methyl ester 88 with Pd(PPh3)2Cl2, CuI and diethylamine at 55 °C yielded the product 
93 in 31% isolated yield (Scheme 24). In this case returned starting material 84 was 
isolated in 30% yield, whilst the homocoupled product 94 was isolated in 23% yield 
with respect to the ester starting material, despite best-effort inert conditions. 
Scheme 24: Sonogashira reaction conditions - increased temperature. 
Application of 5-hexyn-1-ol reactants to the desired pyridazine arylbromide substrate 
86 yielded the desired alcohol product 95 in 15% yield, whilst 77% of the starting 
material 86 was returned (Scheme 25). It was noted that alcohol 95 could still be useful 
in the synthetic pathway as it could form the amide linker after oxidation. 
 
Scheme 25: Sonogashira reaction conditions. 
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Unfortunately, in the reaction between 86 and 5-hexynoic methyl ester 88, the product 
was detected by 1H NMR spectroscopy along with starting material 86 but the product 
was not isolable (Scheme 26). 
  
Scheme 26: Sonogashira reaction conditions. 
It was thought that the failure of this reaction was due mainly to slow conversion and 
the competing homocoupling reaction. As such it was envisaged that replacement of 
the bromide with an iodide would aid the reaction. It is well reported that the rate-
limiting step of a Sonogashira reaction is the oxidative addition of palladium into the 
carbon−halogen bond.77 This goes some way to explain the reactivity of the sp2 species 
towards the Sonogashira reaction as the relative reactivities are as follows: aryl iodide 
> aryl triflate ≥ aryl bromide >> aryl chloride, i.e. inversely to the strength of the 
carbon−halogen bond.77 With this in mind, an iodo analogue of 84 was synthesised in 
two steps in 46% overall yield following previous reaction conditions (Scheme 25). 3-
Iodo-4-methylbenzoic acid 96 was reacted with thionyl chloride and the resulting acid 
chloride was heated in benzene in the presence of AlCl3 to give analogue 97, which 
was brominated to give 98 in 46% overall yield (Scheme 27). A small percentage of 
de-iodination (3%) was detected when the reagent was heated in the presence of AlCl3, 
which is in accordance with literature precedent.78 
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Scheme 27: Iodine analogue of benzophenone fragment. 
For a direct comparison between the reactivity of aryl-iodide 97 and aryl-bromide 84, 
iodide 97 was reacted with 5-hexyn-1-ol in the presence of Pd(PPh3)4, CuI and 
triethylamine to give alcohol 95 in 90% yield, encouragingly higher in yield than the 
bromo analogue {69%} (Scheme 28). 
 
Scheme 28: Sonogashira reaction conditions. 
The next step in the synthesis of the iodo analogue, the ether synthesis, was attempted 
between 6-arylpyridazine 31 and benzophenone derivative 98 using the previously 
reported reaction conditions {KOtBu, 18-crown-6 and DMF}. This led to the synthesis 
of the required product 99 in 23% yield, but also to the formation of an amino-dimethyl 
derivative 100 in 57% yield, alongside 30% returned starting material 31 (Scheme 29). 
The side product 100 is formed through nucleophilic substitution by dimethylamine, 
a degradation product of DMF. In this case, however, freshly distilled DMF did not 
eliminate the formation of dimethylamino derivative 100, which suggests that the 
presence of dimethylamine arises from interactions between KOtBu and DMF.79  
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Scheme 29: Product distribution in the ether synthesis of iodo analogue. 
The formation of this side product was eliminated with the use of NaH as the base, 
and 99 was formed in 82% yield (Scheme 30). 
 
Scheme 30: Optimised ether synthesis reaction conditions. 
With this in hand, a Sonogashira reaction was undertaken, following previous reaction 
conditions, between iodo analogue 99 and 5-hexyn-1-ol, yielding alcohol 95 in 74% 
yield (Scheme 31). 
 
Scheme 31: Sonogashira reaction conditions. 
Given the great improvement in yield between the iodo analogue 99 and bromo 
analogue 86 {74% compared to 15%}, the Sonogashira reaction with 5-hexynoic acid 
was undertaken and yielded 87 in 49% yield as an insoluble white solid (Scheme 32).  
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Scheme 32: Successful Sonogashira reaction conditions. 
Acid 87 was insoluble in a wide range of organic solvents, including THF and DMSO, 
and as such, only a broad 1H NMR spectrum was obtained. A tentative assignment 
was made, and after the compound’s derivatisation in the next step of the synthesis, 
alongside mass spectrometry results, this assignment was confirmed. Its insolubility 
could be due to the crystallisation into a zwitterion after column chromatography. 
Attention was then turned to the synthesis of the ethylene glycol tether 101, initially 
of three units length, which would be connected to the photoaffinity labelled 
pyridazine 87. The tether was synthesised in 3 steps in 62% overall yield following 
literature conditions.80,81 Commercially available 2,2'-(ethane-1,2-diylbis(oxy)) 
diethanamine was mono-Boc protected with 0.1 equivalent of Boc-anhydride to give 
102 in 98% yield with respect to Boc-anhydride. Amine 102 was then reacted with  
D-biotin 50 in the presence of HBTU and DIPEA to give 103 in 63% yield. Boc-
deprotection was accomplished upon addition of TFA, to give biotinyl-PEG amine 
101 in quantitative yield (Scheme 33). 
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Scheme 33: Preparation of the biotin linker for incorporation into the probe structure. 
The coupling between biotinylated amine 101 and Sonogashira product 87 was 
achieved using HBTU and DIPEA, and yielded 104 in 55% yield. Isolation of the pure 
product proved lengthy due to HBTU contamination, so the reaction was attempted 
with DCC and triethylamine which yielded 104 in a comparable 52% yield, but with 
a more straightforward purification (Scheme 34). 
 
 
Scheme 34: Incorporation of the linker and biotin functionality. 
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The next stage in the synthesis was the alkylation of the pyridazine N(2) nitrogen with 
allyl 4-bromobutyrate, initially reacted in DMF at 50 °C for 5 h according to the 
previously reported protocol,30 but this led only to a return of starting material. The 
reaction conditions were altered to 120 °C for 16 h, which yielded the N-alkylated 
product 105 in 77% yield (Scheme 35). 
 
Scheme 35: N-Alkylation reaction conditions. 
The final deprotection step was achieved via base-catalysed hydrolysis of the allyl 
ester group with sodium hydroxide, and yielded the target molecule 106 in 65% yield 
(Scheme 36). 
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Scheme 36: Allyl ester hydrolysis as the final step in the synthesis of photoaffinity labelled probe 109. 
This then completed the targeted synthesis of the photoaffinity labelled probe for the 
GABAA receptor 106 from commercially available 4-hydroxyphenylboronic acid 32 
and 3-amino-6-chloropyridazine 33 in an overall yield of 7%.  
2.3 Quantum dot tracking of GABAA receptors 
The biological evaluation of gabazine probe 106 was then conducted by Dr Martin 
Mortensen in the Smart group. Firstly an IC50 value was obtained from inhibition 
experiments in recombinant α1β2γ2S GABAA receptors expressed in HEK293 cells, 
which was measured as 1.49 µM (Figure 30). Whilst this is less potent than previous, 
smaller analogues it still gave an acceptable activity for further experiments. 
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Figure 30: Dose response curve, showing the response of different concentrations of 106 relative to 
maximal GABA response, giving an IC50 of 1.49 µM. 
Secondly, the photolytic block of the probe was measured to assess the efficacy of the 
benzophenone photoaffinity label. Encouragingly a photolytic block of ~30% was 
seen as probe 106 underwent the irradiation protocol reported vide supra (Figure 31). 
   
Figure 31: Photolytic block of biotinylated probe 106. 
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With the knowledge that probe 106 was successfully antagonising GABAA receptors, 
and that it was forming a covalent attachment with the receptor upon irradiation with 
UV light, experiments to track native GABAA receptors in live neurons were then 
undertaken. 
The quantum dot-streptavidin nanocrystals used in these experiments were purchased 
from Invitrogen Molecular Probes®, which have a narrow maximum in their emission 
spectrum at 655 nm, independent of excitation wavelength. They are comprised of 
CdSe core which is coated in an additional semiconductor shell made from ZnS. This 
core-shell material is further coated with a polymer shell, which is covalently coupled 
to 5-10 streptavidin molecules per quantum dot (Figure 32).82 
 
Figure 32: Schematic of a quantum dot-streptavidin conjugate used in these experiments. 
The hippocampal cells used for these imaging experiments were prepared as a primary 
culture from rats. Live hippocampal cells, isolated via enzyme dissociation and 
trituration, were placed on a cover slip and grown in a monolayer containing astroglial 
cells, which provide support for the hippocampal cell development. Over ten days, 
dendrites grew out from the soma of the cells to make a synaptically connected 
network, similar to neuronal tissue.83 For localisation purposes, some cells were 
transfected with green fluorescent protein (GFP) to visualise the network of dendrites 
belonging to any one of the transfected cells and allow identification after the cover 
slip was removed for washes and returned. 
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The cover slips containing the cells were loaded into a microscope sample holder to 
be imaged. The microscope set-up allowed the cells to be viewed through several light 
filters, allowing the transmission of defined wavelengths of light. These filters were 
used to visualise GFP at 488 nm, quantum dots at 655 nm, and the whole cells with 
white light (Figure 39). The set-up also contained a UV irradiation source, which could 
be directed onto regions of the cover slip. 
After the cells were treated with the quantum dot-106 conjugates and a section was 
irradiated, the whole cover slip was removed from the microscope and washed with 
Kreb’s solution84 to remove any non-covalently bound quantum dot-106 constructs. 
The dish was then replaced on the microscope stage, and the region previously UV 
exposed was located using the particular shape of the GFP transfected neurons at 488 
nm. Viewing this area through a 655 nm light filter showed the quantum dots which 
were still bound to the cells (Figure 33). The movement of these quantum dots was 
recorded for several seconds. 
 
Figure 33: (i) Hippocampal cells seen under visible light; (ii) Cells seen with 488 nm light, 
highlighting the GFP used for recognition of particular cells on the slide; (iii) Cells seen with 655 nm 
light, showing the presence of quantum dots on GABA receptors at synapses. Each quantum dot could 
be filmed and followed. 
Control experiments were conducted to ascertain the specificity of the quantum dot-
106 construct to GABAA receptors, and the efficacy of the photoaffinity label in the 
presence of the quantum dot. In these experiments, it was shown that quantum dots 
(i) (ii) (iii) 
Cells seen with 655 nm light, showing the 
presence of quantum dots on GABA 
receptors at synapses. Each quantum dot 
could be filmed and followed. 
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alone were washed away easily during our procedure. However, it was also discovered 
that quantum dot-106 constructs, despite not being irradiated, persisted even after 
washes, and this accounted for on average eight quantum dots per cell area (Figure 40). 
Further experiments also showed no significant difference in the numbers of quantum 
dots bound to the cells, after washing, in the area of the cells directly under the beam 
of UV light, and those in surrounding areas, not directly exposed. This could 
potentially be due to the scattering of UV light over the entire dish (Figure 34). 
     
Figure 34: Numbers of quantum dots seen in control experiments; some quantum dots appeared 
strongly bound despite not being irradiated in the control experiment. 
With confidence that a significant number of the quantum dots seen through the 
655 nm filter were indeed covalently bound to GABAA receptors, the recordings of 
quantum dot movement were analysed and their individual trajectories were plotted 
(Figure 35). These show a mixture of mobile and confined quantum dots, indicating 
whether the receptor is freely diffusing along the membrane, or whether it is confined 
by a synapse. 
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Figure 35: (i) Trajectories (coloured lines) of quantum dots photolinked to GABAA receptors via 
probe 106; Highlighted are trajectories of (ii) a mobile extrasynaptic receptor (M), and; (iii) a 
constrained synaptic receptor (C). 
This work has shown the use of a photoaffinity labelled probe, conjugated with a 
quantum dot, to investigate the movement of native GABAA receptors in a live system. 
They provided an excellent opportunity to study single native GABAA receptors, 
although having some bound quantum dot-106 conjugates present in the control 
experiment was not optimal. A second biotinylated compound with a longer ethylene 
glycol linker was designed to increase the distance between the quantum dot and the 
binding site. It was thought that this would allow the gabazine binding motif to be 
more flexible and bind more strongly to the receptor. If this occurred, the background 
presence of non-specific membrane-binding quantum dots would have less 
significance. The longer, 19 unit, oligo ethylene glycol (OEG) linker was prepared by 
mono-Boc protection of the commercially available diamine OEG 107 and stored as 
an acetic acid salt 108 (Scheme 37). 
(i) (ii) 
(iii) 
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Scheme 37: Preparation of the longer PEG linker section. 
This acetic acid salt 108 was reacted with D-biotin N-hydroxysuccinimide ester D-109, 
in the presence of triethylamine to give fragment 110 in 76% yield. Then a DCC-
mediated amide bond formation gave biotinylated pyridazine skeleton 111 in 55% 
yield (Scheme 38). 
 
Scheme 38: Construction of longer PEG linker chemical probe. 
Unfortunately the next step, the N-alkylation of the pyridazine core proved 
unsuccessful, despite numerous applied reaction conditions (Scheme 39). The 
oligomeric ethylene glycol chain may have prevented the precipitation of the product, 
although subsequent column chromatography yielded returned starting material only. 
It was hypothesised that the hydrophilic nature of the long chain enfolded the 
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pyridazine nitrogen, making it less accessible for nucleophilic attack. Further reaction 
conditions were tried with up to five equivalents of allyl 4-bromobutyrate and with 
heating up to 120 ºC in DMF. However, no product was observed in any case, and the 
starting pyridazine was always returned. This led to attention being turned away from 
the synthesis of this chemical probe. 
 
Scheme 39: Unsuccessful N-alkylation reaction conditions. 
2.4 Conclusions 
This chapter describes the successful use of a benzophenone photoaffinity antagonist 
for GABAA receptors, and then goes on to describe the synthesis of a novel photo-
activatable probe for the GABAA receptor. This probe formed an adduct with a 
streptavidin-coated quantum dot, and was incubated with neurons. UV irradiation 
created a covalent link between neuronal receptors and the probe, irreversibly blocking 
and tagging it. Microscopy then followed the movement of quantum dots, as they 
tracked the movement of GABA receptors in synaptic and extra-synaptic sites. 
Membrane dynamics of GABAA receptors are incredibly varied, and are reliant on 
numerous factors, including the presence of ligands. This means that there is a 
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remaining need for another type of chemical tool, one which could track unblocked 
GABAA receptors in the membrane. A synthesis of a photocleavable probe, with this 
aim, is described in Chapter 4. 
Chapter 3 describes a short investigation into alternative benzophenone analogues, and 
the development of an assay to discover a way to quantify H-abstraction ability. 
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Chapter 3 
Testing alternative photoaffinity labels 
3.1 UV spectra and photoaffinity labels 
Alongside this work on functionalised chemical probes to track the GABAA receptor, 
a study was initiated to explore alternative benzophenone analogues that could be used 
in photoaffinity labelling. The reactivity of benzophenone 13 is derived from 
excitation with a requisite wavelength, usually around 350 nm, of light to form a n,π* 
electronic state, which readily undergoes H-abstraction followed by intermolecular 
radical recombination to form a photoadduct.85 The UV spectra of benzophenone 
comprises of an absorbance at 250 nm, which is ascribed to a π,π* electronic transition, 
and a weaker absorbance corresponding to the n,π* transition at 345 nm (Figure 36). 
The UV spectra taken of benzophenone 13 was considerably altered upon the 
introduction of electron donating or withdrawing substituents onto the phenyl rings, 
as shown with the p-methoxy and p-nitro analogues 112 and 113 respectively. 
 
Figure 36: UV spectra of substituted benzophenones, with particular look at transition at 350 nm. 
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In the first instance, it was a dramatic increase in n,π* absorbance at a wavelength 
greater than 350 nm which was desired, as this wavelength is less harmful to biological 
samples. At this point the search was broadened to include, amongst others, 
naphthalene analogue 114 (Figure 37). 
 
Figure 37: UV spectra of benzophenone 13 and naphthalen-2-yl(phenyl)methanone 114, highlighting 
absorbance at λ = 340 – 360 nm. c = 5 × 10-4 M. 
This naphthalenylphenylmethanone 114 had a very much increased intensity of 
absorbance at 355 nm. With this in mind, the six step synthesis of a naphthalenyl 
gabazine analogue 115 was undertaken. An electrophilic aromatic addition of 
napthalene to 4-methylbenzoic acid gave ketone 116 in 23% yield. This was then 
brominated to give 117 and underwent an ether synthesis with phenol 31 to give 
pyridazine 118. This was then subjected to N-alkylation, giving allyl ester 119 and the 
resulting ester was hydrolysed to give naphthalene analogue 115 in an overall, 
unoptimised yield of 10% over five steps (Scheme 40). 
-0.2
0
0.2
0.4
0.6
0.8
1
250 300 350 400 450 500
A
b
s
o
rb
a
n
c
e
 /
 a
u
λ / nm
Testing alternative photoaffinity labels   Chapter 3: Results and Discussion 
 
73 
 
Scheme 40: Synthesis of napthalenyl photoaffinity label 115 for the GABAA receptor. 
However, once made, the UV spectra of the naphthalene analogue 115 and 
benzophenone photoaffinity label 30 turned out to be similar, with absorbance at 
350 nm being slightly stronger for the original benzophenone analogue 39 (Figure 38).  
 
Figure 38: UV absorbance spectra of gabazine based antagonists, 39 and 115; c = 2.0 × 10-4 M. 
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This result, along with the increased hydrophobicity of analogue 115, leading to its 
insolubility in polar solvents, meant that it became a non-viable alternative to 
benzophenone gabazine analogue 39. 
3.2 Testing potential photoaffinity labels 
The completion of an analogue synthesis was the impetus for the development of an 
assay to test the H-abstraction ability of other potential photoaffinity labels. The H-
abstraction reaction by benzophenone is widely known, and could be used as a 
standard to compare the potential of other photoaffinity labels. There is evidence that 
an excited benzophenone in a protein environment would preferentially react with a 
methionine residue, even when other abstractable hydrogens are closer,86 and this, 
alongside other literature results, directed our research. 
There are few reports describing testing of new photoaffinity labels, although many 
groups report irradiation in the presence of a hydrogen source. A brief description of 
some known literature techniques are given here to contextualise the direction of our 
efforts. Firstly, the irradiation of benzophenone in the presence of 2-propanol is well 
documented, and indeed is a popular undergraduate practical experiment.87  
Secondly, in order to test the reactivity of heterobifunctional benzophenone 120, it 
was irradiated in the presence of a ‘protein mimicking’ solvent, namely N-
methylpropionamide, to arrive at pH-dependent cleavable protein crosslinker 121 
(Scheme 41).88 
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Scheme 41: Testing photoaffinity label in ‘protein mimicking’ solvent, N-methylpropionamide. 
Another way to mimic protein conditions to test for H-abstraction ability is to irradiate 
in the presence of a small peptide as shown for the case of 3-(4-benzoylphenyl)alanine 
(Bpa 122), a popular probe for photoaffinity labelling. Good results were obtained 
when Bpa 122 was irradiated in the presence of a hexapeptide, which showed that 
excited benzophenone reacted preferentially with Gly α-, Met γ- and Met ε- 
hydrogens.89 The photoreactivity of a partially constrained analogue of Bpa, 123, was 
probed using dipeptide Boc-Met-Aib-OMe 124, a reaction which yielded photoadduct 
125, as seen by 1H NMR spectroscopy and ESI-ToF mass spectrometry (Scheme 42).90 
 
Scheme 42: Testing photoaffinity label 123 with methionine-containing dipeptide 124. 
From this short literature review, it was envisaged that an assay could be developed in 
which potential photoaffinity labels could be irradiated in the presence of a protected 
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methionine or glycine amino acid. The syntheses of these protected amino acids 126 
and 127 were then undertaken following well known protocols in excellent yields 
(Scheme 43). 
 
Scheme 43: Synthesis of protected methionine and glycine. 
An irradiation procedure was devised in which the potential photoaffinity label was 
mixed with the amino acids in degassed acetonitrile in a photoreactor immersion well. 
Irradiation of benzophenone with a 125 W medium power mercury lamp as a control 
led to the formation of benzopinacol 128 and benzopinacolone 129 homoaddition and 
rearrangement products in good yield (Figure 39). 
 
Figure 39: Benzopinacol 128 and benzopinacolone 129. 
In addition, irradiation of benzophenone in the presence of Boc-Met-OMe 126 
produced a mixture of products, the formation of which were traced by 1H NMR 
spectroscopy (Figure 40). Typical isolated yields for this reaction after 100 min 
irradiation are shown in Scheme 44. 
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Scheme 44: Product distribution from irradiation of benzophenone 13 with methionine 125. 
 
Figure 40: 1H NMR spectroscopic analysis of benzophenone 13 irradiation with methionine 125. 
The formation of photoadducts 130 and 131 seemed to require at least 20 minutes of 
irradiation, and disappearance of all benzophenone starting material takes at least 5.5 
hours (330 minutes). Although this is not the time scale upon which cross-linking in 
cells seems to occur,46,28 this assay still shows which photoadducts are likely formed 
upon irradiation. In this case it is the diastereomeric γ-adduct 131, alongside the ε-
adduct 130 and a complex mixture containing benzopinacol 128 and benzopinacolone 
129. 
Chemical shift / ppm 
N
o
rm
a
lis
e
d
 i
n
te
n
s
it
y
 
330 min 
150 min 
100 min 
80 min 
40 min 
20 min 
0 min 
Testing alternative photoaffinity labels   Chapter 3: Results and Discussion 
 
78 
 
Irradiation of benzophenone in the presence of Boc-Gly-OMe 127 forms an α-glycine 
adduct 132, isolated in 13% yield after a 100 minute irradiation. Again, the majority 
of the material was isolated as a mixture of aromatic byproducts (Scheme 45). 
Photoadduct 132, was thought to be unstable, undergoing a retro-aldol reaction under 
the reaction conditions, and indeed upon stirring 132 in water and acetonitrile, 
benzophenone was recovered after extraction in organic solvent. 
 
Scheme 45: Irradiation of benzophenone 13 in the presence of glycine 126. 
An irradiation time of 100 minutes in degassed acetonitrile was chosen as an assay to 
test the efficacy of a photoaffinity label to abstract a hydrogen from a methionine 
residue. The results are given as a ratio between remaining amino acid 125 and 
requisite major photoadduct 133, which should give an indication of H-abstraction 
ability by 1H NMR analysis (Scheme 46). Other aromatic degradation pathways 
proved difficult to quantify. The potential photoactive groups, alongside UV spectra 
highlighting a relevant λmax and molar extinction co-efficient (ε), are reported in Table 
2 alongside their assay results. 
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Scheme 46: General assay for determining H-abstraction ability. 
Photoactive group 
(R) 
UV spectra 
Assay result 
126 : 133 
 
 
 
 
1 : 0.4 
 
 
  
 
1 : 0.2 
 
 
 
 
 
1: 0 
-0.2
0
0.2
0.4
0.6
0.8
1
200 300 400 500
λ / nm
-0.2
0
0.2
0.4
0.6
0.8
1
200 300 400 500
λ / nm
-0.2
0
0.2
0.4
0.6
0.8
1
200 300 400 500
λ / nm
c = 5 ×10-4 M 
ε(333 nm) = 170 M-1cm-1 
c = 5 ×10-4 M 
ε(254 nm) = 290 M-1cm-1 
 
c = 5 ×10-4 M 
ε(273 nm) = 9360 M-1cm-1 
 
Testing alternative photoaffinity labels   Chapter 3: Results and Discussion 
 
80 
 
 
 
 
 
1 : 0 
 
 
 
 
 
1 : 0.3 
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Table 2: UV spectra and [unreacted methionine 91: requisite photoadduct 96] ratio after 100 min 
irradiation; R group shown in blue. 
The assay also gave negative results for acetophenone 136, succinimide 137, 
phthalimide 138, benzil 139 and benzophenone imine 140: no photoadducts were 
observed (Figure 41). 
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Figure 41: Other potential photoaffinity labels which showed no H-abstraction under irradiation 
conditions. 
This led to the result that only benzophenone 13, methoxy- and dioxole- substituted 
benzophenones 112 and 134 were able to undergo H–abstraction from methionine 91. 
Of these, the benzophenone 13 remained the most successful, with an unreacted 
methionine 125 : photoadduct 132 ratio of 1.0 : 0.4. 
3.3 Conclusions 
This chapter describes a method to compare potential photoaffinity labels, by 
irradiating them in an assay containing a methionine or glycine amino acid. The 
products of this irradiation were analysed by 1H NMR spectroscopy, in an attempt to 
quantify the ability of a compound to undergo H-abstraction reactions to estimate its 
potential as a photoaffinity label in a protein binding site. 
Despite this largely negative result for H-abstraction in this chapter, the list of potential 
photoaffinity labels tested was by no means exhaustive, and a method to 
experimentally test the ability of a chromophore to undergo photochemical reactions 
remains an interesting and understudied area of research. 
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Chapter 4 
Photocleavable antagonists for the GABAA receptor 
4.1 Photocleavable antagonists for the GABAA receptor 
It is known that the conformation of the receptor affects how it interacts with 
scaffolding proteins, and how it moves in the membrane.10 The differences in lateral 
dynamics between blocked and unblocked receptors is an understudied area, and the 
photoaffinity probe described in Chapter 2 will necessarily only give information 
about blocked receptors. It became apparent that an imaging tool for unblocked 
receptors, conducted with our useful gabazine analogue, would have to include a 
method to cleave off the gabazine fragment, leaving the binding site unblocked, but 
the fluorescent probe still attached. The dynamics of these unblocked receptors could 
be compared to those which were followed whilst blocked, for example with previous 
probe 106 {Scheme 36, Chapter 2}. A gabazine moiety will bring the compound into 
the binding site, and the covalent attachment onto the acrylamide would be accelerated 
by the proximity of a nucleophilic residue. Irradiation of the receptor-probe construct 
would release the gabazine moiety, which would diffuse out of the binding site, 
leaving a tagged receptor with an open GABA binding site (Figure 42). 
 
Figure 42: General mechanism of action for a photocleavable-affinity ligand. 
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4.2 A modular synthesis approach to a photocleavable antagonist for the GABAA 
receptor 
In this task, the development of a different, modular approach to the synthesis was 
deemed beneficial. This ‘building blocks’ method would include the addition of a 
complete gabazine fragment directly onto the rest of the structure in the last stages, 
allowing for a faster turnover in a screen of linker length and photocaging moiety. It 
would remove the need for allyl ester hydrolysis in the presence of the photolabile 
ester, and, furthermore, a modular approach would allow the capricious N-alkylation 
reaction to be undertaken earlier in the synthesis on simpler, reliable substrates. 
There were many different alternatives for the precise structure of this complete 
gabazine fragment. Alkyne derivative 141, which had previously been synthesised in 
the group and shown to have an IC50 value on HEK293 GABAA receptors of 40 nM, 
alongside azide analogue 38, also previously synthesised as a photoaffinity label with 
an IC50 of 28 nM,
30 were chosen (Figure 43). These both could conceivably be joined 
to the rest of the molecule at a late stage in the synthesis via a copper catalysed alkyne-
azide click reaction.91 
 
Figure 43: “Clickable” gabazine fragments. 
The first step of the synthesis of alkyne 141, the Williamson ether synthesis between 
pyridazinyl phenol 31 and propargyl bromide, was attempted. This initially yielded 
the desired product 142 in 16% yield, with a further 6% starting material isolated. Also 
isolated from this reaction were imidazo[1,2-b]pyridazine compounds 143 and 144 as 
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byproducts (Scheme 47). This is an interesting and novel mode of reactivity, and was 
subject to a slight further investigation. 
    
Scheme 47: Product distribution in ether synthesis. 
It was hypothesised that in the absence of a fully deprotonated alkoxide anion, the 
pyridazine N(2) reacted with propargyl bromide and the resulting compound forms an 
imidazo[1,2-b]pyridazine compound in the presence of sodium hydride. This is similar 
to the reported reactivity of N(2)-propargyl pyridin-2-amines, such as 145, which are 
known to cyclise upon treatment with base, forming imidazopyridine 3-isomer 146 
(Scheme 48). Reported 1H NMR reaction studies on this reaction suggested the 
intermediate formation of an allene promoted by the potassium tert butoxide as the 
first mechanistic step.92 
 
Scheme 48: Formation of imidazo[1,2]pyridines.92 
In order to establish the likely regioselectivity of our byproducts and investigate this 
novel mode of reaction further, N(2)-alkylated pyridazine 147 was synthesised in 80% 
yield upon reaction of propargyl bromide on 6-phenylpyridazin-3-amine 148 (Scheme 
49). Treatment of the N(2)-alkylated product 148 with sodium hydride lead to 
Photocleavable antagonists for the GABAA receptor   Chapter 4: Results and Discussion 
 
 
85 
 
complete conversion to imidazopyridazine 149 via TLC, with product isolation in 69% 
yield (Scheme 49). 
  
Scheme 49: Investigating a novel reaction to form methyl imidazo[1,2-b]pyridazine 149. 
The regiochemistry of this compound 149 was assigned through 1H and 13C NMR 
spectroscopic comparison with the product of a condensation of 6-phenylpyridazin-3-
amines with chloroacetone, which is known to give the 2-isomer according to literature 
precedent (Scheme 50).93 
 
Scheme 50: Chloroacetone condensation reaction conditions. 
In order to suppress the formation of these imidazo[1,2-b]pyridazine byproducts in our 
synthesis, phenol 31 was treated with sodium hydride to form the alkoxide ion for an 
additional hour, and the equivalents of propargyl bromide were lowered from 1.2 
equivalents to 1.0. This slightly optimised procedure yielded desired product 142 in 
34% yield (Scheme 51). 
 
Scheme 51: Ether synthesis reaction conditions. 
N-Alkylation of alkyne 142 proceeded in 67% yield, and subsequent deprotection of 
the allyl ester 150 was achieved quantitatively (Scheme 52). 
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Scheme 52: N-Alkylation and ester deprotection reaction conditions. 
An alkyne-azide click reaction was performed between alkyne-gabazine fragment 141 
and Boc-protected amine azide PEG unit 151, in a model system, and triazole 152 was 
generated in 29% yield (Scheme 53). 
 
Scheme 53: Model click reaction conditions. 
This triazole 152 was tested for potency as an antagonist for GABAA receptors 
transiently expressed in HEK293 cells, by Dr Martin Mortensen in the Smart group. 
It has an IC50 value of 435 nM, which is comparable to the value for gabazine 4 itself. 
Moreover, triazole 152 does not exhibit any non-competitive antagonism, which had 
been shown with other triazoles in the literature.94 This was an encouraging result in 
the search for a versatile gabazine ‘block’ from which to develop highly functionalised 
molecules. 
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Meanwhile, the synthesis of the azide analogue 38 was attempted, with less success. 
Benzylbromide 35 was synthesised in two steps from p-toluidine in 76% overall yield 
(Scheme 54). 
 
Scheme 54: Construction of azide fragment. 
This benzyl bromide 35 was then introduced onto the pyridazine skeleton in a 
Williamson ether synthesis to form compound 36 in a 51% yield (Scheme 55). 
 
Scheme 55: Ether synthesis reaction conditions. 
Application of previously used N-alkylation conditions, yielded 37, which was 
isolated upon recrystallisation from a mixture of starting material and product, in a 
disappointing 4% yield (Scheme 56). The returned starting material was reapplied to 
the reaction conditions, at an elevated temperature of 80 ºC, but this led to the 
degradation of the compound. In addition the attempted ester deprotection of the N-
alkylated species 37 led to a complex mixture of degradation products, potentially via 
reactions involving the azide, or cleavage of the benzyl ether previously seen in the 
group.28,95 
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Scheme 56: N-alkylation and ester deprotection reaction conditions. 
This result led to the progression of the alkyne gabazine fragment 141, over the azide 
variant 39, in the development of a modular, adaptable synthesis for further tools to 
study the GABAA receptor. 
4.3 Development of a photocleavable antagonist for the GABAA receptor 
A modular, retrosynthetic pathway to the first tethered photocleavable affinity probe 
for the GABAA receptor was devised. A probe, such as that described in Figure 42, 
has a vast array of functionality. In order to test for retained potency of the analogue, 
to discover the efficacy of photouncaging, as well as to test a new modular synthetic 
ethos, a simpler structure 153 was designed and synthesised. In this structure the 
attachment of the fluorescent probe was left out. The synthesis of this simpler model 
system involved a photocaging fragment 154 (synthesised from commercially 
available hydroxyethylphotolinker 155), an acrylamide with a carboxylic acid moiety 
156, and installation of an azide via an azide – amine OEG chain 157 (Scheme 57).  
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Scheme 57: Retrosynthetic analysis of photocleavable affinity ligand 153, initially without a 
fluorescent probe attachment. 
Firstly the amine OEG chain 157 underwent HBTU amide bond formation on the acid 
functionality of the hydroxyethyl photolinker 155 to give fragment 158 in 86% yield, 
and the acrylamide acid fragment 156 was synthesised from 6-aminohexanoic acid 
and acryloyl chloride in 36% yield (Scheme 58). 
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Scheme 58: Synthesis of photocaging fragment 158 and electrophile fragment 156. 
The installation of the photolabile ester was facilitated by an EDC coupling between 
hydroxyethylphotolinker fragment 158 and carboxylic acid 156, which proceeded in 
75% yield (Scheme 59). 
 
Scheme 59: Completion of the photocleavable affinity fragment 154. 
Initial attempts at the alkyne-azide click reaction following the previous protocol 
(Scheme 50) were unsuccessful. However, a low but sufficient yield of 18% desired 
product 153 was achieved through optimising the procedure, which involved a higher 
catalyst loading, a higher temperature of 50 ºC and the addition of THPTA96 as a ligand 
to stabilise the copper (I) species formed in situ (Scheme 60). 
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Scheme 60: Copper catalysed azide-alkyne click reaction to form photocleavable affinity probe 153. 
In proximity-accelerated electrophilic attachment, a covalent bond is formed between 
the ligand and the receptor via a nucleophilic residue from, in this case, an unknown 
location near the binding site. With the exact location unknown, it seemed prudent to 
vary the length of linker between the photocaging group and the acrylamide in a 
second compound. This was achieved with the substitution of the hexanoic acid linker, 
which provided a ten atom bridge between the photolabile carbonyl carbon and the 
electrophilic terminal carbon, with a longer ethylene glycol chain, providing a bridge 
of sixteen atoms. 
The ethylene glycol linker for this second variant was synthesised from commercially 
available tert butyl-12-amino-4,7,10-trioxadodecanoate, which underwent addition to 
acryloyl chloride yielding 159 followed by tert-butyl ester hydrolysis to give 160 in 
83% overall yield (Scheme 61). 
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Scheme 61: Preparation of longer linker fragment. 
Acrylamide 160 was then reacted in an EDC coupling reaction with azide 158 to give 
161 in 33% yield (Scheme 62). 
 
Scheme 62: Completion of a photocleavable affinity ligand with a longer linker. 
This was then reacted in a copper catalysed alkyne-azide click reaction with alkyne-
gabazine, to form the second variant 162 in 24% yield, to be used alongside the initial 
variant 153 in electrophilic tagging of the GABAA receptors (Scheme 63). 
 
Scheme 63: Copper catalysed azide-alkyne click reaction conditions. 
 
Photocleavable antagonists for the GABAA receptor   Chapter 4: Results and Discussion 
 
 
93 
 
4.4 Conclusions 
These chemical tools 153 and 162 are currently undergoing biological testing by Dr 
Martin Mortensen in the Smart group, and will firstly be analysed in the dark for 
potency against recombinant GABAA receptors. Any covalent attachment will be 
apparent as antagonism which persists even after flushing of the cells with buffer 
solution. UV irradiation and further washing will be able to demonstrate the release of 
gabazine from the binding site as a drop in receptor inhibition i.e. reappearance of a 
GABA response (Figure 44). 
 
Figure 44: General mechanism for the action of affinity antagonists 153 and 162. 
Once GABAA receptor specificity and covalent attachment is proven, and the efficacy 
of the photocaging motif is established, the next stage would be the tracking of 
receptors. This would require an additional functionality – a fluorescent probe, 
incorporated near the electrophile. Potentially this could be a streptavidin coated 
quantum dot (associated, as in the previous chapter, via a biotin moiety). This future 
construct would be able to track these unblocked receptors in a vital comparison of 
conformation-dependent receptor dynamics.  
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Chapter 5 
Photoswitchable antagonists for the GABAA receptor 
5.1 Photoswitchable antagonists for the GABAA receptor 
The small molecular probes reported in Chapters 2 and 4 provide unique functionality 
to track GABAA receptors as they move in the membrane, adapting to chemical and 
electrical signals. All previous constructs rely on a light-induced irreversible change. 
This next chapter describes the design and synthesis of a photoswitchable antagonist, 
one which continues to change shape in alternating wavelengths of light. By being 
able to turn functionality of the receptors on and off reversibly, additional information 
will be afforded about how the conformation of the receptor affects its movement. In 
another application it also allows the activation of receptors under a defined spot of 
UV irradiation, compared to previous photoaffinity labels deactivating the receptors. 
This activation can be quantified and so can help build a picture of which areas on the 
cell contain the most GABAA receptors (Figure 45). 
 
Figure 45: Use of photoswitching ligand and UV spot light to block and then unblock receptors at 
different points on the neurons. 
The process for designing both tethered and non-tethered photoswitching compounds 
for GABAA receptors has been described and encouraged in the literature.
97 The 
development of such compounds is often reported as beginning with an evaluation of 
ligands for their potential to include a photoswitching group. It is necessary that this 
group does not alter the specificity of a ligand for the target, and instead confers a 
Photoswitchable antagonists for the GABAA receptor  Chapter 5: Results and Discussion 
 
95 
 
‘switch’ at a position likely to modulate binding efficacy. A rational introduction of 
an azobenzene photoswitch would be, for example, in place of a similarly-shaped 
moiety already present in the ligand. Such “azosters” could include stilbenes, 1,2-
diphenyl ethanes, 1,2-diphenyl hydrazines, N-benzyl anilines, benzyl-phenyl ethers, 
benzyl-phenyl thioethers, diaryl esters and diaryl amides.98 
Following this rationale, “azologization” of one antagonist to the GABAA receptor, 
the benzyl analogue of gabazine 26, previously made in the group and shown to have 
a greatly increased potency to gabazine itself,30 could result in an azogabazine 
synthetic target 156, whereby an azobenzene moiety replaces a benzyl-phenyl ether in 
a position where receptor-ligand interactions are important for potency (Figure 46). 
 
Figure 46: “Azologization” of benzyl gabazine analogue 28. 
This azo-gabazine could allow for the photomodulation of GABAA receptors, which 
would mean that a short burst of UV or indeed visible light could produce reversible 
antagonism of the receptors in recombinant cells or in a primary culture. This would 
lead to spatial and temporal control of receptors, giving valuable information on the 
effect of antagonism in different areas of a neuron. 
5.2 Synthesis of azo-gabazine 
A retrosynthetic analysis of azo-gabazine 163 leads, via our previous N-alkylation 
strategy to Suzuki coupling product 164, potentially formed from commercially 
available 3-chloro-2-aminopyridazine 33, and azobenzene boronic acid 165 
(Scheme 64). 
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Scheme 64: Retrosynthetic analysis of azogabazine derivative 163. 
Firstly, the synthesis of azobenzene fragment 165 was attempted, for which 4-
iodoaniline was refluxed with nitrosobenzene in glacial acetic acid for 24 h to yield 4-
iodo-azobenzene 166 in an excellent yield (Scheme 65). 
 
Scheme 65: Condensation reaction conditions to form azobenzene 166. 
A boronylation reaction was then attempted, firstly by heating 166 with pinacolborane 
and Pd2(PPh3)2Cl2 in triethylamine and toluene for 2 h. However, this only resulted in 
a 17% yield of azobenzene pinacol borane 167, with the hydrazine 168 and homodimer 
162 side products formed in 58 and 4% yield respectively (Scheme 66). Further 
attempts using bis(pinacolato)diboron were also low yielding. 
 
Scheme 66: Product distribution of pinacolboronate installation reaction conditions. 
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A synthetic route which involved the pre-installation of the pinacolborane was then 
undertaken, with more success. 4-Iodoaniline was heated to 90 °C in the presence of 
caesium carbonate and bis-(pinacolato)diboron, and yielded 4-aminophenylboronic 
acid pinacol ester 170 in 48% yield. This product then underwent condensation with 
nitrosobenzene to yield the desired azobenzene-boronic acid pinacol ester 167 in 27% 
yield (Scheme 67). The low yield of the latter reaction was attributed to difficulty in 
purification using column chromatography; the collection of the clean material was 
prohibitively slow. 
  
Scheme 67: Formation of pinacol boronate azobenzene 167. 
A trifluoroborate salt of this azobenzene had been reported to undergo Suzuki 
couplings directly on a variety of substrates with [bis(diphenylphosphino)ferrocene]-
palladium dichloride catalyst.99 The conversion of pinacolborane 167 to the 
corresponding trifluoroborate salt 171 was facilitated with potassium hydrogen 
fluoride in good yield. The synthesis of this complete azobenzene fragment 171 was 
further optimised by omitting the purification of azobenzene-boronic acid pinacol 
ester 167, and taking forward the crude mixture to form the trifluoroborate salt in 53% 
overall yield from 4-aminophenylboronic acid pinacol ester 170 (Figure 68). The 
procedure was developed as follows: petroleum ether was added to the crude product 
of the condensation reaction, and the suspension was filtered. The filtrate was then 
concentrated in vacuo, redissolved in acetonitrile and water (10:1 ratio), and three 
equivalents of potassium hydrogen fluoride were added. The reaction mixture was 
stirred at room temperature for 2.5 h, before being quenched with saturated sodium 
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hydrogen carbonate solution. The solvent was removed in vacuo and triturated with 
petroleum ether and the product purified by recrystallisation from acetone. 
Scheme 68: Optimised reaction conditions for the formation of trifluoroborate salt 171. 
The use of 171 in the subsequent Suzuki coupling under literature conditions 
unfortunately gave a poor result; the pyridazine product was produced in a low 38% 
yield (Scheme 69). 
 
Scheme 69: Suzuki reaction conditions. 
R X Conditions Yield of 164 
BF3K Cl 
PdCl2(dppf) 
K2CO3, MeOH, 70 °C, 2 h. 
38% 
B(OH)2 Cl 
PdCl2(dppf) 
K2CO3, MeOH, 70 °C, >16 h. 
0% 
BF3K I 
PdCl2(dppf) 
K2CO3, MeOH, 70 °C, >16 h. 
0% 
BF3K Cl 
Pd(PPh3)2Cl2, MeCN, H2O, μW 120 
°C, 10 min. 
37% 
Table 3: Azobenzene Suzuki reaction conditions. 
In order to optimise this Suzuki reaction, the boronic acid 165 was formed from the 
trifluoroborate salt 171 upon reaction with iron trichloride in 66% yield (Scheme 70). 
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The boronic acid was also formed in 58% yield upon reaction of pinacolborane 167 
with saturated aqueous ammonium chloride (Scheme 66). 
 
Scheme 70: Hydrolysis of trifluoroborate salt 171 and boron pinacol ester 167 yield boronic acid 165. 
However, when reacted under the stated Suzuki conditions, no product formation was 
detected. In a second strategy, iodo-pyridazine 172 was synthesised from the reaction 
of 3-amino-6-chloropyridazine 33 with hydrogen iodide in reasonable yield (Scheme 
71); however this also proved unsuccessful at forming the desired product under 
various Suzuki reaction conditions (Scheme 69). 
 
Scheme 71: Halogen exchange reaction of pyridazine fragment. 
Finally it was a return to our previous Suzuki conditions involving microwave 
irradiation in the presence of Pd(PPh3)2Cl2, which allowed us to improve on the 
reaction time for this reaction, if not the product yield (Table 3). 
The Suzuki product 164 was then N-alkylated under conditions reported vide supra, 
to yield 173 in 73% yield, which was subsequently deprotected to give acid 163 in 
80% yield (Scheme 72). 
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Scheme 72: Endgame in the synthesis of azo-gabazine 156. 
This gives the azo-gabazine 163 compound in four steps and 12% overall yield from 
aminophenylboronic pinacol ester 170. 
5.3 Investigation of photoswitching ability by UV/Vis and NMR spectroscopy 
In order to characterise the photoisomerisation of azobenzene 163 (Figure 47), firstly 
UV/Vis and 1H NMR spectroscopic analysis was carried out. 
 
Figure 47: Photoisomerisation of azo-gabazine 163. 
A UV spectrum of the thermodynamic mixture was taken, which showed characteristic 
peaks for a trans azobenzene-containing compound (Figure 48).100 These include a 
large absorbance with λmax of 342 nm describing a π,π* transition. After 30 seconds of 
irradiation from a hand-held torch containing LEDs of 365 nm wavelength placed on 
top of the cuvette, a further UV spectrum was taken immediately. This was now 
characteristic of a cis azobenzene-containing compound, with an increase in 
absorbance at 435 nm, describing an n,π* transition (Figure 48). The cuvette was left 
in the dark for a further twelve minutes, with UV spectra taken every four minutes. 
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The UV spectra of these were identical to the spectrum acquired immediately after 
irradiation. 
 
Figure 48: UV/Vis spectrum of azo-gabazine 163 pre- and post- irradiation; c = 5.5 ×10-5 moldm-3. 
Secondly, for 1H NMR analysis, a solution of 163 (10 mM in DMSO-d6) was diluted 
ten-fold with deuterium oxide, to give a clear yellow 1 mM solution, which was 
ascertained to be the minimum concentration necessary to allow for defined 600 MHz 
1H NMR signals for the minor isomer. In order to crudely replicate the set-up of 
electrophysiology experiments and to achieve effective sample irradiation, an LED 
was clamped just above a 0.7 mL droplet of the 1 mM solution as it rested on a square 
of laboratory film. After irradiation the sample was transferred via syringe to an NMR 
tube, which was then placed onto the carousel and loaded into the NMR machine by 
the automaton. In general the NMR tube was in ambient light for around 20 seconds 
before reaching the darkness inside the instrument, and a complete spectrum was 
obtained in around 4 minutes. 
By comparing integration for non-overlapping 1H NMR signals for each isomer a 
trans : cis ratio was calculated. It became clear that the trans : cis resting point in 
ambient light was solvent dependent, and that it could take up to 1 h for this ratio to 
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equilibrate. The isolated material, previously concentrated in vacuo from methanol, 
formed a 92:8 ratio initially in DMSO-d6, but this relaxed to 75:25 under ambient light 
in less than an hour. Addition of sodium chloride to the sample did not change the 
trans : cis ratio. 
Five different LEDs were used, with wavelengths of 365, 405, 470, 530 and 565 nm 
and the percentage of cis isomer was ascertained after 2, 10, 60 and 300 seconds of 
irradiation (Figure 49).  
 
Figure 49: Graph showing percentage cis isomer after t seconds of irradiation with LEDs with 
different wavelengths. NR: non radiated sample. 
Pleasingly after just two seconds of irradiation with the 365 nm LED, a large 
percentage of cis isomer was obtained, and an 80% cis enriched photostationary point 
was reached in under 60 seconds. This was illustrated clearly in the 1H NMR analysis 
of the aromatic region of the spectra (Figure 50). 
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Figure 50: 1H NMR spectroscopic analysis of aromatic region of 163 spectrum showing signals 
arising from formation of majority cis-163 photostationary state from a trans-rich mixture, upon 
irradiation with 365 nm light for 60 s. 
Disconcertingly at first, none of the other LEDs appeared to change the ratio at all, 
and indeed it appeared that two seconds of irradiation decreased the percentage of cis 
isomer more than a longer irradiation time for 470, 530 and 565 nm LEDs (Figure 47). 
This was due to the fact that the time spent in ambient light, though only seconds, was 
deemed enough to convert the mixture to its ambient cis : trans resting ratio of around 
25:75 in DMSO:H2O. Greater conversion to trans isomer (99%) was seen when 
additional steps were taken to ensure that the sample was in ambient light for less than 
two seconds, with the removal of a shield for the NMR tube removed moments before 
it was entered into the NMR machine. This was also true when applied after UV light 
irradiation, with the cis isomer reaching 91% after 60 s of illumination. This is in line 
with current literature protocols, which suggests constant illumination during 
spectrum acquisition.101 Unfortunately, equipment limitations meant this was 
unfeasible for us at this time. 
In order to observe thermal relaxation from cis-163 to trans-163, a UV irradiated and 
a sample that had equilibrated at an 80:20 ratio in ambient light were placed in 
darkness, with a 1H NMR taken after 0.5, 1.5, 6 and 24 hours (Figure 51). The thermal 
relaxation for both was observable, but slow. In contrast, relaxation of a UV irradiated 
Chemical shift / ppm 
Cis-163 
Trans-163 
Pre-irradiation 
60 s 365 nm 
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sample to the ambient photostationary state, if left in ambient light, took only six 
hours. 
 
Figure 51: Relaxation of cis isomer to trans isomer in dark conditions over time after 60 s 365 nm 
irradiation. 
A 1H NMR spectrum of both samples after ten days in the dark showed a decrease in 
cis isomer from 95 to 46% in the irradiated sample, and from 25 to 0% cis in the non-
irradiated sample. After fourteen days kept in the dark, the irradiated sample had also 
converted to 99% the thermodynamic trans isomer. 
These UV/Vis and 1H NMR spectroscopy results combine to show that azo-gabazine 
163 does undergo robust photoswitching with these LEDs, and provides a foundation 
for biological testing experiments. 
5.4 Biological evaluation and azo-gabazine photoswitching in cells 
With the knowledge that cis and trans isomerisation could be efficiently induced with 
our LEDs, the compound was taken onto a biological system, and tested for potency 
on α1β2γ2 GABAA receptors expressed in HEK293 cells (Figure 52). Work by Dr 
Martin Mortensen in the Smart group showed azo-gabazine 163 to be a very potent 
antagonist for the receptor, with an IC50 of 12.2 nM at ambient light; similar to the 
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benzoxy gabazine analogue 28 (IC50 = 11 nM), and also over ten times more potent 
than gabazine 4. 
 
Figure 52: Dose response curve for azo-gabazine 163, giving an IC50 of 12.2 nM. 
Experiments to investigate the antagonist properties of azo-gabazine 163 under 
different wavelengths of light were carried out by Dr Martin Mortensen, firstly in 
synaptic GABAA receptors comprised of α1β2γ2S subunits expressed in HEK293 
cells. Azo-gabazine was applied to the cell along with GABA, and the current across 
the membrane was measured by whole cell patch clamping. Application of 365 nm 
light elicits a large GABA response suggesting the cis isomer is a less potent 
antagonist, and azo-gabazine in this conformation allows more GABA into the binding 
site to activate the receptor. However, it also appears in the first instance that 
irradiation with 470 nm light elicits a lesser response, but in the same direction. This 
could suggest that the act of switching cis to trans also frees the binding site 
momentarily to allow an influx of GABA and consequently hyperpolarises the 
membrane (Figure 53).  
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Figure 53 Whole cell patch clamp recordings of GABAA receptors expressed in HEK293 cells and 
tested with cis- and trans-163.102 
It was shown that azo-gabazine 163 could indeed be used as a photoswitch, to activate 
these expressed GABAA receptors in cycles when alternately irradiated with 470nm 
light and 365 nm light, shown as blue and purple bars respectively in Figure 54. 
 
Figure 54: Photoswitching in three different GABAA receptors expressed in HEK293 cells.
102
 
Kreb’s solution 
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1000 pA 
10 µM GABA 
1 µM azo-gabazine 
10 µM GABA 
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10 µM GABA + 1 µM azo-gabazine 
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With these experiments demonstrating that alternating between 470 nm and 365 nm 
light produces cycles of GABA receptor activation, azo-gabazine was taken onto 
cerebellar granule cells. These were treated with CNQX and AP5 to block excitatory 
post synaptic currents, and underwent whole cell patch clamp recording. Spontaneous 
inhibitory post synaptic currents (sIPSCs) were apparent, arising from the action of 
endogenous GABA on the receptors, but these were inhibited upon perfusion with the 
azo-gabazine antagonist 163, including in the presence of 470 nm light – as expected. 
Irradiation with 365 nm light restored the sIPSCs. Once the perfusion was stopped, 
sIPSCs were reinstated (Figure 55). 
 
Figure 55: Photoswitchable GABAA receptors in cerebellar granule cells. 
Currently further work in the Smart group is ongoing to include spatial control of 
photoswitching, by irradiating a neuron at different points, for example on the soma 
or along the dendrites. Any differences in intensity of the sIPSCs during UV 
irradiation between the two areas could give valuable information about the 
distribution of GABAA receptors, and how each area recovers from receptor blockage. 
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5.5 Conclusions 
This chapter describes how the replacement of a benzylphenyl ether with an 
azobenzene moiety in a potent GABAA receptor antagonist created a photoswitchable 
ligand for the GABAA receptor. This promising ligand was used to reversibly unblock 
GABAA receptors in recombinant cells as well as live neurons. Azo-gabazine 163 is 
currently undergoing further experiments in cells, which will demonstrate the power 
of being able to switch on neuronal inhibition with spatial and temporal control. 
 
 
 
 
 109 
 
Conclusions 
This thesis has shown the development of a range of small molecule chemical probes 
to elucidate the mechanisms of GABAA receptor movement. Quantum dots were 
photocrosslinked to GABAA receptors, via a highly functionalised small molecule. 
These constructs were followed as they moved in the membrane of live neuronal cells 
(Figure 56). This revealed free diffusion of GABAA receptors in extrasynaptic sites, 
and more constrained movement of GABAA receptors in the synaptic cleft. 
 
Figure 56: A photoaffinity labelled probe for the GABAA receptor 
An assay was developed and tested for a small number of potential aryl ketone 
photoaffinity labels. The products of an irradiation of benzophenone in the presence 
of amino acids were isolated and analysed. An unreliable link between UV spectrum 
absorbance and H-abstraction ability was highlighted, as even after the assay, 
benzophenone remained the front runner in ability to form photoadducts. 
A photocleavable chemical probe was also designed, in order to track unblocked 
GABAA receptors in live cells. To this end a modular synthetic ethos was developed, 
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providing methodology for the rapid turnover of various characteristics required in the 
search for an optimised chemical probe (Figure 57). 
 
Figure 57: Photocleavable antagonist for the GABAA receptor 
This thesis also describes the synthesis of photoswitchable GABAA receptors, through 
the development of an azobenzene molecule with high affinity for the receptor. This 
photoswitching has been shown both in recombinant cells as well as in live neuronal 
cultures (Figure 58). 
 
Figure 58: Photoswitchable antagonist 163 for the GABAA receptor. 
10 µM GABA + 1 µM 156 
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Future work 
Photocleavable fluorescent probes for tracking the GABAA receptor 
A further iteration on the design for a photocleavable antagonist (Chapter 4) could be 
the addition, not only a fluorescent probe to track the receptors, but one which would 
be photoactivatable. Upon irradiation with low intensity 407 nm light, azido-2-
dicyanomethylene-3-cyano-2,5-dihydrofuran (Azido-DCDHF, 174) converts to the 
fluorescent 175 (Figure 59).103,104 This would allow the single-molecule tracking of 
bound, unblocked receptors. Spot photolysis at particular points on the membrane 
would release ligands just from this area, and trigger a fluorescent response just from 
specific populations of GABAA receptors. From this the number of GABAA receptors 
at certain points could be quantified, and the dispersal of the fluorescence would give 
information about how the receptors move. 
 
Figure 59: (i) Azido-DCDHF 174 photoconverts to the fluorescent DCDHF 175; (ii) General 
mechanism showing spatial control of fluorescence in cells. 
“Turn on” fluorescent affinity labels for the GABAA receptor 
Another method to label and track receptors, could be to use the affinity properties of 
the ligand itself to ‘turn on’ fluorescence. Yamaguchi et al. describe the synthesis of 
an small bifunctional chemical probe, bearing a ligand bound to a non-fluorescent O-
Future work 
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nitrobenzoxadiazole unit 176. Upon ligand-target interaction, a nearby lysine residue 
irreversibly binds, forming a fluorescent monoalkylamino-nitrobenzoxadiazole 
species 177 and releasing the ligand from the binding site (Figure 60). 
 
Figure 60: General mechanism for “turn-on” fluorescent affinity labelling. 
It was shown that that, with a biotin ligand and linker lengths of over 11.9 Ȧ, their O-
nitrobenzoxadiazole probe was very selective for the lysine residue, K-111, on avidin, 
even in the presence of lysine-rich bovine serum albumin and a whole cell lysate,  
HL-60, which contains many non-target proteins. The group also synthesised an O-
nitrobenzoxadiazole derivative 178 of N,N-dialkyl-2-phenylindol-3-ylglyoxylamide 
179, which is a recently developed ligand for the translocator protein and peripheral-
type benzodiazepine receptor, TSPO, found in the outer mitochondrial membrane 
(Figure 61). Interestingly here, it was the partner protein of TSPO, a voltage dependent 
anion channel which was labelled, reflecting its relative abundance of available lysine 
residues, and giving the location of the binding site as where these two proteins 
meet.105 
 
Figure 61: Bifunctional probes for turn-on fluorescent labelling. 
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With its focus on generating small, highly functionalised chemical probes to follow 
receptors, an approach such as above has many merits. Any fluorescence of 
monoalkylamino-compounds originates from tagged proteins, from which the ligand 
is displaced. Although this strategy relies somewhat on available lysine residues, a 
correct linker length between ligand and probe can make a compound, such as 180, 
specific to certain GABAA receptors, and even to certain α and β subunits (Figure 62). 
 
Figure 62: Potential affinity probe for the GABAA receptor. 
Future perspectives for tracking the GABAA receptor 
There are many small molecular probes for the GABAA receptor which could be 
envisaged. These, for example, could include chemical probes which themselves 
change as a bound GABAA receptor experiences diffferent stimuli. It could be a probe 
targeting GABAA receptors alongside a complementary probe targeting a different 
protein and could potentially show interactions between the receptor and the 
membrane. 
Photoswitchable ligands show the use of molecular mechanics in controlling 
receptors, and inspiration for future molecular machines could come from the 
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mechanical proteins which exist in the biological GABAA receptor trafficking system: 
transporters, filaments, scaffolding proteins and even organelles. 
Work to discover more about how receptors and membrane proteins work together to 
respond and adapt to chemical and electrical stimuli is still only just beginning. Just 
last year, the first crystal structure of a GABAA receptor was published.
106 This, 
alongside existing homology modelling, can now be used in the design of chemical 
probes, particularly helpful for those which rely upon particular residues for affinity 
labelling. Elucidation of working biological systems is also advancing due to 
progresses being made in imaging, in particular two-photon excitation microscopy. 
The dysfunction of GABA-mediated inhibition is implicated in many diseases, and 
progression in medicinal chemistry will continue to accelerate as GABAA receptor 
trafficking is further understood, and perhaps new proteins are highlighted as drug 
targets.
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General experimental 
All reactions were carried out at atmospheric pressure with stirring unless otherwise 
stated. All reagents and solvents were purchased from suppliers and used without 
further purification unless otherwise stated. N-Bromosuccinimde was recrystallised 
from water prior to use. Photoreactions were carried out in pyrex immersion well 
(Photochemical Reactors Ltd), which was cooled via running water, and irradiated 
with a 125 W, medium pressure mercury lamp (Photochemical Reactors Ltd). All 
reactions were monitored by TLC or 1H NMR as stated. TLC plates pre-coated with 
silica gel 60 F254 on aluminium (Merck KGaA) were used, being visualized by UV 
(254 or 365 nm) or chemical stain (KMnO4, I2, ninhydrin). Normal phase silica gel 
(BDH) was used for flash chromatography and the eluting solvent or solvent gradient 
given. 1H NMR and were recorded at 500 or 600 MHz and 13C NMR spectra were 
recorded at 125 or 150 MHz on a Bruker AMX500 or AMX600-cryoprobe 
respectively, at ambient temperature, unless otherwise stated; all chemical shifts are 
measure in ppm and referenced to the residual proton impurity of the deuterated 
solvent. The multiplicity of the signal is indicated as s (singlet), d (doublet), t (triplet), 
dd (doublet of doublets), dt (doublet of triplets), quint (quintet) or a m (multiplet) 
which is defined as all signals where overlap or complex coupling makes definitive 
descriptions of peaks difficult. All peaks should be taken as sharp unless otherwise 
described. Coupling constants are defined as J given in Hz. For NMR experiments, 
CDCl3 denotes deuterated (d3) chloroform, DMSO denotes deuterated (d6) 
dimethylsulfoxide, and CD3OD denotes deuterated (d4) methanol. Deuterated solvents 
were chosen according to the position of solvent peak in spectra and solubility of 
substrate. High and low resolution mass spectrometry was performed using a VG70 
SE operating in modes CI, EI, ES and FAB. Infrared spectra were obtained on a Perkin 
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Elmer Spectrum 100 ATR FTIR Spectrometer or a Bruker Αlpha Platinum ATR FT-
IR spectrometer. Melting points were measured with a Gallenkamp apparatus and 
given with recrystallisation solvent where appropriate. Room temperature (rt) is 
defined as between 19-22 ºC. In vacuo is used to describe solvent removal by rotary 
evaporation between 20 ºC and 60 ºC, at approximately 10 mmHg unless otherwise 
stated. The term “dried” refers to the process of adding then filtering away solid 
magnesium sulfate or sodium sulfate from an organic solvent to remove trace amounts 
of water. The term ‘degassed’ refers to the process of removing oxygen from a solution 
by bubbling argon through the solution prior to use. Microwave irradiation was carried 
out in a CEM 150W microwave reactor. 
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Experimental 
5-(1-Amino-pyridazin-4-yl)-phenol, 31.30 
 
Method A: A microwave vial containing 4-hydroxyphenylboronic acid 32 (163 mg, 
1.26 mmol), 3-amino-6-chloropyridazine 33 (102 mg, 0.74 mmol), Pd(PPh3)2Cl2 (27 
mg, 0.04 mmol) and K2CO3 (202 mg, 1.46 mmol) in MeCN (2.0 mL) and H2O (1.3 
mL) was degassed for 5 min, then irradiated for 10 min at 120 °C. The reaction mixture 
was diluted with H2O (50 mL), then extracted with EtOAc (3×100 mL). The combined 
organic layers were washed with brine (100 mL), dried and concentrated in vacuo. 
Purification via flash column chromatography (EtOAc) gave 31 (81 mg, 58%) as a 
white solid. 
Method B: 4-Hydroxyphenylboronic acid 32 (1.00 g, 7.25 mmol), 3-amino-6-
chloropyridazine 33 (817 mg, 6.30 mmol) and Pd(PPh3)2Cl2 (221 mg, 0.32 mmol) 
were added sequentially to degassed 1,4-dioxane (50 mL) and stirred at rt for 10 min. 
Degassed 1 M aqueous Na2CO3 (18.9 mL) was added and the reaction mixture was 
heated rapidly to reflux for 16 h. The resulting mixture was then concentrated in vacuo. 
Purification via flash column chromatography (EtOAc : CH3OH, 50:1) gave 31 (659 
mg, 56%) as a white solid. 
 δH (500 MHz, CD3OD) 6.87 (2H, d, J 8.8, 2×C(7)H), 6.97 (1H, d, J 9.5, C(2)H), 7.70 
(1H, d, J 9.5, C(3)H), 7.71 (2H, d, J 8.8, 2×C(6)H), δC (125 MHz, CD3OD); 116.6 
(C(7)H), 117.6 (C(2)H), 128.0 (C(3)H), 128.6 (C(6)H), 129.3 (C(5)), 153.1 (C(4)), 
159.7 (C), 160.6 (C); νmax (ATR) 3463, 3326, 3200, 1628, 1605, 1458; mp (PhMe) 
262-263 °C {lit:30 250-252 °C}; m/z (EI+) 187 (100%, [M]+); HRMS (EI) C10H8N3O
+ 
([M-H]+) requires 186.06619, measured 186.06679. 
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(4-((4-(6-aminopyridazin-3-yl)phenoxy)methyl)phenyl)(phenyl)methanone, 41.70 
 
To a solution of KOtBu (197 mg, 1.76 mmol) and 18-crown-6 (10 mg, 0.04 mmol) in 
DMF (15 mL) was added a solution of alcohol 31 (300 mg, 1.60 mmol) in DMF (15 
mL) at 0 °C and the reaction mixture was stirred at 0 °C for 20 min. (4-
Bromomethylphenyl)(phenyl)methanone 40 (485 mg, 1.76 mmol) was added in one 
portion and the reaction was allowed to warm to rt and stirred for 16 h. The reaction 
mixture was partitioned between saturated aqueous LiCl (50 mL) and EtOAc (200 
mL). The aqueous layer was extracted with EtOAc (3×100 mL) and the combined 
organic layers were dried and concentrated in vacuo. Purification via flash column 
chromatography (EtOAc) gave 41 (266 mg, 44%) as a white solid. 
δH (500 MHz, DMSO-d6) 5.29 (2H, s, C(9)H2), 6.36 (2H, s, NH2), 6.82 (1H, d, J 9.1, 
C(2)H), 7.12 (2H, d, J 9.1, 2×C(7)H), 7.56 (2H, t, J 7.7, 2×o-PhH), 7.63-7.70 (3H, m, 
C(3)H, 2×C(11)H), 7.72-7.79 (5H, m, C(2)H, 2×m-PhH, 2×C(12)H), 7.91 (2H, d, J 
9.1, C(6)H); δC (125 MHz, DMSO-d6) 68.6 (C(9)H2), 114.3 (C(2)H), 115.0 (C(7)H), 
124.9 (CH), 126.7 (CH), 127.4 (C(3)H), 128.6 (C(11)), 129.6 (CH), 129.9 (CH), 130.1 
(C), 132.7 (C), 136.4 (C), 137.0 (C), 142.0 (C), 149.6 (C), 158.4 (C), 159.5 (C), 195.5 
(C(1)); νmax (solid) 3307, 3053, 2917, 2873, 2849, 1645; mp (PhMe) 200-203 °C ; m/z 
(ES+) 382 (100%, [M+H]+), HRMS (ES+) C24H20N3O2
+ ([M+H]+) requires 382.1556, 
measured 382.1551. 
Allyl 4-bromobutyrate.107 
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4-Bromobutyryl chloride (2.00 mL, 17.3 mmol) was added dropwise to allyl alcohol 
(6.00 mL, 138 mmol) at 0 ºC over 2 h and the resulting mixture stirred at rt for a further 
4 h. Excess allyl alcohol was removed in vacuo and the residue was redissolved in 
CH2Cl2 (50 mL), washed with saturated aqueous NaHCO3 (50 mL) and brine (50 mL), 
dried and concentrated in vacuo to give allyl 4-bromobutyrate (3.17 g, 89%) as a 
colourless oil. 
δH (600 MHz, CDCl3) 2.18 (2H, quin, J 7.2, C(6)H2), 2.53 (2H, t, J 8.0, C(5)H2), 3.46 
(2H, t, J 7.5, C(7)H2), 4.59 (2H, dd, J 6.0, 1.1, C(3)H2), 5.24 (1H, d, J 10.5, C(1)HA), 
5.32 (1H, d, J 17.3, C(1)HB), 5.87-5.95 (1H, m, C(2)H); δC (150 MHz, CDCl3) 27.8 
(C(6)H2), 32.5 (CH2), 32.8 (CH2), 65.4 (C(3)H2), 118.5 (C(1)H2), 132.1 (C(2)H), 
172.3 (C(4)); m/z (CI+) 209 (90%, [81M+H]+), 207 (100%, [79M+H]+). 
Allyl 4-(3-(4-((4-benzoylbenzyl)oxy)phenyl)-6-iminopyridazin-1(6H)-
yl)butanoate hydrobromide, 80.70 
 
A reaction mixture of allyl 4-bromobutyrate (97 mg, 0.47 mmol) and pyridazine 41 
(120 mg, 0.31 mmol) in DMF (0.4 mL) was heated to 80 °C for 16 h. The product 
precipitated upon addition of cold EtOAc (3 mL) and filtered to give 80 (135 mg, 85%) 
as a grey solid. 
δH (500 MHz, CD3OD:CDCl3, 1:1) 2.25 (2H, quint. J 6.9, C(2ʹ)H2), 2.59 (2H, t, J 6.8, 
C(3ʹ)H2), 4.42, (2H, t, J 7.1, C(1ʹ)H2), 4.50 (2H, d, J 5.7, C(5ʹ)H2), 5.16 (1H, dd, J 
10.6, 1.1, C(7ʹ)HA), 5.24 (1H, dd, J 17.0, 1.4, C(7ʹ)HB), 5.26 (2H, s, C(9)H2), 5.81 (1H, 
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ddt, J 17.0, 10.6, 5.7, C(6ʹ)H), 7.12 (2H, d, J 8.8, 2×C(7)H), 7.48 (2H, t, J 7.3 2×o-
PhH), 7.56-7.63 (3H, m, p-PhH, 2×C(11)H), 7.66 (1H, d, J 9.8 C(3)H), 7.75 (2H, d, J 
7.3, 2×m-PhH), 7.80 (2H, d, J 8.2, 2×C(12)H), 7.88 (2H, d, J 9.1, 2×C(6)H), 8.19 (1H, 
d, J 9.8 C(2)H); δC (125 MHz, CD3OD:CDCl3, 1:1) 22.8 (C(2ʹ)H2), 31.5 (C(3ʹ)H2), 
57.0 (C(1ʹ)H2), 67.0 (C(5ʹ)H2), 70.7 (C(9)H2), 117.0 (C(7)H), 119.7 (C(7ʹ)H2), 126.6 
(C), 127.0 (C(3)H), 128.4 (C(11)H), 129.6 (CH), 129.7 (CH), 131.1 (CH), 131.7 (CH), 
132.8 (CH), 133.0 (CH), 134.1 (p-PhH), 138.4 (C), 138.7 (C), 142.9 (C), 152.1 (C), 
162.5 (C), 174.1 (C(14)), 198.6 (C(1)); νmax (solid) 3218, 3019, 1735, 1651, 1607, 
1581, 1536, 1510; mp 210-214 °C; m/z (ES+) 508 (90%, [M+H]+), 351 (100%, [M-
C6H8O2]
+); HRMS C31H30N3O4
+ ([M+H]+) requires 508.2236, measured 508.2236. 
4-(3-(4-((4-benzoylbenzyl)oxy)phenyl)-6-iminopyridazin-1(6H)-yl)butanoic acid 
hydrobromide, 39. 
 
To a mixture of 80 (121 mg, 0.238 mmol) and DMBA (376 mg, 2.38 mmol) in 
degassed CH2Cl2 (2.5 mL) was added Pd(PPh3)4 (23 mg, 0.02 mmol). The reaction 
mixture was stirred at 35 °C for 3 h in the dark. The resulting mixture was partitioned 
between CH2Cl2 (10 mL) and saturated aqueous NaHCO3 (10 mL). The aqueous layer 
was extracted with CH2Cl2 (2×30 mL), and the combined organic layers were washed 
with brine (30 mL) then dried and concentrated in vacuo. Purification via flash column 
chromatography (CHCl3 : CH3OH, 10:1) gave 39 (53 mg, 41%) as a white solid. 
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δH (500 MHz, CDCl3: CD3OD, 1:1) 2.04-2.12 (2H, m, C(3ʹ)H2), 2.32-2.36 (2H, m, 
C(2ʹ)H2), 3.28-3.31 (2H, m, C(4ʹ)H2), 5.25 (2H, s, C(9)H2), 7.11 (2H, d, J 8.8, 
2×C(7)H), 7.48 (2H, d, J 7.8, 2×m-PhH), 7.56-7.62 (4H, m, C(3)H, 2×C(11)H, p-
PhH), 7.73-7.77 (2H, m, 2×o-PhH), 7.78-7.81 (2H, m, 2×C(12)H), 7.86 (2H, d, J 8.8, 
2×C(6)H), 8.09 (1H, d, J 9.8, C(2)H); δC (125 MHz, CDCl3:CD3OD, 1:1) 23.8 (C(3ʹ)), 
32.8 (C(2ʹ)), 57.9 (C(4ʹ)), 69.1 (C(9)H2), 116.9 (CH), 126.7 (CH) 126.8 (C), 128.4 
(CH), 129.5 (CH), 129.7 (CH), 131.3 (CH), 131.7 (CH), 132.5 (CH), 134.2 (CH), 
138.4 (C), 138.6 (C), 143.0 (C), 151.7 (C), 153.6 (C), 162.3 (C), 179.5 (C(14)), 198.6 
(C(1)); νmax (solid) 3340 (O−H), 2935, 1738, 1650 (C=O), 1609, 1567, 1535, 1510; 
mp 234 °C; m/z (ES+) 468 (100%, [M+H]+); HRMS (ES+) C28H26N3O4
+ ([M+H]+) 
requires 468.1923, measured 468.1945.  
 (3-Bromo-4-methylphenyl)(phenyl)methanone, 84.108 
 
Thionyl chloride (5 mL) was added dropwise to 3-bromo-4-methylbenzoic acid 83 
(1.00 g, 4.65 mmol) and stirred at rt for 2 min. The reaction mixture was then heated 
to reflux and stirred for 2 h. The reaction mixture was cooled to rt, concentrated in 
vacuo, and the residue was redissolved in benzene (5 mL). A solution of AlCl3 (0.7 g) 
in benzene (5 mL) was then added dropwise and the reaction mixture was heated to 
50 °C for 3 h. The resulting mixture was washed with 3 M aqueous HCl (25 mL) and 
brine (25 mL), dried and concentrated in vacuo. Purification via flash column 
chromatography (40-60 °C petrol: Et2O, 10:1) gave 84 (676 mg, 53%) as a white 
crystalline solid. 
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δH (500 MHz, CDCl3) 2.49 (3H, s, C(7)H3), 7.35 (1H, d, J 7.6, C(5)H), 7.49 (2H, ddt, 
J 7.9, 7.6, 1.6, 2×m-PhH), 7.60 (1H, ddt, J 7.9, 7.6, 1.6, p-PhH), 7.65 (1H, dd, J 7.6, 
1.6, C(6)H), 7.78 (2H, ddt, J 7.9, 1.4, 1.4, 2×o-PhH), 7.98 (1H, d, J 1.6, C(2)H); δC 
(125 MHz, CDCl3) 23.3 (C(7)H3), 125.0 (C(3)), 128.5 (m-PhH), 129.1 (C(6)H), 130.0 
(o-PhH), 130.7 (C(5)H), 132.7 (p-PhH), 134.0 (C(2)H), 137.0 (C), 137.4 (C), 140.0 
(C(4)), 195.1 (C); νmax (solid) 3056, 2567, 1734, 1651, 1593, 1579, 1549; mp 76-
77 °C; m/z (EI+) 276 (50%, [81M]+), 274 (51%, [79M]+), 199 (48%, [81M-C6H5]
+), 197 
(50%, [79M-C6H5]
+), 105 (100%, [M-C7H6Br]
+); HRMS (EI) C14H11O
79Br (M+) 
requires 273.9988, measured 273.9991. 
[(3-Bromo-4-bromomethyl)phenyl](phenyl)methanone 82,108,109  
[3-Bromo-4-(di-bromomethyl)phenyl](phenyl)methanone 85. 
 
N-Bromosuccinimide (398 mg, 2.23 mmol) and AIBN (48 mg, 0.29 mmol) were added 
sequentially to benzophenone 84 (614 mg, 2.23 mmol) in benzene (12 mL). The 
mixture was heated to 80 °C for 16 h, before the reaction solvent was removed in 
vacuo. Purification via flash column chromatography (40-60 °C petrol : Et2O, 50:1) 
gave 85 (40 mg, 4%), starting material 84 (101 mg, 16%) followed by 82 (555 mg, 
70%). 
Data for 85: δH (500 MHz, CDCl3) 7.10 (1H, s, C(7)H), 7.51 (2H, t, J 7.6, 2×m-PhH), 
7.63 (1H, t, J 7.6, p-PhH), 7.78-7.82 (3H, m, C(5)H, 2×o-PhH), 7.93 (1H, d, J 1.6, 
C(2)H), 8.13 (1H, d, J 8.2, C(6)H); δC (125 MHz, CDCl3) 38.8 (C(7)H), 119.8 (C), 
128.1 (m-PhH), 129.1 (C(5)H), 130.1 (o-PhH), 131.1 (C(6)H), 133.2 (p-PhH), 133.9 
(C(2)H), 136.6 (C), 134.0 (C), 143.9 (C), 194.1 (C); νmax 3073, 1735, 1650 (C=O), 
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1592, 1578, 1551; mp 68-69 °C; m/z (EI+) 436 (28%, [79,81,81M]+), 432 (86%, 
[79,79,81M]+), 430 (29%, [79,79,79M]+), 106 (100%, [M-C7H4Br3]
+); HRMS (EI) 
C14H9OBr3
+ (79,79,79M+) requires 429.81980, measured 429.81912. 
Data for 82: δH (500 MHz, CDCl3) 4.64 (2H, s, C(7)H2), 7.50 (2H, t, J 7.6, 2×m-PhH), 
7.57 (1H, d, J 7.9, C(5)H), 7.62 (1H, t, J 7.6, p-PhH), 7.71 (1H, d, J 7.6, C(6)H), 7.77 
(2H, d, J 7.6, 2×o-PhH), 8.01 (1H, s, C(2)H); δC (125 MHz, CDCl3) 32.4 (CH2), 124.5 
(C(3)), 128.6 (m-PhH), 129.4 (C(6)H), 130.1 (o-PhH), 131.1 (C(5)H), 133.0 (p-PhH), 
134.7 (C(2H)), 136.8 (C), 139.2 (C), 141.2 (C(4)), 194.5 (C); νmax (solid) 3057, 1651, 
1595, 1579, 1555, 1480; mp 59-60 °C {lit109 68-69 ºC}; m/z (EI+) 356 (6%, [81,81M]+), 
354 (13%, [79.81M]+), 352 (6%, [79,79M]+), 276 (37%), 275 (100%), 274 (38%), 273 
(97%), 199 (24%, [81M-C6H5Br]
+), 197 [79M-C6H5Br]
+), 105 (50%, [M-C7H5Br2]
+); 
HRMS (EI) C14H10OBr2 (
79,79M+) requires 351.90929, measured 351.908979. 
(4-((4-(6-aminopyridazin-3-yl)phenoxy)methyl)-3-bromophenyl) 
(phenyl)methanone, 86. 
 
A solution of arylpyridazine 31 (240 mg, 1.28 mmol) in DMF (15 mL) was added to 
a solution of KOtBu (172 mg, 1.54 mmol) and 18-crown-6 in DMF (7 mL) at 0 °C and 
the reaction mixture was stirred at 0 °C for 20 min. Benzophenone 82 (500 mg, 1.41 
mmol) was added in one portion and the reaction was allowed to warm to rt over 16 
h. The reaction mixture was partitioned between saturated aqueous LiCl (50 mL) and 
EtOAc (200 mL). The aqueous layer was extracted with EtOAc (3×100 mL) and the 
combined organic layers were dried and concentrated in vacuo. Purification via flash 
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column chromatography (40-60 °C petrol : Et2O, 50:1) gave 86 (375 mg, 63%) as a 
white solid. 
δH (500 MHz, CDCl3:CD3OD, 1:1 ) 5.26 (2H, s, C(9)H2), 6.96 (1H, d, J 9.1, C(2)H), 
7.09 (2H, d, J 9.0, 2×C(7)H), 7.51 (2H, t, J 7.7, 2×o-PhH), 7.63 (1H, t, J 6.9, p-PhH), 
7.66 (1H, d, J 9.1, C(3)H), 7.71-7.77 (4H, m, 2×m-PhH, C(15)H, C(16)H), 7.81 (2H, 
d, J 9.0, 2×C(6)H), 8.00 (1H, d, J 1.6, C(12)H); δC (125 MHz, CDCl3:CD3OD, 1:1) 
70.5 (C(9)H2), 115.5 (C(7)H), 116.6 (C(2)H), 122.4 (C), 127.1 (CH), 127.9 (CH), 
128.8 (CH), 128.8 (CH), 129.5 (CH), 130.3 (CH), 130.4 (C), 130.5 (C), 133.4 (CH), 
134.2 (CH), 137.1 (C), 138.7 (C), 141.2 (C), 159.3 (C), 161.0 (C), 194.4 (C); νmax 
(ATR) 3200, 3057, 2929, 1657, 1608, 1460; mp 170-172 °C; m/z (EI+) 461 (49%, 
[81M]+), 459 (48%, [79M]+), 275 (35%, [81M-C10H8N3O]
+), 273 (35%, [79M-
C10H8N3O]
+), 186 (100%, [M-C13H10BrO]
+); HRMS (EI) C24H18O2N3Br
+ (79M+) 
requires 459.05769, measured 459.05709. 
[3-(6′-Methyl hex-5′-ynoate)-4-methylphenyl](phenyl)methanone, 93, and 
Dimethyl dodeca-5,7-diynedioate, 94.110 
 
Degassed diethylamine (5 mL) was added to a mixture of 84 (75.0 mg, 0.273 mmol), 
Pd(PPh3)2Cl2 (18.0 mg, 0.027mmol) and CuI (5.1 mg, 0.027 mmol). 5-Hexynoic acid 
methyl ester 50 (51.7 mg, 0.410 mmol) was then added dropwise and the reaction 
mixture was stirred at 55 °C for 16 h. The reaction solvent was removed in vacuo and 
purification via flash column chromatography (40-60 °C petrol : EtOAc, 50:1) firstly 
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gave 93 (24 mg, 31%) as a colourless oil, and with further elution gave 94 (12 mg, 
23%) as a colourless oil. 
Data for 93: δH (500 MHz, CDCl3) 1.94 (2H, quint, J 7.2, C(11)H2), 2.49 (3H, s, 
C(9)H3), 2.52 (4H, app q, J 7.2, C(10)H2, C(12)H2), 3.68 (3H, s, C(14)H3), 7.29 (1H, 
d, J 8.2, C(5)H), 7.48 (2H, t, J 7.6, 2×m-PhH), 7.58 (1H, t, J 7.6, p-PhH), 7.63 (1H, 
dd, J 7.9, 1.9, C(6)H), 7.75-7.78 (2H, m, 2×o-PhH), 7.79 (1H, d, J, 1.6, C(2)H); δC 
(125 MHz, CDCl3) 19.1 (C(12)H2), 21.1 (C(9)H3), 24.0 (C(11)), 33.0 (C(10)), 51.7 
(C(14)H3), 79.5 (C(8)), 94.0 (C(9)), 123.9 (C(3)), 128.4 (m-Ph), 129.3, 129.5 (C(5)H, 
C(6)H), 130.0 (o-PhH), 132.4 (p-PhH), 133.7 (C(2)H), 135.2 (C), 137.7 (C), 145.0 
(C(4)), 173.6 (C(13)), 196.0 (C(15)); νmax (oil) 3444, 2952, 1736; m/z (EI+) 320 (16%, 
[M]+), 207 (100%, [M-C7H9O2]
+), 105 (33%, [M-C14H15O2]
+); HRMS (EI) C21H20O3
+ 
(M+) requires 320.14070, measured 320.14064. 
Data for 94: δH (500 MHz, CDCl3) 1.84 (4H, quint. J 7.1 , 2×C(3)H2), 2.33 (4H, t, J 
7.1, 2×C(2)H2), 2.44 (4H, t, J 7.1, 2×C(4)H2), 3.67 (6H, s, 2×CH3); δC (125 MHz 
CDCl3) 18.7 (C(4)H2), 23.5 (C(3)H2), 32.7 (C(2)H2), 51.7 (CH3), 66.1 (C(6)), 76.5 
(C(5)), 173.5 (C(1)); νmax 3444, 2952, 1736; m/z (EI+) 250 (13%, [M]+), 219 (54%, 
[M-C2H6]
+), 177 (58%, [M-C3H5O2]
+), 117 (100%, [M-C5H8O4]
+); HRMS (EI) 
C14H18O4
+ (M+) requires 250.11996, measured 250.12030. 
[3-(6′-Hydroxyhex-1′-yn-1′-yl)phenyl](phenyl)methanone, 92. 
 
Method A: A solution of aryl bromide 84 (50.0 mg, 0.182 mmol), in degassed Et3N (2 
mL) was treated with 5-hexyn-1-ol (22.0 μL, 0.200 mmol), Pd(PPh3)4 (4.2 mg, 0.004 
mmol) and CuI (1.0 mg, 0.005 mmol) and the reaction mixture was stirred in the dark 
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at 80 °C for 16 h. The solvent was concentrated in vacuo and the resulting residue was 
treated with saturated aqueous NH4Cl (5 mL), extracted with Et2O (3×10 mL) and the 
combined organic layers were dried and concentrated in vacuo. Purification via flash 
column chromatography (40-60 °C petrol : Et2O, 1:1) gave 92 (37 mg, 69%) as a 
yellow oil. 
Method B: A solution of aryl iodide 61 (37.0 mg, 0.115 mmol), in degassed Et3N (2 
mL) was treated with 5-hexyn-1-ol (13.9 μL, 0.126 mmol), Pd(PPh3)4 (2.7 mg, 0.002 
mmol) and CuI (0.7 mg, 0.004 mmol) and the reaction mixture was stirred in the dark 
at 80 °C for 16 h. The solvent was concentrated in vacuo and the resulting residue was 
treated with saturated aqueous NH4Cl (5 mL), extracted with Et2O (3×10 mL) and the 
combined organic layers were dried and concentrated in vacuo. Purification via flash 
column chromatography (40-60 °C petrol: Et2O, 1:1) gave 92 (30.2 mg, 90%) as a 
yellow oil. 
δH (500 MHz, CDCl3) 1.67-1.79 (4H, m, C(11)H2, C(12)H2), 2.49 (3H, s, C(7)H3), 
2.49 (2H, overlapping t, J 6.9, C(10)H2), 3.70 (2H, t, J 6.2, C(13)H2), 7.29 (1H, d, J 
7.9, C(5)H), 7.47 (2H, t, J 7.6, 2×m-PhH), 7.58 (1H, t, J 7.6, p-PhH), 7.62 (1H, dd, J 
7.9, 1.9, C(6)H), 7.75-7.80 (3H, m, C(2)H, 2×o-PhH); δC (125 MHz, CDCl3) 19.5 
(C(10)H2), 21.1 (C(7)H3), 25.1 (C(11)H2), 32.0 (C(12)H2), 62.5 (C(13)H2), 79.0 (C), 
95.1 (C), 124.1 (C), 128.4 (CH), 129.2 (C(6)H), 129.6 (C(5)H), 130.0 (CH), 132.4 (p-
PhH), 133.7 (C(2)H), 135.2 (C), 137.7 (C), 145.0 (C), 196.1 (C(14)); νmax (oil) 3388, 
3060, 2930, 2227, 1654, 1597, 1578; m/z (EI+) 292 (51%, [M]+), 105 (100%, [M-
C13H15O]
+); HRMS (EI) C20H20O2
+ (M+) requires 292.14578, measured 292.14633. 
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(4-((4-(6-Aminopyridazin-3-yl)phenoxy)methyl)-3-(6-hydroxyhex-1-yn-1-
yl)phenyl)(phenyl)methanone, 95. 
 
Method A: A solution of 86 (31.9 mg, 0.068 mmol), in degassed Et3N (1 mL) was 
treated with 5-hexyn-1-ol (8.2 μL, 0.075 mmol), Pd(PPh3)4 (1.6 mg, 0.001 mmol) and 
CuI (0.4 mg, 0.002 mmol) and the reaction mixture was stirred at 80 °C in the dark for 
16 h. The solvent was concentrated in vacuo and the resulting residue was treated with 
saturated aqueous NH4Cl (5 mL) and extracted with Et2O (3×10 mL). The combined 
organic layers were dried and concentrated in vacuo. Purification via flash column 
chromatography (EtOAc: CDCl3, 100:1) gave starting material 86 (24.1 mg, 77%) as 
a yellow solid. Further elution gave 95 (4.5 mg, 15%) as a yellow solid. 
Method B: A solution of 99 (15.4 mg, 0.030 mmol), in degassed Et3N (1 mL) under 
Ar was treated with 5-hexyn-1-ol (3.7 μL, 0.033 mmol), Pd(PPh3)4 (0.7 mg, 0.001 
mmol) and CuI (0.2 mg, 0.001 mmol) and the reaction mixture was stirred at 80 °C in 
the dark for 16 h. The solvent was concentrated in vacuo and the resulting residue was 
treated with saturated aqueous NH4Cl (5 mL) and extracted with Et2O (3×10 mL). The 
combined organic layers were dried and concentrated in vacuo. Purification via flash 
column chromatography (EtOAc: CDCl3, 100:5) gave 95 (10.6 mg, 74%) as a yellow 
solid. 
δH (500 MHz, CDCl3:CD3OD 1:1) 1.60-1.70 (4H, m, C(20)H2, C(21)H2), 2.46 (2H, t, 
J 6.6, C(19)H2), 3.55 (2H, t, J 6.1, C(22)H2), 5.31 (2H, s, C(9)H2), 6.93 (1H, br d, J 
8.7, C(2)H), 7.07 (2H, d, J 8.7, 2×C(7)H), 7.48 (2H, t, J 7.9, 2×m-PhH), 7.57-7.64 
(3H, m, p-PhH, C(16)H, C(15)H), 7.69 (1H, dd, J 8.0, 1.7, C(3)H), 7.75 (2H, dd, J 
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8.5, 1.3, 2×o-PhH), 7.78 (2H, d, J 8.9, 2×C(6)H), 7.81 (1H, d, J 1.7, C(12)H); δC (125 
MHz, CDCl3:CD3OD, 1:1) 20.7 (C(19)H2), 26.3 (C(20)H2), 33.0 (C(21)H2), 62.8 
(C(22)H2), 69.4 (C(9)H2), 78.9 (C), 98.5 (C), 115.3 (C), 116.5 (C(7)H), 118.0 (C(2)H), 
124.0 (C), 124.0 (C) 128.4, 128.4 (C(16)H, C(15)H), 129.0 (C(6)H), 129.8 (m-PhH), 
130.7 (C(3)H), 130.9 (C), 131.4 (o-PhH), 134.3 (p-PhH), 135.0 (C(12)H), 144.2 (C), 
159.2 (C), 160.0 (C), 160.8 (C), 160.8 (C), 198.0 (C(14)); νmax (solid) 3316, 3193, 
2931, 2861; mp (CH3OH) 82-84 °C; m/z (EI
+) 477 (6%, [M]+), 207 (26%, [M-
C16H15N3O2]
+), 84 (100%, [M-C25H18N3O3]
+); HRMS (EI) C30H27N3O3
+ (M+) requires 
477.20469; measured 477.20513. 
(3-Iodo-4-methylphenyl)(phenyl)methanone, 97. 
 
Thionyl chloride (7.00 mL, 96.5 mmol) was added dropwise to 2-iodo-4-
methylbenzoic acid 96 (5.00 g, 19.1 mmol) and the reaction mixture was heated to 
reflux for 2 h. The reaction mixture was allowed to cool and then was concentrated in 
vacuo. The residue was redissolved in benzene (20 mL) and AlCl3 (2.80g, 21.0 mmol) 
was added. The mixture was then heated to 50°C for 3 h. After having cooled, the 
reaction mixture was partitioned between 3 M aqueous HCl (20 mL) and EtOAc (20 
mL). The aqueous layer was extracted with EtOAc (3×20 mL), and the combined 
organic layers were washed with brine (50 mL), dried and concentrated in vacuo. 
Purification via flash column chromatography (40-60 °C petrol:Et2O, 9:1) gave 97 
(5.09 g, 83%) as a white solid. 
δH (500 MHz, CDCl3) 2.52 (3H, s, C(7)H3), 7.34 (1H, d, J 7.9, C(5)H), 7.49 (2H, dd, 
J 7.9, 7.6, 2×m-PhH), 7.60 (1H, tt, J 7.3, 1.3, p-PhH), 7.68 (1H, dd, J 7.9, 1.7, C(6)H), 
7.76-7.79 (2H, m, 2×o-PhH), 8.25 (1H, d, J 1.6, C(2)H); δC (125 MHz, CDCl3) 28.5 
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(C(7)H3), 100.8 (C), 128.5 (m-PhH), 129.5 (C(5)), 130.0 (C(6)), 130.0 (o-PhH), 132.7 
(p-PhH), 136.9 (C), 137.3 (C), 140.5 (C(2)), 146.4 (C), 194.9 (C=O); νmax (solid) 3050, 
1722, 1652, 1595, 1587, 1577, 1544; mp 78-79 °C; m/z (EI+) 322 (100%, M+), 245 
(62%, [M-C6H5]
+), 105 (51%, [M-C7H6I]
+); HRMS (EI) C14H11OI
+ (M+) requires 
321.98491, measured 321.98516. 
(4-(Bromomethyl)-3-iodophenyl)(phenyl)methanone, 98. 
 
NBS (527 mg, 2.96 mmol) and AIBN (63 mg, 0.39 mmol) were added sequentially to 
97 (955 mg, 2.96 mmol) in benzene (20 mL). The mixture was then heated to 80 °C 
for 16 h then the reaction solvent was removed in vacuo. Purification via flash column 
chromatography (40-60 °C petrol: Et2O, 100:1) gave starting material 97 (372 mg, 
39%) and further elution gave 98 (666 mg, 56%) as a yellow solid. 
δH (500 MHz, CDCl3) 4.63 (2H, s, C(7)H2), 7.50 (2H, t, J 7.6, 2×m-PhH), 7.57 (1H, 
d, J 7.9, C(5)H), 7.62 (1H, tt, J 7.6, 1.9, p-PhH), 7.74 (1H, dd, J 7.9, 1.9, C(6)H), 7.79 
(2H, dt, J 7.6, 1.9, 2×o-PhH), 8.27 (1H, d, J 1.9, C(2)H); δC (125 MHz, CDCl3) 37.8 
(C(7)H2), 99.7 (C(3)), 128.6 (m-PhH), 130.1 (o-PhH), 130.2 (CH), 130.4 (CH), 133.1 
(p-PhH), 136.8 (C), 140.0 (C), 141.3 (C(2)H), 144.3 (C(4)), 194.4 (C(8)); νmax (solid) 
3030, 2927, 1734, 1649, 1594, 1562, 1550, 1510; mp (Et2O) 54-56 °C; m/z (EI
+) 402 
(16%, [81M]+), 400 (16%, [79M]+), 321 (100%, [M-Br]+); HRMS (EI) C14H10BrIO
+ 
(79M+) requires 399.89542, measured 399.89584. 
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(4-((4-(6-Aminopyridazin-3-yl)phenoxy)methyl)-3-iodophenyl) 
(phenyl)methanone, 95. 
 
Method A: To a solution of KOtBu (322 mg, 2.89 mmol) in DMF (5 mL) was added a 
solution of 31 (448 mg, 2.39 mmol) in DMF (15 mL) at 0 °C and the reaction mixture 
was stirred at 0 °C for 20 min. Benzylbromide 98 (1.06 g, 2.63 mmol) was added in 
one portion and the reaction was allowed to warm to rt over 16 h. The reaction mixture 
was concentrated in vacuo, and the residue was partitioned between saturated aqueous 
LiCl (100 mL) and EtOAc (200 mL). The aqueous layer was extracted with EtOAc 
(3×300 mL) and the combined organic layers were dried and concentrated in vacuo. 
Purification via flash column chromatography (EtOAc) 100 (358 mg, 57%). Further 
elution gave 99 (278 mg, 23%) as a white solid. Further elution gave starting material 
31 (70 mg, 30%). 
Method B: To a solution of NaH (131 mg, 3.56 mmol) in DMF (5 mL) at 0 °C was 
added 31 (606 mg, 3.24 mmol) in one portion. The resulting solution was stirred at 0 
°C for 20 min, before a solution of 98 (1.56 g, 3.88 mmol) in DMF (5 mL) was added 
via cannula. The reaction mixture was the stirred at rt for 4 h, quenched with H2O (2 
mL), and concentrated in vacuo. Purification via flash column chromatography 
(EtOAc) gave 95 (1.25 g, 82%) as a white solid. 
δH (600 MHz, CDCl3) 4.82 (2H, br s, NH2), 5.16 (2H, s, C(9)H2), 6.84 (1H, d, J 8.9, 
C(2)H), 7.09 (2H, d, J 8.9, 2×C(7)H), 7.50 (2H, t, J 7.7, 2×o-PhH), 7.59-7.63 (2H, m, 
C(3)H, C(15)H), 7.65 (1H, d, J 8.0, p-PhH), 7.77-7.81 (3H, m, 2×m-PhH, C(16)H), 
7.94 (2H, d, J 8.9, 2×C(6)H), 8.31 (1H, d, J 1.5, C(12)H); δC (150 MHz, CDCl3) 73.8 
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(C(9)H2), 96.4 (C(11)), 115.1 (C(2)H), 115.3 (2×C(7)H), 125.9 (C(15)H), 127.7 (p-
PhH), 128.0 (C(6)H), 128.6 (o-PhH), 130.1 (C(16)H), 130.2 (m-PhH), 130.3 (C), 
133.0 (C(3)H), 137.0 (C), 138.6 (C), 140.5 (C(12)H), 143.4 (C), 153.3 (C), 158.1 (C), 
159.0 (C), 194.9 (C(14)); νmax (solid) 3420, 3312, 3168, 2928, 2349, 1653; mp 
(CH3OH) 90-91°C; m/z (EI
+) 507 (100%, [M]+); HRMS (EI) C24H18IN2O2
+ (M+) 
requires 507.04382, measured 507.04450. 
6-(2-((4-(6-Aminopyridazin-3-yl)phenoxy)methyl)-5-benzoylphenyl)hex-5-ynoic 
acid, 87. 
 
A solution of 99 (160 mg, 0.32 mmol) in degassed Et3N (5 mL) and THF (5 mL), was 
treated sequentially with 5-hexynoic acid (38 μL, 0.35 mmol), Pd(PPh3)3 (7.3 mg, 
0.006 mmol) and CuI (1.8 mg, 0.010 mmol), and the reaction was heated to 65 °C for 
16 h in the dark. The crude product was redissolved in CH3OH (20 mL) and the 
reaction mixture was concentrated in vacuo. Purification via flash column 
chromatography (CHCl3 : CH3OH, 10:1) gave 87 (76.6 mg, 49%) as an insoluble white 
solid. 
1H and 13C NMR data was unavailable for this compound due to its high insolubility 
in deuterated solvents (yes, including DMSO-d6); νmax (solid) 3521, 2917, 2235, 1689; 
mp 239-240 °C; m/z (ES+) 492 (100%, [M+H]+); HRMS (ES+) C30H26N3O
+ ([M+H]+) 
requires 492.1923, measured 492.1901. 
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tert Butyl N-{2-[2′-(2″-aminoethoxy)ethoxy]ethyl}carbamate, 102.111 
 
A solution of Boc2O (1.18 g, 5.40 mmol) in CH2Cl2 (20 mL) was added dropwise to a 
solution of 2-[2-(2-aminoethoxy)ethoxy]ethanamine (8.00 g, 54.0 mmol) in CH2Cl2 
(20 mL) at 0 °C, and the reaction mixture left to stir at rt for 16 h before being 
concentrated in vacuo. The resulting residue was redissolved in CH2Cl2 (40 mL) and 
washed with H2O (40 mL). The aqueous layer was extracted with CH2Cl2 (2×40 mL) 
and the combined organic layers were dried and concentrated in vacuo to give 102 
(1.38 g, 99%) as a colourless oil. 
δH (500 MHz, CDCl3) 1.43 (9H, s, 3×C(1)H3), 1.87 (2H, br s, NH2), 2.89 (2H, t, J 5.2, 
C(9)H2), 3.32 (2H, q, J 5.2, C(4)H2), 3.51-3.56 (4H, m, C(5)H2, C(8)H2), 3.61 (4H, s, 
C(6)H2, C(7)H2), 5.16 (1H, br s, NH); δC (125 MHz, CDCl3) 28.5 (3×C(1)H3), 40.4 
(C(4)H2), 41.4 (C(9)H2), 70.2 (CH2), 70.2 (CH2), 70.3 (CH2), 72.6 (C(8)H2), 79.2 
(C(2)), 156.1 (C(3)); νmax (oil) 3366, 2973, 2927, 2865, 1703; m/z (CI+) 249 (20%, 
[M]+), 193 (100%, [M-C(CH3)3]
+), 149 (79%, [M-CO2C(CH3)3]
+), 57 (81%, 
[C(CH3)3]
+); HRMS (CI+) C11H24N2O4
+ (M+) requires 249.18088, measured 
249.17974. 
N-(2-(2′-(2″-(N-Boc-amino)ethoxy)ethoxy)ethyl)biotinylamine, 103.112 
 
A solution of D-biotin (221 mg, 0.91 mmol), HBTU (298 mg, 0.79 mmol) and DIPEA 
(310 μL, 1.81 mmol) in DMF (3 mL) was stirred for 20 mins at rt before being added 
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via cannula to a solution of 65 (150 mg, 0.60 mmol) in DMF (5 mL). The reaction 
mixture was stirred for 2 h before the solvent was removed in vacuo. Purification via 
flash column chromatography (CH2Cl2 : CH3OH, 20:1) gave 103 (183 mg, 63%) as a 
colourless oil. 
δH (600 MHz, CD3OD); 1.42-1.48 (11H, m, 3×C(19)H3, C(11)HA, C(10)HA), 1.56-
1.77 (4H, m, C(9)H2, C(11)HB, C(10)HB), 2.22 (2H, t, J 7.2, C(8)H2), 2.71 (1H, d, J 
12.7, C(16)HA), 2.93 (1H, dd, 12.7, 4.8, C(16)HB), 3.19-3.24 (3H, m, C(12)H, 
C(1)H2), 3.37 (2H, t, J 5.5, C(6)H2), 3.52 (2H, t, J 5.7, C(2)H2), 3.55 (2H, t, J 5.5, 
C(5)H2), 3.61 (4H, app s, C(3)H2, C(4)H2), 4.31 (1H, dd, J 7.8, 4.8, C(13)H), 4.50 
(1H, dd, J 7.8, 4.3, C(15)H); δC (125 MHz, CD3OD) 26.9 (C(9)H2), 28.9 (C(19)H3), 
29.5 (C(11)H2), 29.8 (C(10)H2), 36.7 (C(8)H2), 40.3 (C(6)H2), 41.1 (C(16)H2), 41.2 
(C(1)H2), 57.0 (C(12)H), 61.6 (C(15)H), 63.4 (C(13)H), 70.6 (CH2), 71.1 (CH2), 71.2 
(CH2), 71.3 (CH2), 80.1 (C(18)), 158.4 (C(17), 166.1 (C(14)), 176.2 (C(7)); νmax (oil) 
3292, 2930, 2867, 1693; m/z (FTMS) 497 (37%, [M+Na]+), 375 (100%, [M-
C5H14O2]
+); HRMS (FTMS) C21H38O6N4NaS
+ ([M+Na]+) requires 497.2404, 
measured 497.2394. 
N-(2-(2′-(2″-Aminoethoxy)ethoxy)ethyl)biotinylamine TFA salt, 101. 
 
 
TFA (4 mL, 52.2 mmol) was added to a solution of 103 (700 mg, 1.48 mmol) in 
CH2Cl2 (4 mL) and stirred at rt for 3 h. The reaction mixture was then concentrated in 
vacuo to give 101 (725 mg, quant) as a yellow oil. 
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δH (600 MHz, CD3OD) 1.41-1.48 (2H, m, 2×C(10)H), 1.55-1.77 (4H, m, C(9)H2, 
2×C(11)H), 2.23 (2H, t, J 7.3, C(8)H2), 2.71 (1H, d, J 12.8, C(16)HA), 2.93 (1H, d, J 
12.8, C(16)HB), 3.12 (2H, t, J 4.8, C(1)H2), 3.21 (1H, m, C(12)H2), 3.37 (2H, t, J 5.7, 
C(6)H2), 3.56 (2H, t, J 5.7, C(5)H2), 3.64-3.68 (4H, m, C(3)H2, C(4)H2), 3.70 (2H, t, 
J 4.8, C(2)H2), 4.32 (1H, dd, J 7.9, 4.5, C(13)H), 4.51 (1H, dd, J 7.9, 4.7, C(15)H); δC 
(150 MHz, CD3OD) 26.9 (C(9)H2), 29.5 (C(11)H2), 29.7 (C(10)H2), 36.7 (C(8)H2), 
40.2 (CH2), 40.7 (CH2), 41.7 (CH2), 57.0 (C(12)H), 61.7 (C(15)H), 63.4 (C(13)H), 
70.7 (CH2), 71.3 (CH2), 71.3 (CH2), 71.4 (CH2), 117.3 (q, J 289, CF3), 161.3 (q, J 38, 
CF3COO
-), 166.2 (C(14)), 176.3 (C(7)); νmax (oil) 3293, 3075, 2929, 1777, 1673; m/z 
(CI+) 375 (100%, [M]+); HRMS (CI+) C16H32N4O4S
+ ([M+H]+) requires 375.20605, 
measured 375.20509. 
6-(2-((4-(6-Aminopyridazin-3-yl)phenoxy)methyl)-5-benzoylphenyl)-N-(2-(2-(2-
(biotinylamino)ethoxy)ethoxy)ethyl)hex-5-ynamide, 104. 
 
 
Method A: A suspension of 87 (10.4 mg, 0.021 mmol), HBTU (10.5 mg, 0.28 mmol) 
and DIPEA (10.8 μL, 0.063 mmol) in DMF (2 mL) was stirred for 20 mins at rt before 
being added via cannula to a solution of 101 (10.4 mg, 0.021 mmol) in DMF (1 mL). 
The reaction mixture was stirred for 2 h before the solvent was removed in vacuo. 
Purification via flash column chromatography (CH2Cl2: CH3OH, 20:1), followed by 
the recrystallisation out of impurity, followed by trituration (CHCl3) gave 104 (9.86 
mg, 55%) as a colourless oil. 
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Method B: DCC (58 mg, 0.28 mmol) was added to a solution of 87 (126 mg, 0.26 
mmol) in DMF (3 mL) and the resulting mixture was stirred at 0 °C for 30 mins, then 
allowed to warm to rt over 20 min. Et3N (36 μL, 0.26 mmol) and 101 (125 mg, 0.26 
mmol) were then added and the reaction mixture was stirred at rt for 16 h. The reaction 
mixture was diluted with EtOAc (3 mL) and washed with saturated aqueous LiCl (5 
mL), dried and concentrated in vacuo. Purification via flash column chromatography 
(CHCl3:CH3OH, 9:1) gave 104 (113 mg, 52%) as a yellow oil. 
δH (600 MHz, CD3OD) 1.37-1.42 (2H, m, C(33)H2), 1.51-1.73 (4H, m, C(31)H2, 
C(32)H2), 1.89 (2H, quint, J 7.2 C(20)H2), 2.17 (2H, t, J 7.3, C(30)H2), 2.36 (2H, t, J 
7.4, C(21)H2), 2.53 (2H, t, J 7.6, C(19)H2), 2.68 (1H, d, J 12.8, C(38)HA), 2.89 (1H, 
d, J 12.8, C(38)HB), 3.13-3.17 (1H, m, C(34)H), 3.32-3.35 (4H, m, C(23)H2, C(28)H2), 
3.50 (4H, t, J 5.4, C(24)H2, C(27)H2), 3.57 (4H, app s, C(25)H2, C(26)H2), 4.26 (1H, 
dd, J 8.0, 4.4, C(35)H), 4.46 (1H, dd, J 8.0, 4.5, C(37)H), 5.38 (2H, s, C(9)H2), 7.01 
(1H, d, J 9.4, C(2)H), 7.14 (2H, d, J 8.6, 2×C(7)H), 7.56 (2H, t, J 7.9, 2×m-PhH), 7.67 
(1H, t, J 7.4, C(14)H), 7.70-7.75 (2H, m, p-PhH, C(15)H), 7.76-7.80 (3H, m, 2×o-
PhH, C(3)H), 7.87 (2H, d, J 8.6, 2×C(6)H), 7.91 (1H, s, C(12)H); δC (150 MHz, 
CD3OD) 19.2 (CH2), 25.9 (CH2), 26.8 (CH2), 29.5 (CH2), 29.8 (CH2), 36.0 (CH2), 36.7 
(CH2), 40.3 (CH2), 40.3 (CH2), 41.0 (CH2), 57.0 (CH), 61.6 (CH), 63.3 (CH), 66.9 
(CH2), 69.2 (CH2), 70.6 (CH2), 70.6 (CH2), 71.3 (CH2), 78.7 (C), 79.5 (C), 79.5 (CH), 
97.3 (C), 116.2 (CH), 117.5 (CH) 124.2 (C), 128.0 (CH), 128.6 (CH), 129.7 (CH), 
130.4 (CH), 131.0 (C), 131.0 (CH), 131.2 (C), 134.1 (CH), 134.4 (CH), 138.4 (C), 
138.5 (C), 144.1 (C), 160.9 (C), 163.6 (C), 175.4 (C), 176.1 (C), 197.4 (C); νmax (oil) 
3301, 2926, 2856, 2349, 1693, 1650; m/z (ES+) 848 (100%, [M+H]+). 
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Allyl 4-(3-(4-((4-benzoyl-2-(5,16-dioxo-1-((3aS,4S,6aR)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)-9,12-dioxa-6,15-diazahenicos-20-yn-21-
yl)benzyl)oxy)phenyl)-6-iminopyridazin-1(6H)-yl)butanoate hydrobromide, 105. 
 
A reaction mixture of allyl 4-bromobutyrate (7.0 mg, 0.03 mmol), 67 (19 mg, 0.02 
mmol) in DMF (0.1 mL) was heated to 120 °C for 16 h. The product precipitated upon 
addition of cold EtOAc (2 mL), and filtered to give 105 (18.2 mg, 77%) as a brown 
oil. 
δH (600 MHz, CD3OD) 1.37-1.44 (2H, m, C(32)H2), 1.50-1.74 (4H, m, C(31)H2, 
C(33)H2), 1.89 (2H, quint, J 7.3, C(20)H2), 2.18 (2H, t, J 7.3, C(30)H2), 2.27 (2H, t, J 
6.8, C(2ʹ)H2), 2.37 (2H, t, J 7.3, C(21)H2), 2.53 (2H, t, J 7.0, C(19)H2), 2.63 (2H, t, J 
6.8, C(3ʹ)H2), 2.68 (1H, d, J 13.0, C(38)HA), 2.90 (1H, dd, J 12.6, 4.9, C(38)HB), 3.14-
3.20 (1H, m, C(34)H), 3.32-3.36 (4H, m, C(23)H2, C(28)H2), 3.52 (4H, app q, J 5.8, 
C(24)H2, C(27)H2), 3.58 (4H, app s, C(25)H2, C(26)H2), 4.28 (1H, dd, J 7.7, 7.5, 
C(35)H), 4.44-4.50 (5H, m, C(5ʹ)H2, C(1ʹ)H2, C(37)H), 5.16 (1H, dd, J 10.5, 1.3, 
C(7ʹ)HA), 5.24 (1H, dd, J 17.3, 1.3, C(7ʹ)HB), 5.41 (2H, s, C(9)H2), 5.80-5.88 (1H, m, 
C(6ʹ)H), 7.20 (2H, d, J 9.0, 2×C(7)H), 7.56 (2H, t, J 7.8, 2×m-PhH), 7.62 (1H, d, J 
9.6, C(3)H), 7.67 (1H, t, J 7.4 C(15)H), 7.70 (1H, d, J 8.1, p-PhH), 7.72 (1H, td, J 7.9, 
1.7, C(14)H), 7.78 (2H, d, J 8.1, 2×o-PhH), 7.82 (1H, s, C(12)H), 7.99 (2H, d, J 8.8, 
2×C(6)H), 8.32 (1H, d, J 9.6, C(2)H); δC (150 MHz, CD3OD) 19.8 (CH2), 22.5 (CH2), 
25.9 (CH2), 26.9 (CH2), 29.5 (CH2), 29.8 (CH2), 31.3 (CH2), 36.0 (CH2), 36.7 (CH2), 
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40.3 (CH2), 40.3 (CH2), 41.1 (CH2), 43.8 (CH2), 55.9 (CH), 56.9 (CH2), 57.0 (CH), 
61.6 (CH), 63.3 (CH), 66.5 (CH2), 69.3 (CH2), 70.6 (CH2), 70.6 (CH2), 71.3 (CH2), 
81.6 (C), 97.3 (C), 116.7 (CH), 118.7 (CH2), 122.5 (C), 126.7 (C), 127.1 (CH), 127.2 
(CH), 129.5 (CH), 129.7 (CH), 130.4 (CH), 131.0 (CH), 133.5 (CH), 133.6 (CH), 
134.1 (CH), 134.5 (C), 138.1 (C) 144.0 (C), 152.9 (C), 153.9 (C), 158.8 (C), 160.5 
(C), 162.5 (C), 174.0 (C), 175.4 (C), 175.9 (C), 197.3 (C); νmax (oil) 3323, 2939, 1726; 
m/z (ES+) 974 (100%, [M+H]+). 
4-(3-(4-((4-benzoyl-2-(5,16-dioxo-1-((3aS,4S,6aR)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)-9,12-dioxa-6,15-diazahenicos-20-yn-21-
yl)benzyl)oxy)phenyl)-6-iminopyridazin-1(6H)-yl)butanoic acid, 106. 
 
A solution of NaOH (1.0 mg, 0.025 mmol) and 105 (8.6 mg, 0.009 mmol) in THF (1 
mL) and H2O (1 mL) was stirred at 50 °C for 3 h. After cooling to 10 °C the reaction 
mixture was washed with EtOAc (2 mL) and the aqueous layer separated, then 
acidified to pH 1 by addition of 0.1 M aqueous HCl and stirred at 0 °C for 1 h. The 
solvent was removed in vacuo and the residue triturated with H2O (1 mL) to leave 106 
(11.9 mg, 65%) as a brown solid. 
δH (600 MHz, CD3OD) 1.37-1.43 (2H, m, C(32)H2), 1.52-1.73 (4H, m, C(31)H2, 
C(33)H2), 1.88 (2H, quint, J 7.2, C(20)H2), 2.15-2.24 (4H, m, C(2ʹ)H2, C(30)H2), 2.36 
(2H, t, J 7.4, C(21)H2), 2.50-2.54 (4H, m, C(3ʹ)H2, C(19)H2), 2.68 (1H, d, J 12.7, 
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C(38)HA), 2.90 (1H, dd, J 12.7, 4.9, C(38)HB), 3.14-3.18 (1H, m, C(34)H), 3.32-3.36 
(4H, m, C(23)H2, C(28)H2), 3.51 (4H, app q, J 5.7, C(24)H2, C(27)H2), 3.58 (4H, app 
s, C(25)H2, C(26)H2), 4.25-4.28 (1H, m, C(35)H), 4.42-4.48 (3H, m, C(1ʹ)H2, 
C(37)H), 5.41 (2H, s, C(9)H2), 7.20 (2H, d, J 9.0, 2×C(7)H), 7.56 (2H, t, J 7.8, 2×m-
PhH), 7.62 (1H, d, J 9.6, C(3)H), 7.65-7.69 (1H, m, C(15)H), 7.70 (1H, d, J 8.1, p-
PhH), 7.74 (1H, dd, J 8.1, 1.7, C(14)H), 7.77-7.80 (2H, m, 2×o-PhH), 7.83 (1H, d, J 
1.7, C(12)H), 7.99 (2H, d, J 9.0, 2×C(6)H), 8.30 (1H, d, J 9.6, C(2)H); δC (150 MHz, 
CD3OD) 19.8 (CH2), 23.0 (CH2), 25.9 (CH2), 26.9 (CH2), 29.5 (CH2), 29.8 (CH2), 31.6 
(CH2), 36.0 (CH2), 36.7 (CH2), 40.2 (CH2), 40.3 (CH2), 41.0 (CH2), 57.0 (CH), 61.6 
(CH), 61.6 (CH), 63.3 (CH), 69.3 (CH2), 69.6 (CH2), 70.6 (CH2), 70.6 (CH2), 71.3 
(CH2), 78.6 (C), 98.0 (C), 116.6 (CH), 117.2 (CH), 124.5 (C), 126.6 (C), 127.1 (CH), 
128.7 (CH), 129.5 (CH), 129.7 (CH), 130.4 (CH), 131.0 (C), 132.6 (C), 134.1 (CH), 
134.5 (CH), 138.4 (C), 144.0 (C), 151.8 (C), 153.0 (C), 162.5 (C), 173.7 (C), 175.4 
(C), 176.1 (C), 177.1 (C), 197.4 (C); νmax (solid) 3263, 2832, 2380, 1650; mp (EtOH) 
178-180 ºC; m/z (ES+) 934, (30%, [M+H]+), 468 (100%); HRMS (ESI+) C50H59N7O9S 
([M+H]+) requires 934.4173; measured 934.4884. 
NH-OEG880-NHBoc acetic acid salt, 108.113 
 
A suspension of crushed O,Oʹ-bis(2-aminoethyl)octadecaethylene glycol (144 mg, 
0.161 mmol) in CH3OH (10 mL) was treated dropwise with a solution of Boc2O (35.1 
mg, 0.161 mmol) in CH3OH (10 mL) over 1 h. The resulting mixture was stirred at rt 
for 19 h, before acetic acid (10 mL) and toluene (70 mL) were added and the reaction 
solvent was removed in vacuo. Purification via flash column chromatography 
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(CHCl3:CH3OH:CH3CO2H, 80:20:3) gave mono- protected OEG diamine 108 (142 
mg, 83%) as a white solid. 
δH (600 MHz, CDCl3) 1.39 (9H, s, 3×C(1)H3), 3.24-3.28 (2H, m, C(4)H2), 3.46-3.50 
(2H, m, C(5)H2), 3.54-3.71 (~74H, m, 37×CH2), 3.80-3.85 (2H, m, C(9)H2); δC (150 
MHz, CDCl3) 28.5 (C(1)H3), 40.4 (CH2), 69.9 (CH2), 70.0 (CH2), 70.0 (CH2), 70.2 
(CH2), 70.2 (CH2), 70.2 (CH2), 70.3 (CH2), 70.3 (CH2), 70.4 (CH2), 70.4 (CH2), 70.5 
(CH2), 70.6 (CH2), 70.6 (CH2), 70.6 (CH2), 79.2 (C(2)), 156.1 (C(3)); m/z (ES
+) 1020 
(60%, [M+CH3COO
-]), 997, (100%, [M+H]+); HRMS (ES+) C45H92N2O21
+ ([M+H]+) 
requires 997.6271; measured 997.6266. 
D-Biotin-NH-OEG880-NHBoc, 110.113 
 
A solution of BocNH-PEG-NH2.CH3CO2H 108 (40.4 mg, 0.038 mmol) in dry DMF 
(1 mL) was treated with D-Biotin-NHS (18.4 mg, 0.054 mmol) and triethylamine (9.1 
µL, 0.07 mmol) and stirred at rt for 24 h. The reaction was quenched upon addition of 
H2O (0.5 mL), and stirred for a further 2 h. The reaction solvent was removed in vacuo, 
and the residue was redissolved in 0.2 M aqueous Na2CO3 (5 mL), and filtered. The 
filtrate was saturated with NaOH, extracted with CHCl3 (2×50 mL) and the combined 
organic layers were dried and conentrated in vacuo to give 110 (35.2 mg, 76%) as a 
white solid.  
δH (600 MHz, CDCl3) 1.44 (9H, s, 3×C(1)H3), 1.60-1.82 (6H, m, C(10)H2, C(11)H2, 
C(12)H2). 2.18-2.26 (2H, m, C(9)H2), 2.74 (1H, d, J 12.8, C(17)HA), 2.92 (1H, dd, J 
12.8, 4.5, C(17)HB), 3.12-3.19 (1H, C(13)H), 3.27-3.34 (2H, m, C(7)H2), 3.40-3.46 
(2H, m, C(4)H2), 3.50-3.58 (4H, m, C(6)H2, C(5)H2), 3.58-3.73 (72H, s, 36×CH2), 
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4.29-4.35 (1H, m, C(14)H), 4.48-4.54 (1H, m, C(16)H), 5.08 (2H, s, C(3)NH), 5.89 
(1H, s, NH), 6.70 (1H, s, NH); δC (150 MHz, CDCl3) 25.6 (CH2), 28.1 (CH2), 28.6 
(C), 35.8 (CH2), 39.3 (CH2), 40.6 (CH2), 55.5 (CH), 60.3 (CH), 61.9 (CH), 70.0 (CH2), 
70.2 (CH2), 70.4 (CH2), 70.5 (CH2), 70.6 (CH2), 70.6 (CH2), 70.6 (CH2), 70.7 (CH2), 
79.3 (C), 166.3 (C), 167.8 (C), 173.4 (C); m/z (ES+) 1245, (50%, [M+H]+), 562 
(100%); HRMS (ESI+) C55H106N4O23S
+ ([M+Na]+) requires 124.57090, measured 
124.56866. 
6-(2-((4-(6-Aminopyridazin-3-yl)phenoxy)methyl)-5-benzoylphenyl)-N-(61-oxo-
65-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-
3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57-nonadecaoxa-60-
azapentahexacontyl)hex-5-ynamide, 111. 
 
A mixture of acid 87 (29.4 mg, 0.060 mmol) and HOAt (8.2 mg, 0.060 mmol) in DMF 
(0.5 mL) was stirred at 0 ºC for 10 minutes before DCC (13.6 mg, 0.066 mmol) was 
added and the resulting mixture was stirred at 0 ºC for 30 min, and then at rt for 30 
min. Biotin-NH-PEG880-NHBoc 110 (74.2 mg, 0.060 mmol) and triethylamine (16.8 
µL, 0.120 mmol) were added and the reaction was sitrred at rt for 20 h, before being 
concentrated in vacuo. Purification via flash column chromatography (CHCl3:CH3OH, 
100:20) gave 111 (53.0 mg, 55%) as a yellow oil. 
δH (600 MHz, CDCl3:CD3OD, 1:2) 1.36-1.45 (2H, m, C(30)H2), 1.54-1.74 (4H, m, 
C(29)H2, C(31)H2), 1.89 (2H, quin, J 7.2, C(20)H2), 2.16-2.23 (2H, m, C(28)H2), 2.32 
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(2H, t, J 7.7, C(21)H2), 2.50 (2H, t, J 7.2, C(19)H2), 2.70 (1H, d, J 13.2, C(36)HA), 
2.89 (1H, dd, J 12.7, 5.0, C(36)HB), 3.11-3.17 (1H, m, C(32)H), 3.32-3.37 (2H, m, 
C(23)H2), 3.48-3.53 (2H, m, C(26)H2), 3.59-3.64 (76H, m, 38×CH2), 4.27-4.30 (1H, 
m, C(33)H), 4.46-4.50 (1H, m, C(35)H), 5.36 (2H, s, C(9)H2), 7.11-7.14 (3H, m, 
C(2)H, 2×C(7)H), 7.46-7.52 (1H, m, p-PhH), 7.58 (1H, d, J 9.6, C(14)H), 7.61-7.65 
(2H, m, 2×m-PhH), 7.69-7.72 (1H, m, C(3)H), 7.74-7.79 (2H, m, 2×o-PhH), 7.83 (1H, 
d, J 1.7, C(12)H), 7.86-7.89 (2H, m, 2×C(6)H), 8.19-8.22 (1H, m, C(15)H); {Signals 
in 13C NMR were too weak to characterise}; νmax (solid) 3266, 2829, 2376, 1650; m/z 
(ES+) 1618 (90%, [M+Na]+), 1596 (70%, [M+H]+), 1242 (100%); HRMS (ES+), 
C80H122N7O24S
+ ([M+H]+) requires 1596.8262, found 1596.7903. 
Benzo[d][1,3]dioxol-5-yl(phenyl)methanone, 134.114 
 
Solid FeCl3 (1.00 g, 6.17 mmol) was slowly added to a solution of benzoyl chloride 
(703 µL, 6.06 mmol) and 1,3-benzodioxole (631 µL, 5.50 mmol) in CH2Cl2 (250 mL) 
at 0 ºC, and the reaction mixture was stirred at rt for 3 h. The mixture was poured into 
ice, acidified with concentrated HCl, and extracted with CH2Cl2 (2×150 mL). The 
combined organics were washed with H2O (150 mL), dried and concentrated in vacuo. 
Purification via flash column chromatography (40-60 ºC petrol:Et2O, 10:1) gave 134 
(174 mg, 14%) as a grey solid. 
δH (600 MHz, CDCl3) 6.07 (2H, s, C(8)H2), 6.86 (1H, dd, J 8.0, 0.5, C(6)H), 7.36-7.39 
(2H, m, C(7)H, C(3)H), 7.47 (2H, t, J 7.3, 2×m-PhH), 7.57 (1H, t, J 7.4, p-PhH), 7.73-
7.76 (2H, m, 2×o-PhH); δC (150 MHz, CDCl3) 102.0, (C(8)H2), 107.8 (C(6)H), 110.0 
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(CH), 127.0 (CH), 128.3 (m-PhH), 129.8 (o-PhH), 132.0 (C(2)), 132.1 (p-PhH), 138.2 
(i-Ph), 148.1 (C), 151.6 (C), 195.3 (C(1)); m/z (ES+) 227 (100%, [M+H]+). 
(4-Methoxyphenyl)(phenyl)methanone, 112.115 
 
A solution of 4-methoxy benzoylchloride (1.00 g, 5.86 mmol) in benzene (5 mL) was 
treated with AlCl3 (860 mg, 6.45 mmol), and the resulting mixture was stirred at reflux 
for 16 h. The reaction was then poured onto ice and extracted with CH2Cl2 (2×100 
mL). The combined organic layers were washed with H2O (100 mL), 5% aqueous 
NaOH (100 mL), dried and concentrated in vacuo. Purification via flash column 
chromatography (40-60 ºC petrol:Et2O, 10:1 to 0:1) gave 134 (168 mg, 13%) as a 
cream solid. 
δH (600 MHz, CDCl3) 3.86 (3H, s, C(6)H3), 6.95 (2H, d, J 9.0, 2×C(4)H), 7.46 (2H, t, 
J 7.5, 2×m-PhH), 7.55 (1H, t, J 7.5, p-PhH), 7.75 (2H, d, J 8.3, 2×o-PhH), 7.82 (2H, 
d, J 9.0, 2×C(3)H); δC (150 MHz, CDCl3) 51.6 (CH3), 109.6, (CH), 124.3 (CH), 125.8 
(CH), 126.2 (C), 128.0 (CH), 128.7 (CH), 134.3 (C), 159.3 (C), 191.7 (C(1)); m/z (CI) 
213 (100%, [M+H]+). 
Phenyl(thiophen-2-yl)methanone, 133.116 
 
A solution of diisopropyl 1-benzoylhydrazine-1,2-dicarboxylate117 (308 mg, 1.00 
mmol) in dry THF (20 mL) was cooled to -78 ºC and thiophen-2-ylmagnesium 
bromide (1.0 M in THF, 2.5 mL, 2.5 mmol) was added. The reaction mixture was 
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stirred at -78 ºC for 30 min, then at 0 ºC for a further 30 min before being quenched 
by addition of saturated aqueous NH4Cl (5 mL). The aqueous layer was extracted with 
Et2O (3×50 mL), and the combined organic layers were dried and concentrated in 
vacuo. Purification via flash column chromatography (40-60 ºC petrol:Et2O, 100:1) 
gave 133 (54 mg, 29%) as a white solid. 
δH (600 MHz, CDCl3) 6.16 (1H, dd, J 4.9, 3.8, C(4)H), 7.50 (2H, t, J 7.5 (2×m-PhH), 
7.59 (1H, t, J 7.5, p-PhH), 7.65 (1H, dd, J, 3.8, 1.1, (C(3)H), 7.72 (1H, dd, J 4.9, 1.1, 
C(5)H), 7.85-7.88 (2H, m, 2×o-PhH); δc (150 MHz, CDCl3) 128.1 (C(2)H), 128.5 
(CH), 129.3 (CH), 132.4 (CH), 134.4 (CH), 135.0 (CH), 138.2 (C), 143.7 (C), 188.4 
(C(1)); m/z (CI) 189 (100%, [M+H]+).  
Methyl (tert-butoxycarbonyl)-L-methioninate {Boc-L-Met-OMe}, 125.118 
 
A mixture of thionyl chloride (0.80 mL, 13.2 mmol) in CH3OH (7 mL), was stirred at 
0 ºC for 10 min before L-methionine (4.00g, 26.8 mmol) was added and the reaction 
was stirred at rt for a 18 h. The reaction mixture was then concentrated in vacuo, 
redissolved in CH2Cl2 (250 mL), and cooled to 0 ºC. Triethylamine (15.1 mL, 107 
mmol) was then added slowly, followed by Boc2O (10.5 g, 48.2 mmol), and the 
reaction was stirred at rt for 15 h before being concentrated in vacuo. Purification via 
flash column chromatography (40-60 ºC petrol:Et2O, 5:1) yielded Boc-L-Met-OMe 
125 (7.00 g, 99%) as a colourless oil. 
δH (600 MHz, CDCl3) 1.43 (9H, s, 3×C(9)H3), 1.88-1.96 (1H, m, C(4)HA), 2.09 (3H, 
s, C(6)H3), 2.09-2.16 (1H, m, C(4)HB), 2.53 (2H, t, J 7.9, C(5)H2), 3.75 (3H, s, 
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C(1)H3), 4.39-4.44 (1H, m, C(3)H), 5.12 (1H, d, J 7.2, NH); δc (150 MHz, CDCl3) 
15.6 (C(6)H3), 28.4 (C(9)H3), 30.1 (C(5)H2), 32.3 (C(4)H2), 52.6 (C(1)H3), 52.8 
(C(3)H). 80.2 (C(8)), 155.4 (C(7)) 175.0 (C(2)); m/z (CI) 104 (100%), 264 (5%, 
[M+H]+). 
Methyl (tert-butoxycarbonyl)glycinate {Boc-Gly-OMe}, 126.119 
 
A stirring suspension of glycine methyl ester hydrochloride (3.00 g, 23.9 mmol) and 
NaCl (4.74 g, 81.2 mmol) in CHCl3 was treated with a solution of NaHCO3 (2.01 g, 
23.9 mmol) in H2O (20 mL), followed by a solution of Boc2O (5.22 g, 23.9 mmol) in 
CHCl3 (30 mL). The resulting biphasic mixture was stirred vigorously at reflux for 2 
h, then allowed to cool to rt, before the layers were separated. The aqueous layer was 
extracted with CHCl3 (2×50 mL) and the combined organics were dried and 
concentrated in vacuo to yield Boc-Gly-OMe 126 (4.37 g, 97%) as a colourless oil. 
δH (600 MHz, CDCl3) 1.41 (9H, d, 3×C(3)H3), 3.71 (3H, s, C(1)H3), 3.88 (2H, d, J 
5.7, C(3)H2), 5.11 (1H, br s, NH); δC (150 MHz, CDCl3) 28.4 (C(6)H3), 42.3 (C(3)H2), 
52.3 (C(1)H3), 80.1 (C(5)), 115.8 (C), 171.0 (C); m/z (ES
+) 190 (100%, [M+H]+). 
Methyl N-(tert-butoxycarbonyl)-S-(2-hydroxy-2,2-diphenylethyl)-L-
homocysteinate, 129. 
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A reaction mixure of benzophenone (273 mg, 1.5 mmol) and Boc-L-Met-OMe 125 
(502 mg, 1.91 mmol) in acetonitrile (15 mL) in a pyrex photoreactor immersion well, 
were degassed for 30 min, then irradiated with a 125 W, medium pressure mercury 
lamp for 40 min. The reaction solvent was concentrated in vacuo. Purification of the 
crude mixture via flash column chromatgraphy (40-60 ºC petrol:Et2O, 7:3) gave 
benzophenone 13 (173 mg, 64%), Boc-L-Met-OMe 125 (336 mg, 67% wrt 125 starting 
material), ε-photoadduct 129 (88 mg, 13%) as a yellow oil. 
δH (600 MHz, CDCl3) 1.43 (9H, s, 3×C(9)H3), 1.81-1.88 (1H, m, C(4)HA), 2.02-2.08 
(1H, m, C(4)HB), 2.46 (2H, t, J 7.5, C(5)H2), 3.43 (2H, s, C(6)H2), 3.70 (3H, s, 
C(1)H3), 4.36-4.42 (1H, m, C(3)H), 5.04 (1H, d, J 7.9, NH), 7.24 (2H, t, J 7.9, 2×p-
PhH), 7.31 (4H, t, J 7.9, 4×m-PhH), 7.43 (4H, d, J 7.9, 4×o-PhH); δc (150 MHz, 
CDCl3) 28.4 (CH3), 30.0 (CH2), 33.1 (CH2), 46.4 (CH2), 52.5 (CH3), 52.6 (CH), 80.3 
(C), 126.2 (CH), 127.4 (CH), 128.4 (CH), 145.6 (C), 145.7 (C), 155.4 (C), 172.9 (C); 
νmax (solid) 2954, 2832, 2380, 1710, 1601; m/z (ES+) 468 (100%, [M+Na]+); HRMS 
(ESI+) C24H31NO5SNa
+ ([M+Na]+) requires 468.1815, measured 468.1800. 
(S,S), (S,R) Benzophenone-Methionine γ-photoadduct disastereoisomers, 
(2S,2R)-130 and (2S,4R)-130. 
 
A reaction mixure of benzophenone (233 mg, 1.28 mmol) and Boc-L-Met-OMe 125 
(427 mg, 1.62 mmol) in acetonitrile (30 mL) in ) in a pyrex photoreactor immersion 
well, was degassed for 30 min, then irradiated with a 125 W, medium pressure mercury 
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lamp for 3 h. The reaction solvent was concentrated in vacuo. Purification of the crude 
mixture via flash column chromatgraphy (40-60 ºC petrol:Et2O, 7:3) isolated Boc-L-
Met-OMe 125 (102 mg, 24%) and γ-photoadduct (15 mg, 3%) as a 1 : 0.52 mixture of 
diastereoisomers 130a and 130b.  
δH (600 MHz, CDCl3) 1.45 (3×130a-C(9)H3), 1.53 (3×130b-C(9)H3), 1.59 (130a-
C(6)H3), 1.70 (130b-C(6)H3), 1.73-1.82 (130b-C(4)H2), 1.82-1.80 (130a-C(4)HA), 
2.12-2.18 (130a-C(4)HB), 3.44 (130b-OH), 3.49 (130a-OH), 3.68 (130b-C(1)H3), 
3.75 (130a-C(1)H3), 3.75-3.80 (130a-C(5)H, 130b-C(5)H), 4.51-4.59 (130b-C(3)H), 
5.03-5.08 (130b-NH), 5.20-5.26 (130a-NH), 7.16-7.22 (ArH), 7.26-7.33 (ArH), 7.47-
7.55 (ArH); δC (150 MHz, CDCl3) 17.3 (CH), 173 (CH), 28.5 (CH3), 35.2 (CH2), 36.1 
(CH2), 52.2 (CH3), 52.4 (CH3), 52.5 (CH3), 55.1 (CH), 56.2 (CH), 80.1 (C), 80.2 (C), 
80.4 (C), 80.5 (C), 125.7 (CH) 125.8 (CH), 125.8 (CH), 126.0 (CH), 127.1 (CH), 128.2 
(CH), 128.3 (CH), 128.5 (CH), 128.6 (CH), 144.3 (C), 146.1 (C), 146.3 (C), 155.2 
(C), 156.0 (C), 173.1 (C), 173.4 (C). m/z (FTMS) 468 (100%, [M+Na]+). 
Methyl 2-((tert-butoxycarbonyl)amino)-3-hydroxy-3,3-diphenylpropanoate, 131. 
 
A reaction mixure of benzophenone (547 mg, 3.00 mmol) and Boc-Gly-OMe 126 (568 
mg, 3.00 mmol) in acetonitrile (30 mL) in ) in a pyrex photoreactor immersion well, 
were degassed for 30 min, then irradiated with a 125 W, medium pressure mercury 
lamp for 40 100 min. The reaction solvent was concentrated in vacuo. Purification of 
the crude mixture via flash column chromatgraphy (40-60 ºC petrol:Et2O, 7:3) isolated 
Experimental 
 
148 
 
benzophenone (294 mg, 54%), Boc-Gly-OMe (184 mg, 32%) and photoadduct 131 
(150 mg, 13%) as a yellow oil. 
NB Diastereotopic protons on phenyl ring adjacent to a stereogenic centre in carbon 
NMR. 
δH (600 MHz, CDCl3) 1.30 (9H, s, 3×C(7)H3), 3.50, (3H, s, C(1)H3), 4.44 (1H, s, 
OH), 5.35 (1H, d, J 9.1, C(3)H), 5.50 (1H, s, J 9.1, NH), 7.17-7.23 (2H, m, 2×p-
PhH), 7.27-7.32 (4H, m, 4×m-PhH), 7.46-7.52 (4H, m, 4×o-PhH); δC (150 MHz, 
CDCl3) 28.2 (C(7)H3), 52.3 (C(1)H3), 58.3 (C(3)H), 79.4 (C(4)H), 80.4 (C(6)), 125.3 
(o-PhH), 125.7 (o-PhH), 127.4 (p-PhH), 127.7 (p-PhH), 128.4 (m-PhH), 128.6 (2×m-
PhH), 142.2 (C), 144.0 (C), 173.6 (C); m/z (ES) 394 (100%, [M+Na]+), 371 (15%, 
[M+H]+). 
Naphthalen-2-yl(p-tolyl)methanone, 116.120 
 
Thionyl chloride (1.0 mL, 13.8 mmol) was added dropwise to 4-methyl benzoic acid 
(500 mg, 3.67 mmol) and stirred at rt for 2 min, then at reflux for 2 h. The reaction 
mixture was cooled to rt and concentrated in vacuo. The residue redissolved in dry 
dichloroethane (100 mL) and naphthalene (941 mg, 7.34 mmol) then AlCl3 (538mg, 
4.04 mmol) were added. The resulting mixture was heated at 80 ºC for 14 h, and then 
the reaction solvent was removed in vacuo. Purification via flash column 
chromatography (40-60 ºC petrol:Et2O, 50:1) twice yielded 116 (204 mg, 23%) as a 
yellow solid. 
δH (600 MHz, CDCl3) 2.43 (3H, s, C(1)H3), 7.27 (2H, dd, J 8.5, 0.6, 2×C(4)H), 7.47-
7.55 (3H, m, 3×C(Ar)H), 7.57 (1H, dd, J 7.0, 1.3 C(Ar)H), 7.78 (2H, br d, J 8.3, 
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2×C(3)H), 7.92 (1H, br d J 8.1, C(Ar)H), 8.00 (1H, dd, J 8.1, C(Ar)H), 8.05 (1H, br 
d, J 8.3, C(Ar)H); δC (150 MHz, CDCl3) 21.9 (CH3), 124.5 (CH), 125.8 (CH), 126.5 
(CH), 127.3 (CH), 127.5 (CH), 128.5 (CH), 129.3 (CH), 130.7 (CH), 131.0 (C), 131.1 
(CH), 133.8 (C), 135.8 (C), 136.8 (C), 144.4 (C), 197.9 (C(6)); νmax (oil) 3009, 2980, 
2932, 2837, 1676, 1659, 1610; m/z (CI) 247 (100%, [M+H]+); HRMS (CI) C18H15O
+ 
([M+H]+) requires 247.11174, measured 247.11132. 
(4-(Bromomethyl)phenyl)(naphthalen-2-yl)methanone, 117.120 
 
A solution of naphthalen-2-yl(p-tolyl)methanone 116 (121 mg, 0.49 mmol) in benzene 
(3 mL) was treated with N-bromosuccinimide (87 mg, 0.49 mmol) then AIBN (12 mg, 
0.07 mmol) and heated to 80 ºC for 16 h. The reaction solvent was then removed in 
vacuo. Purification via flash column chromatography (40-60 ºC petrol:Et2O, 100:1) 
gave 117 (96 mg, 60%) as a yellow crystalline solid. 
δH (600 MHz, CDCl3) 2.52 (2H, s, C(1)H2), 746-7.59 (6H, m, 6×C(Ar)H), 7.85 (2H, 
dt, J 8.6, 1.9, 2×C(Ar)H), 7.94 (1H, br d, J 8.1, C(Ar)H), 8.02 (1H, d, J 8.1, C(Ar)H), 
8.09 (1H, d, J 8.5, C(Ar)H); δC (150 MHz, CDCl3) 32.3 (CH2), 124.5 (CH), 125.7 
(CH), 126.7 (CH), 127.5 (CH), 128.0 (CH), 128.6 (CH), 129.2 (CH), 131.0 (C), 131.0 
(CH), 131.6 (CH), 133.8 (C), 136.1 (C), 138.2 (C), 143.0 (C), 197.4 (C(6)); νmax (solid) 
2942, 2831, 1652; m/z (CI) 326 (38%, [81M]+), 324 (39%, [79M]+), 247 (100%, [M-
Br]+); HRMS (CI) C18H14BrO
+
 requires 325.02225; measured 325.02190. 
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(4-((4-(6-Imino-1,6-dihydropyridazin-3-l)phenoxy)methyl)phenyl)(naphthalen-
2-yl) methanone, 118. 
 
A solution of aryl pyridazine 31 (18.3 mg, 0.098 mmol) in DMF (0.1 mL)2.21.1 was 
added to NaH (4.0 mg, 0.11 mmol) in DMF (0.3 mL) at 0 ºC and stirred for 20 min. 
Naphthalene 117 (35 mg, 0.11 mmol) was added in one portion and the reaction 
mixture stirred at rt for 16 h, before the reaction solvent was removed in vacuo. 
Purification via flash column chromatography (EtOAc) gave 118 (33 mg, 77%) as a 
white solid. 
δH (600 MHz, CDCl3) 4.97 (2H, s, NH2), 5.20 (2H, s, C(9)H2), 6.87 (1H, d, J 9.0, 
C(3)H), 7.07 (2H, d, J 8.7, 2×C(6)H), 7.49-7.56 (5H, m, 5×C(Ar)H), 7.57-7.62 (2H, 
m, 2×C(Ar)H), 7.87-7.95 (4H, m, 5×C(Ar)H), 8.01 (1H, d, J 7.9, C(Ar)H), 8.09 (1H, 
d, J 8.3, C(Ar)H); δC (150 MHz, CDCl3) 69.5 (CH2), 115.3 (CH), 115.4 (CH), 124.5 
(CH), 125.8 (CH), 126.0 (CH), 126.6 (CH), 127.2 (CH), 127.5 (CH), 127.7 (CH), 
127.9 (CH), 128.6 (CH), 130.0 (C), 130.9 (CH), 131.0 (C), 131.5 (CH), 133.8 (C), 
136.3 (C), 138.0 (C), 142.5 (C), 152.2 (C), 158.0 (C), 159.3 (C), 197.7 (C); νmax (solid) 
2830, 2350, 1650; mp (EtOH) 101-105 ºC; m/z (ES+) 432, (100%, [M+H]+); HRMS 
(ES+) C28H22N3O2
+ ([M+H]+) requires 432.1712, measured 432.1712. 
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Allyl 4-(3-(4-((4-(2-naphthoyl)benzyl)oxy)phenyl)-6-iminopyridazin-1(6H)-
yl)butanoate, 119. 
 
A reaction mixture of allyl-4-bromobutrate (7.2 mg, 0.035 mmol) and pyridazine 118 
(10 mg, 0.023 mmol) in DMF (0.1 mL) was heated to 80 °C for 72 h. The reaction 
solvent was removed in vacuo and the residue was tritruated with EtOAc (2×5 mL) to 
give 119 (10 mg, 98%) as a grey solid. 
δH (600 MHz, CDCl3:CD3OD, 1:1) 2.24 (2H, quin, J 7.0, C(2ʹ)H2), 2.59 (2H, t, J 6.8, 
C(3ʹ)H2), 4.41 (2H, t, J 7.3, C(1ʹ)H2), 4.51 (2H, dt, J 5.8, 1.3, C(5ʹ)H2), 5.18 (1H, dq, 
J 10.4, 1.2, C(7ʹ)HA), 5.22-5.26 (3H, m, C(9)H2, C(7ʹ)HB), 5.78-5.85 (1H, m, C(6ʹ)H), 
7.11 (2H, d, J 9.0, 2×C(Ar)H), 7.47-7.57 (7H, m, 7×C(Ar)H), 7.65 (1H, d, J 9.6, 
C(Ar)H), 7.84-7.88 (3H, m, 3×C(Ar)H), 7.94 (1H, d, J 8.1, C(Ar)H), 8.01 (1H, d, J 
8.5 C(Ar)H), 8.04 (1H, d, J 8.0 C(Ar)H), 8.15 (1H, d, J 9.6, C(Ar)H); δC (150 MHz, 
CDCl3:CD3OD, 1:1) 22.8 (C(2ʹ)H2), 31.5 (C(3ʹ)H2), 57.0 (C(1ʹ)H2), 67.1 (C(5ʹ)H2), 
70.7 (C(9)H2), 117.0 (CH), 119.9 (C(7ʹ)H2), 125.9 (CH), 126.7 (CH), 127.0 (CH), 
127.9 (CH), 128.5 (CH), 128.7 (CH), 129.2 (CH), 129.6 (CH), 132.2 (CH), 132.7 
(CH), 132.8 (C), 132.9 (CH), 133.0 (CH), 135.2 (C), 137.3 (C), 139.2 (C), 143.7 (C), 
152.1 (C), 153.7 (C), 161.8 (C), 162.4 (C), 174.2 (C(4ʹ), 199.8 (C(14)); νmax (solid) 
3410, 2990, 1648, 1571; mp 242-244 ºC; m/z (ES+) 558, (100%, [M+H]+); HRMS 
(ES+) C35H31N3O4 requires 558.2393; measured 560.0221 [M+2H]
+. 
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4-(3-(4-((4-(2-Naphthoyl)benzyl)oxy)phenyl)-6-iminopyridazin-1(6H)-
yl)butanoic acid, 115. 
 
To a solution of 119 (9.9 mg, 0.017 mmol) in THF (1 mL) and H2O (1mL) was added 
NaOH (5 mg) and the resulting mixture was stirred at 50 °C for 3 h. The reaction 
solution was then cooled to 10 °C and washed with EtOAc (5 mL). The aqueous layer 
was acidified to pH 1.0 by addition of 1 M aqueous HCl and then stirred for 1 h, before 
the solvent was removed in vacuo. Tritruation with H2O (3 mL) yielded 115 (9 mg, 
99%) as a white solid. 
δH (600 MHz, CDCl3:CD3OD, 1:1) 2.08-2.15 (2H, m, C(2ʹ)H2), 2.33-2.38 (2H, m, 
C(3ʹ)H2), 4.39-4.44 (2H, m, C(1ʹ)H2), 5.28 (2H, s, C(9)H2), 6.91 (1H, d, J 8.7, C(3)H), 
7.14 (2H, d, J 8.9, 2×C(7)H), 7.47-7.65 (5H, m, 5×C(Ar)H), 7.81 (1H, d, J 8.7, C(2)H), 
7.86 (2H, d, J 8.3, 2×C(Ar)H), 7.93 (2H, d, J 8.7, 2×C(6)H), 7.97 (1H, d, J 8.1, 
C(Ar)H), 7.99 (1H, d, J 8.9, C(Ar)H), 8.07 (1H, d, J 8.3, C(Ar)H), 8.22 (1H, d, J 9.4, 
C(Ar)H); δC (150 MHz, CDCl3:CD3OD, 1:1) 24.3 (CH2), 38.4 (CH2), 57.9 (CH2), 70.5 
(CH2), 116.7 (CH), 117.3 (CH), 125.6 (CH), 126.5 (CH), 126.7 (CH), 127.8 (CH), 
128.5 (CH), 129.0 (CH), 129.5 (CH), 129.8 (CH), 131.9 (CH), 132.1 (C), 132.5 (CH), 
132.7 (CH), 135.2 (C), 137.4 (C), 139.1 (C), 144.2 (C), 153.4 (C), 153.6 (C), 153.8 
(C), 179.9 (C(4ʹ)), 199.8 (C(14)); νmax (solid) 3410, 2990, 1648, 1571; mp 234-237 ºC; 
m/z (ES+) 518 (100%, [M+H]+); HRMS (ES+) C32H26N3O4
+ (M+) requires 516.1923, 
measured 516.1971. 
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4-(2-Methylimidazo[1,2-b]pyridazin-6-yl)phenol 144, and 
2-Methyl-6-(4-(prop-2-yn-1-yloxy)phenyl)-2,3-dihydroimidazo[1,2-b]pyridazine, 
143. 
 
A solution of NaH (65% in mineral oil, 99 mg, 2.67 mmol) in DMF (5 mL) was added 
dropwise to a solution of 31 (500 mg, 2.67 mmol) in DMF (1 mL) at 0 °C. The 
resulting mixture was stirred at 0 °C for 30 min. Propargyl bromide (85% in toluene, 
357 µL, 3.21 mmol) was then added and the reaction was stirred at 0 ºC for 90 min, 
before being quenched with H2O (1 mL) and concentrated in vacuo. Purification via 
flash column chromatography (40-60 °C petrol: EtOAc, 1:1) yielded 31 (40 mg, 1%), 
142 (94 mg, 16%), 144 (25 mg, 7%) and 143 (40 mg, 1%) with respect to requisite 
starting materials. 
Data for 144: δH (600 MHz, CD3OD) 2.45 (3H, s, C(4ʹ)H3), 6.91 (2H, d, J 8.8, 
2×C(7)H), 7.54 (1H, d, J 9.5, C(2)H), 7.79 (1H, s, C(3ʹ)H), 7.83 (3H, m, C(3)H, 
2×C(6)H); δC (150 MHz, CD3OD) 14.8 (C(4ʹ)H3), 115.6 (C(3ʹ)H), 117.0 (C(7)H), 
117.8 (C(2)H), 124.9 (C(3)H), 128.0 (C(5)), 129.7 (C(6)H), 139.1 (C(1)), 144.2 
(C(2ʹ)), 153.2 (C(4)), 160.6 (C(8)); m/z (EI) 226 (100%, [M+H]+), 210 (95%); HRMS 
(ES+) C13H12N3O
+ ([M+H]+) requires 226.0980, measured 226.0985. 
Data for 143: δH (600 MHz, CD3OD) 2.45 (3H, s, C(4ʹ)H3), 3.00 (1H, t, J 2.4, C(11)H) 
4.80 (2H, d, J 2.4, C(9)H2), 7.10 (2H, d, J 8.9, 2×C(7)H), 7.63 (1H, d, J 9.6, C(2)H), 
7.85-7.87 (3H, m, C(3ʹ)H, C(3)H), 7.95 (2H, d, J 8.9, 2×C(6)H); δC (150 MHz, 
CD3OD) 14.3 (C(4ʹ)H3), 56.7 (C(9)H2), 77.1 (C(11)H), 115.7 (C(3ʹ)H), 116.3 
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(2×C(7)H), 117.6 (C(2)H), 124.8 (C(3)H), 129.3 (2×C(6)H), 79.5 (C(10)), 129.7 
(C(5)), 139.1 (C(1)), 144.4 (C(2ʹ)), 152.6 (C(4)), 160.7 (C(8)); m/z (EI) 264 (100%, 
[M+H]+), 279 (20%, [M+Na]+); HRMS (ES+) C16H14N3O
+ ([M+H]+) requires 
264.1137, measured 264.1140. 
6-(4-(Prop-2-yn-1-yloxy)phenyl)pyridazin-3-amine, 142.30 
 
A solution of NaH (65% in mineral oil, 39.5 mg, 1.07 mmol) in DMF (5 mL) was 
added dropwise to a solution of 31 (200 mg, 1.07 mmol) in DMF (5 mL) over 1 h at 0 
°C, and the resulting mixture was stirred at 0 °C for 90 min. Propargyl bromide (85% 
in toluene, 143 µL, 1.28 mmol) was then added and the reaction was allowed to warm 
to rt over 4 h, before being quenched with H2O (1 mL) and concentrated in vacuo. 
Purification via flash column chromatography (40-60 °C petrol: EtOAc, 2:3) yielded 
142 (92.9 mg, 34%) as a white solid. 
δH (600 MHz, CD3OD) 2.94 (1H, t, J 2.4, C(11)H), 4.78 (2H, d, J 2.4, C(9)H2), 7.00 
(1H, d, J 9.3, C(2)H), 7.08 (2H, d, J 8.9, 2×C(7)H), 7.73 (1H, d, J 9.3, C(3)H), 7.82 
(2H, d, J 8.9, 2×C(6)H); δC (150 MHz, CD3OD) 56.7 (C(9)H2), 77.0 (C(11)H), 79.6 
(C(10)), 116.3 (2×C(7)H), 117.6 (C(2)H), 128.1 (C(3)H), 128.5 (C(6)H), 131.3 (C), 
152.7 (C), 159.9 (C), 161.3 (C); νmax (solid) 3436, 3260, 3148, 3046, 2930, 2109, 1630, 
1603; mp (EtOH) 167-168 °C; {Lit30 117-119 ºC}; m/z (ES+) 226 (10%, [M+H]+), 218 
(100%); HRMS (ES+) C13H12N3O ([M+H]
+) requires 226.0980, measured 226.0989. 
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6-phenylpyridazin-3-amine, 148.121 
 
A suspension of phenylboronic acid (1.00 g, 8.20 mmol), 3-amino-6-chloropyridazine 
33 (886 mg, 6.83 mmol) and Pd(PPh3)2Cl2 (240 mg, 0.34 mmol) in 1,4-dioxane (50 
mL) was degassed and stirred at rt for 10 min. Degassed 2 M aqueous Na2CO3 (6.9 
mL) was added and the reaction mixture was heated rapidly to reflux for 16 h. The 
resulting mixture was then concentrated in vacuo. Purification via flash column 
chromatography (40-60 petrol : EtOAc, 1:1 to 0:1) gave 148 (625 mg, 53%) as a 
white solid. 
δH (600 MHz, CDCl3) 6.97 (1H, d, J 9.4, C(2)H), 7.39 (1H, t, J 7.5, C(8)H), 7.44 (2H, 
t, J 7.5, 2×C(7)H), 7.67 (1H, d, J 9.4, C(3)H), 7.82 (2H, d, J 7.5, 2×C(6)H); δC (150 
MHz, CDCl3) 116.2 (C(2)H), 126.1 (C(6)H), 127.2 (C(3)H), 128.8 (C(7)H), 128.8 
(C(8)H), 136.6 (C(5)), 152.0 (C(4)), 159.5 (C(1)); m/z (ES+) 172 (100%, [M+H]+). 
6-phenyl-2-(prop-2-yn-1-yl)pyridazin-3(2H)-imine, 147. 
 
A reaction mixture of 148 (26 mg, 0.15 mmol) and propargyl bromide (89% in toluene, 
20 μL, 0.18 mmol) in DMF (0.1 mL) was heated at 50 °C for 3 h. After this time 
EtOAc (5 mL) was added and the reaction cooled to 0 °C. The resulting precipitate 
was filtered and washed with cold EtOAc (2 mL) to give 147 (35 mg, 80%) as a white 
solid. 
δH (600 MHz, CD3OD) 3.25 (1H, t, J 2.6, C(3ʹ)H), 5.29 (2H, d, J 2.6, C(1ʹ)H2), 7.53-
7.59 (3H, m, C(8)H, 2×C(7)H), 7.67 (1H, d, J 9.4, C(3)H), 7.99-8.03 (2H, m, 
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2×C(6)H), 8.37 (1H, d, J 9.7, C(2)H); δC (150 MHz, CD3OD) 48.2 (C(1ʹ)H2), 74.4 
(C(2ʹ)), 78.9 (C(3ʹ)H), 127.0 (C(3)H), 127.8 (C(6)H), 130.4 (C(7)H), 132.4 (C(8)H), 
133.5 (C(2)H), 134.0 (C(5)), 152.0 (C(4)), 154.0 (C(1)); m/z (ES+) 210 (100%, 
[M+H]+); HRMS (ES+) C13H12N3 ([M+H]
+) requires 210.1031, measured 210.1022. 
2-methyl-6-phenylimidazo[1,2-b]pyridazine, 149. 
 
Method A: To a solution of 6-phenyl-2-(prop-2-yn-1-yl)pyridazin-3(2H)-imine, 147 
(17 mg, 0.06 mmol) in DMF (0.1 mL) was added sodium hydride (4.3 mg, 0.12 mmol) 
at 0 ºC. The reaction mixture was stirred at 0 ºC for 30 min, then rt for 30 min before 
the reaction solvent was removed in vacuo. Purification via flash column 
chromatography (EtOAc) gave 149 (10 mg, 69%) as a white solid. 
Method B:93 A reaction mixture of 1-amino-6-phenylpyridazine 148 (100 mg, 0.58 
mmol), chloroacetone (53 µL, 0.64 mmol) in ethanol (50 mL) was heated at reflux for 
3 h. The reaction mixture was cooled to rt and was treated with 1M aqueous NaHCO3 
(0.3 mL), before being heated at reflux for a further 14 h. The reaction solvents were 
removed in vacuo, and the resulting residue was redissolved in CHCl3 (50 mL), 
washed with H2O (50 mL), dried and concentrated in vacuo to give 149 (82 mg, 68%) 
as a cream solid. 
δH (600 MHz, CDCl3) 2.54, (3H, s, C(4ʹ)H3), 7.44 (1H, d, J 9.4 C(3)H), 7.48-7.54 (3H 
m, C(8)H, 2×C(7)H), 7.80 (1H, s, C(3ʹ)H), 7.91 (1H, d, J 9.4, C(2)H), 7.93-7.96 (2H, 
m, 2×C(6)H); δC (150 MHz, CDCl3) 15.0 (C(4ʹ)H3), 114.5 (C(3ʹ)H), 115.8 (C(3)H), 
124.6 (C(2)H), 127.1 (C(6)H), 129.2 (C(7)H), 136.0 (C(5)), 138.1 (C(1)), 144.4 
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(C(2ʹ)), 151.4 (C(4)); m/z (ES+) 209 (100%, [M]+), 214 (50%); HRMS (ES+) C13H12N3 
([M+H]+) requires 210.1031, measured 210.1036. 
Allyl 4-(6-imino-3-(4-(prop-2-yn-1-yloxy)phenyl)pyridazin-1(6H)-yl)butanoate 
hydrobromide, 150.30 
 
A reaction mixture of 142 (130 mg, 0.58 mmol) and allyl bromobutyrate (120 mg, 
0.58 mmol) in DMF (0.1 mL) was heated at 80 °C for 6 h. The product precipitated 
upon addition of cold EtOAc (7 mL) and was filtered to yield 150 (168 mg, 67%) as a 
white solid. 
δH (600 MHz, CD3OD) 2.24 (2H, quint, J 6.8, C(2′)H2), 2.61 (2H, t, J 6.8, C(3′)H2), 
3.00 (1H, t, J 2.4, C(11)H), 4.41-4.47 (4H, m, C(1′)H2, C(5ʹ)H2), 4.81 (2H, d, J 2.4, 
C(9)H2), 5.14 (1H, dd, J 10.5, 1.2, C(7ʹ)HA), 5.22 (1H, dd, J 17.2, 1.2, C(7ʹ)HB), 5.77-
5.83 (1H, m, C(6ʹ)H), 7.13 (2H, d, J 8.9, 2×C(7)H), 7.60 (1H, d, J 9.5, C(3)H), 7.95 
(2H, d, J 8.9, 2×C(6)H), 8.29 (1H, d, J 9.5, C(2)H); δC (150 MHz, CD3OD) 22.5 
(C(2′)H2), 31.3 (C(3′)H2), 56.8 (CH2), 56.9 (CH2), 66.5 (CH2), 77.3 (C(11)H), 79.3 
(C(10)), 116.7 (C(7)H), 118.7 (C(7ʹ)H2), 126.7 (CH), 127.1 (C), 129.3 (CH), 132.6 
(CH), 133.4 (CH), 151.8 (C), 153.9 (C), 161.5 (C), 174.0 (C(4ʹ)) {1 C signal 
unobserved}; νmax (solid) 3318, 3259, 3218, 3029, 2120; mp (EtOH) 159-161 °C 
{Lit30107-109 ºC}; m/z (ES+) 352 (100%, [M+H]+). 
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4-(6-Imino-3-(4-(prop-2-yn-1-yloxy)phenyl)pyridazin-1(6H)-yl)butanoic acid 
hydrochloride, 141.30 
 
To a solution of 150 (20 mg, 0.046 mmol) in THF (1 mL) and H2O (1mL) was added 
NaOH (5 mg, 0.208 mmol)) and the resulting mixture was stirred at 50 °C for 3 h. The 
reaction solution was then cooled to 10 °C and washed with EtOAc (5 mL). The 
aqueous layer was acidified to pH 1.0 by addition of 1 M aqueous HCl and then stirred 
for 1 h, before the solvent was removed in vacuo. Tritruation with H2O (3 mL) yielded 
141 (18 mg, 99%) as a white solid. 
δH (600 MHz, CD3OD) 2.22 (2H, quint, J 7.1, C(2′)H2), 2.55 (2H, t, J 6.7, C(3′)H2), 
2.87 (1H, t, J 2.2, C(11)H), 4.43 (2H, t, J 7.1, C(1′)H2), 4.75-4.80 (2H, m, C(9)H2), 
7.13 (2H, d, J 8.9, 2×C(7)H), 7.62 (1H, d, J 9.6, C(3)H), 7.93 (2H, d, J 8.9, 2×C(6)H), 
8.24 (1H, d, J 9.6, C(2)H); δC (150 MHz, CD3OD) 22.8 (C(2′)H2), 31.1 (C(3′)H2), 57.0 
(CH2), 57.0 (CH2), 77.3 (C(11)), 79.4 (C(10)) 116.8 (C(7)H), 126.7 (C(3)H), 129.4 
(CH), 132.7 (CH), 136.3, (C), 150.3 (C), 152.2 (C), 161.3 (C), 177.3 (C); νmax (oil) 
3338, 3259, 3069, 1722; mp (EtOH) 261-264 °C {Lit 180-183 ºC}; m/z (ES+) 312 
(100%, [M+H]+). 
tert Butyl (2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)carbamate, 151.122 
 
To a solution of 3,6,9-trioxaundecan-1-amine (90.9 µL, 0.458 mmol) in ethanol (2 
mL) at 0 ºC was added Boc2O (100 mg, 0.458 mmol), and the reaction mixture was 
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allowed to warm to rt over 12 h. The reaction solvent was removed in vacuo, and the 
residue was redissolved in CH2Cl2 (20 mL) before being washed with H2O (20 mL), 
brine (20 mL) and dried and concentrated in vacuo. Purification via flash column 
chromatography (40-60 ºC petrol:EtOAc, 1:1) gave 151 (111 mg, 76%) as a white 
solid. 
δH (600 MHz, CDCl3) 1.39 (9H, s, 3×C(1)H3), 3.26 (2H, q, J 5.1, C(4)H2), 3.34 (2H, 
t, J 5.1, C(11)H2), 3.49 (2H, t, J 5.1, C(5)H2), 3.55-3.58 (2H, m, CH2), 3.59-3.61 (2H, 
m, CH2), 3.61-3.65 (6H, m, 3×CH2), 5.05 (1H, br s, NH); δC (150 MHz, CDCl3) 28.5 
(C(1)H3), 40.4 (C(4)H2), 50.7 (C(11)H2), 70.1 (CH2), 70.3 (CH2), 70.7 (CH2), 70.7 
(CH2), 70.8 (CH2), 70.8 (CH2), 79.2 (C(2)), 156.1 (C(3)); m/z (ES
+) 341 (100%, 
[M+Na]+), 319 ([M+H]+, 15%), 219 (74%, [M-C5H8O2]
+). 
4-(3-(4-((1-(2,2-Dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azahexadecan-16-yl)-1H-
1,2,3-triazol-4-yl)methoxy)phenyl)-6-iminopyridazin-1(6H)-yl)butanoic acid 
hydrochloride, 152. 
 
A mixture of CuSO4.5H2O (1.1 mg, 0.0044 mmol) and sodium ascorbate (2.6 mg, 
0.0131 mmol) were premixed in degassed H2O (0.5 mL), then added to a suspension 
of 141 (10.1 mg, 0.029 mmol) and 151 (9.2 mg, 0.029 mmol) in degassed H2O (1 mL). 
The reaction mixture was stirred at rt for 6 h, before the solvent was removed in vacuo. 
Purification via flash column chromatography (CHCl3:CH3OH, 7:3) yielded 152 (5.1 
mg, 29%) as a white solid. 
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δH (600 MHz, CD3OD) 1.40 (9H, s, (3×C(21)H3), 2.10-2.16 (2H, m, C(2′)H2), 2.47 
(2H, t, J 6.3, C(3′)H2), 3.19 (2H, t, J 5.5, C(19)H2), 3.46 (2H, t, J 5.5, C(18)H2), 3.56 
(6H, s, 3×CH2), 3.57-3.63 (2H, m, CH2), 3.91 (2H, t, J 4.9, CH2), 4.42 (2H, t, J 6.3, 
C(1′)H2), 4.46 (2H, t, J 5.0, CH2), 5.26 (2H, s, C(9)H2), 7.19 (2H, d, J 8.9, 2×C(7)H), 
7.62 (1H, d, J 9.4, C(3)H), 7.97 (2H, d, J 8.9, 2×C(6)H), 8.18 (1H, s, C(11)H), 8.24 
(1H, d, J 9.4, C(2)H); δC (150 MHz, CD3OD) 24.0 (C(2′)H2), 28.8 (C(21)H3), 33.6 
(C(3′)H2), 41.2 (C(19)H2), 51.5 (CH2), 57.7 (C(1′)H2), 62.5 (CH2), 70.3 (CH2), 71.0 
(CH2), 71.2 (CH2), 71.3 (CH2), 71.4 (CH2), 80.3 (C(20)) 166.6 (C(7)H), 126.6 
(C(3)H), 129.3 (CH), 129.4 (CH), 132.4 (C(2)H), 144.4 (C), 151.7 (C), 153.8 (C), 
158.5 (C), 162.0 (C), 180.9 (C) {1 C signal unobserved}; m/z (ES+) 630 (100%, 
[M+H]+); HRMS (ES+) C30H44N7O8
+
 ([M+H]
+) requires 630.3251, measured 
630.3261. 
1-Azido-4-methylbenzene, 34.123 
 
A solution of p-toluidine (1.00 g, 9.33 mmol) in 2M aqueous HCl (15 mL) was cooled 
to –5 C and a solution of NaNO2 (773 mg, 11.2 mmol) in H2O (2.60 mL) was added. 
The reaction mixture was stirred at –5 C for 5 min before urea (67.2 mg, 1.12 mmol) 
was added. This reaction mixture was then added to a solution of NaN3 (1.21 g, 18.7 
mmol), NaOAc (2.30 g, 28.0 mmol) in H2O (15 mL) over 5 min whilst maintaining 
the temperature at 0 C. The resulting solution was stirred for a further 2 h at 0 C. 
Et2O (50 mL) and H2O (50 mL) were added and the organic layer was separated, 
washed with H2O (50 mL), dried, and concentrated in vacuo to give 34 as a yellow oil 
(1.151 g, 93%). 
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δH (600 MHz, CDCl3); 2.33 (3H, s, CH3), 6.93 (2H, d, J 8.4, 2×C(3)H), 7.16 (2H, d, J 
8.4, 2×C(2)H); δC (150 MHz, CDCl3); 21.0 (CH3), 118.9 (CH), 130.5 (CH), 134.7 (C), 
137.2 (C); m/z (ES+) 133 (100%, M+). 
1-azido-4-(bromomethyl)benzene, 35.123 
 
To a solution of 34 (966 mg, 7.25 mmol) in PhH (100 mL) was added N-
bromosuccinimide (1.42 g, 7.98 mmol) followed by AIBN (179 mg, 1.09 mmol) and 
the reaction was heated to 80 C for 4 h. The reaction mixture was concentrated in 
vacuo. Purification via flash column chromatography (petrol 40-60 C) yielded 35 as 
a yellow oil (1.175 g, 76%). 
δH (600 MHz, CDCl3); 4.48 (2H, s, CH2), 7.00 (2H, d, J 8.6, 2×C(3)H), 7.38 (2H, d, J 
8.6, 2×C(2)H); δC (150 MHz, CDCl3); 33.1 (CH2), 119.5 (CH), 130.7 (CH), 134.6 (C), 
140.3 (C); m/z (EI) 210 (100%, 79M+), 212 (100%, 81M+). 
6-(4-((4-Azidobenzyl)oxy)phenyl)pyridazin-3-amine, 36.30 
 
A solution of aryl pyridazine 31 (100 mg, 0.53 mmol) in DMF (0.2 mL) was added to 
NaH (65% in mineral oil, 20 mg, 0.53 mmol) in DMF (0.3 mL) at 0 ºC and stirred for 
30 min. Benzylbromide 35 (125 mg, 0.59 mmol) was added in one portion and the 
reaction mixture stirred at rt for 16 h, before the reaction solvent was removed in 
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vacuo. Purification via flash column chromatography (CH2Cl2:CH3OH, 100:2) gave 
36 (78.6 mg, 51%) as a yellow solid. 
δH (600 MHz, DMSO-d6) 5.14 (2H, s, C(9)H2), 6.38 (2H, s, NH2), 6.82 (1H, d, J 9.2, 
C(2)H), 7.09 (2H, d, J 8.9, 2×C(7)H), 7.16 (2H, d, J 8.6, 2×C(11)H), 7.52 (2H, d, J 
8.6, 2×C(12)H), 7.75 (1H, d, J 9.2, C(3)H), 7.89 (2H, d, J 8.9, 2×C(6)H); δC (150 
MHz, DMSO) 68.7 (CH2), 114.3 (CH), 115.1 (CH), 119.2 (CH), 124.9 (CH), 126.6 
(CH), 129.6 (CH), 133.9 (C), 139.0 (C), 148.6 (C), 149.6 (C), 154.6 (C), 159.5 (C); 
m/z (ES+) 319 (100%, [M+H]+). 
Allyl 4-(3-(4-((4-azidobenzyl)oxy)phenyl)-6-iminopyridazin-1(6H)-yl)butanoate, 
37.30 
 
A reaction mixture of allyl 4-bromobutyrate (50 mg, 0.24 mmol), 36 (76 mg, 0.24 
mmol) in DMF (0.1 mL) was heated to 50 °C for 16 h. The product precipitated upon 
addition of cold EtOAc (2 mL), and filtered to give a mixture of starting material and 
37, which was recrystallised twice with EtOAc (2 mL) to yield 37 (5.1 mg, 4%) as a 
brown oil. 
δH (600 MHz, CD3OD) 2.25 (2H, quint, J 6.8, C(2′)H2), 2.60 (2H, t, J 6.8, C(3′)H2), 
4.42 (2H, t, J 6.8, C(1′)H2), 4.49 (2H, dt, J 5.8, 1.3, C(5ʹ)H2), 5.13 (2H, s, C(9)H2), 
5.17 (1H, dd, J 10.5, 1.3, C(7′)HA), 5.23 (1H, dd, J 17.1, 1.3, C(7′)HB), 5.78-5.85 (1H, 
m, C(6′)H), 7.06 (2H, d, J 8.5, 2×C(11)H), 7.10 (2H, d, J 9.0, 2×C(7)H), 7.45 (2H, d, 
J 8.5, 2×C(12)H), 7.61 (1H, d, J 9.5, C(3)H), 7.88 (2H, d, J 9.0, 2×C(6)H), 8.20 (1H, 
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d, J 9.5, C(2)H); δC (150 MHz, CD3OD) 22.7 (CH2), 31.5 (CH2), 57.0 (CH2), 66.9 
(CH2), 70.8 (CH2), 116.9 (CH), 119.6 (CH2), 120.4 (CH), 126.4 (C), 126.8 (CH), 129.5 
(CH), 130.5 (CH), 132.8 (CH), 133.0 (C), 134.6 (C), 141.4 (C), 152.1 (C), 153.7 (C), 
162.6 (C), 174.1 (C); m/z (EI) 524 (7%, M+). 
6-Acrylamidohexanoic acid, 156.124 
 
Acryloyl chloride (96%, 705 µL, 8.38 mmol) was added dropwie over 15 min to an 
ice-cold solution of 6-aminohexanoic acid (1.00 g, 7.62 mmol) and Ca(OH)2 (1.02 g, 
13.7 mmol) in H2O (15 mL). The reaction was stirred at 0 ºC for a further 10 min 
before being filtered. The filtrate was adjusted to pH 2-6 by addition of concentrated 
HCl and the resulting crystals were filtered to yield 156 (512 mg, 36%) as a white 
crystalline solid, which was used with no further purification. 
δH (600 MHz, DMSO-d6) 1.23-1.29 (2H, m, C(4)H2), 1.41 (2H, quin, J 7.5, C(5)H2), 
1.49 (2H, quin, J 7.5, C(3)H2), 2.19 (2H, t, J 7.5, C(2)H2), 3.10 (2H, dd, J 7.5, 18.2, 
C(6)H2), 5.56 (1H, dd, J 10.2, 2.3, C(9)HA), 6.05 (1H, dd, J 16.9, 2.3, C(9)HB), 6.19 
(1H, dd, J 16.9, 10.22, C(8)H), 8.05-8.10 (1H, m, NH), 12.02 (1H, br s, CO2H); δC 
(150 MHz, DMSO-d6) 24.3 (C(3)H2), 26.0 (C(4)H2), 28.8 (C(5)H2), 33.6 (C(2)H2), 
38.4 (C(6)H2), 124.9 (C(9)H2), 131.9 (C(8)H), 164.5 (C(7)), 174.5 (C(1)); m/z (ES
+) 
208 (52%, [M+Na]+), 186 (100%, [M+H]+). 
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N-(2-(2-Azidoethoxy)ethyl)-4-(4-(1-hydroxyethyl)-2-methoxy-5-
nitrophenoxy)butanamide, 158. 
 
A reaction mixture of 4-[4-(1-hydroxyethyl)-2-methoxy-5-nitrophenoxy]butyric acid 
155 (200 mg, 0.67 mmol), 3,6,9-trioxaundecan-1-amine (265 µL, 1.34 mmol), HBTU 
(510 mg, 1.34 mmol) and HOAt (45.5 mg, 0.33 mmol) in DMF (2 mL) was stirred for 
2 min at rt, before triethylamine (187 µL, 1.34 mmol) was added, and the resulting 
mixture was stirred at rt for 20 h. The reaction mixture was dissolved in EtOAc (15 
mL) and washed with saturated aqueous LiCl (2×15 mL). The organic layer was then 
dried and concentrated in vacuo. Purification via flash column chromatography 
(CH2Cl2:CH3OH, 50:1) yieled 158 (286 mg, 86%) as a yellow oil. 
δH (600 MHz, CDCl3) 1.55 (3H, d, J 6.4, C(21)H3), 2.19 (2H, quin, J 6.8, C(11)H2), 
2.41 (2H, t, J 7.5, C(10)H2), 3.38 (2H, t, J 5.3, C(1)H2), 3.41-3.69 (14H, m, 7×CH2), 
3.98 (3H, s, C(15)H3), 4.10 (2H, t, J 6.4, C(12)H2), 5.56 (1H, dd, J 12.8, 6.4, C(20)H), 
6.21 (1H, m, NH), 7.31 (1H, s, CH)), 7.56 (1H, s, CH); δC (150 MHz, CDCl3) 24.4 
(C(21)H3), 25.0 (C(11)H2), 32.7 (C(10)H2), 39.3, (CH2), 50.8 (C(1)H2), 56.5 
(C(15)H3), 65.8 (C(20)H), 68.6 (CH2), 70.3 (CH2), 70.6 (CH2), 70.7 (CH2), 70.8 
(CH2), 108.8 (CH), 109.2 (CH), 137.2 (C(17)), 139.7 (C(18)), 147.0 (C(13)), 154.2 
(C(14)), 172.2 (C(9)); νmax (oil) 3323, 3098, 2927, 2870, 2100, 1649; m/z (ES+) 522 
(42%, [M+Na]+), 500 (40%, [M+H]+); HRMS (ES+) C21H34N5O9
+ ([M+H]+) requires 
500.2357, measured 500.2364. 
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1-(4-((1-Azido-13-oxo-3,6,9-trioxa-12-azahexadecan-16-yl)oxy)-5-methoxy-2-
nitrophenyl)ethyl 6-acrylamidohexanoate, 154. 
 
To a suspension of 158 (105 mg, 0.209 mmol) and 156 (58 mg, 0.31 mmol) in DMF 
(1 mL) at 0 ºC was added EDC (60 mg, 0.31 mmol) and DMAP (5.11 mg, 0.042 
mmol). The reaction mixture was stirred at rt for 18 h, before being wet loaded and 
undergoing purification via flash column chromatography (40-60 ºC petrol to 
CH2Cl2:CH3OH, 50:1) to yield 154 (104 mg, 75%) as a yellow solid. 
δH (600 MHz, CDCl3) 1.28-1.38 (2H, m, C(6)H2), 1.53 (2H, quin, J 7.5, C(5)H2), 1.61 
(3H, d, J 6.4, C(11)H3), 1.61-1.66 (2H, m, C(7)H2), 2.19 (2H, quin, J 6.7, C(20)H2), 
2.28-2.38 (2H, m, C(8)H2), 2.40 (2H, t, J 7.2, C(21)H2), 3.30 (2H, quin, J 6.0, C(4)H2), 
3.36 (2H, t, J 4.9, C(30)H2), 3.42-3.48 (2H, m, C(23)H2), 3.55 (2H, t, J 4.9, C(24)H2), 
3.59-3.69 (10H, m, CH2), 3.95 (3H, s, C(15)H3), 4.10 (2H, t, J 6.4, C(19)H2), 5.62, 
(1H, d, J 10.2, C(1)HA), 5.83 (1H, br s, C(19)NH), 6.08 (1H, dd, J 16.9, 10.2, C(2)H), 
6.23-6.29 (2H, m, C(23)NH, C(1)HB), 6.45 (1H, q, J 6.4, C(10)H), 6.98 (1H, s, 
C(13)H), 7.56 (1H, s, C(14)H); δC (150 MHz, CDCl3) 22.1 (C(11)H3), 24.4 (CH2), 
24.9 (CH2), 26.4 (C(6)H2), 29.2 (C(5)H2), 32.7 (C(21)H2), 34.3 (C(8)H2), 
39.3(C(4)H2), 39.3 (C(23)H2), 50.8 (C(30)H2), 56.5 (C(15)H3), 68.3 (C(10)H), 68.6 
(C(19)H2), 70.0 (CH2), 70.2 (CH2), 70.3 (CH2), 70.6 (CH2), 70.7 (CH2), 70.8 (CH2), 
108.3 (C(13)H), 109.1 (C(17)H), 126.4 (C(1)H2), 131.0 (C(2)H), 133.2 (C(12)), 140.0 
(C(18)), 147.4 (C(16)), 154.0 (C(14)), 165.7 (C(3)), 172.1 (C), 172.5 (C); νmax (solid) 
3306, 3071, 2933, 2864, 2101, 1724, 1650; mp (CH3OH) 110-119 °C; m/z (ES
+) 689 
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(7%, [M+Na]+), 667 (100%, [M+H]+); HRMS (ES+) C30H47N6O11
+ ([M+H]+) requires 
667.3303, measured 667.3337. 
4-(3-(4-((1-(2-(2-(4-(4-(1-((6-Acrylamidohexanoyl)oxy)ethyl)-2-methoxy-5-
nitrophenoxy)butanamido)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-
6-iminopyridazin-1(6H)-yl)butanoic acid, 153. 
 
To a mixture of 141 (8.1 mg, 0.023 mmol) and 154 (15.0 mg, 0.023 mmol) in H2O 
(0.1 mL) and DMF (0.1 mL) was added a solution of CuSO4.5H2O (1.3 mg, 0.005 
mmol) and THPTA (10 mg, 0.023 mmol) in degassed H2O (0.1 mL), followed by 
sodium ascorbate (3.0 mg, 0.015 mmol) in H2O (0.1 mL). The resulting solution was 
stirred at 50 ºC for 4 h, followed by rt for 16 h. The reaction solvent was removed in 
vacuo. Purification via flash column chromatography (CH2Cl2:CH3OH, 10:1 to 7:3) 
gave 153 (4.0 mg, 18%) as a white solid. 
δH (600 MHz, CD3OD) 1.27-1.36 (4H, m, 2×CH2), 1.52 (2H, quin, J 7.9, CH2), 1.59 
(3H, d, J 6.8 C(11)H3), 1.59-1.65 (2H, m, CH2), 2.07 (2H, quin, J 6.8, CH2), 2.35-2.40 
(4H, m, 2×CH2), 3.21 (2H, t, J 7.2, CH2), 3.31-3.35 (2H, m, PEG-CH2), 3.48 (2H, t, J 
5.3 PEG-CH2), 3.53 (4H, s, PEG-CH2), 3.54-3.61 (8H, m, PEG-CH2), 3.89 (2H, t, J 
4.9, CH2), 3.91 (3H, s, C(15)H3), 3.99-4.05 (2H, m, CH2), 4.38-4.45 (2H, m, CH2), 
4.56 (2H, br s), 4.60 (2H, t, J 4.9, CH2), 5.23 (2H, s, C(13ʹ)H2), 5.63 (1H, dd, J 9.0, 
3.0, C(1)HA), 6.18-6.21 (2H, m, C(1)HB, C(2)H), 6.32 (1H, q, J 6.8, C(10)H), 7.09 
(1H, s, CH), 7.15 (2H, d, J 8.7, 2×CH), 7.51 (1H, s, CH), 7.58 (1H, d, J 9.8, CH), 7.93 
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(2H, d, J 9.0, 2×CH), 8.17 (1H, s, C(15ʹ)H), 8.24 (1H, d J 9.4, CH); δC (150 MHz, 
CD3OD) 22.0 (CH3), 26.6 (CH2), 26.4 (CH2), 27.4 (CH2), 30.0 (CH2), 33.4 (CH2), 35.0 
(CH2), 40.1 (CH2), 40.4 (CH2), 49.6 (CH2), 51.5 (CH2), 56.9 (CH3), 57.5 (CH2), 59.4 
(CH2), 62.5 (CH2), 69.3 (CH), 69.6 (CH2), 70.3 (CH2), 70.5 (CH2), 71.2 (CH2), 71.4 
(CH2), 71.4 (CH2), 71.5 (CH2), 92.8 (C), 109.5 (CH), 109.9 (CH), 116.5 (CH), 126.5 
(CH), 126.5 (CH), 129.3 (C), 132.1 (CH), 132.3 (CH), 134.0 (C), 141.4 (C), 148.8 
(C), 151.6 (C), 155.4 (C), 162.1 (C), 168.1 (C), 174.2 (C), 175.3 (C); νmax (solid) 3305, 
3071, 2933, 2863, 2104, 1724, 1649, 1578; mp 110-119 °C; m/z (ES+) 978 (100%, 
[M+H]+); HRMS (ES+) C47H64N9O14
+ ([M+H]+) requires 978.4573, measured 
978.4598. 
tert Butyl 3-oxo-7,10,13-trioxa-4-azahexadec-1-en-16-oate, 159. 
 
A solution of tert butyl 12-amino-4,7,10-trioxadodecanoate (205 mg, 0.739 mmol) 
and triethylamine (103 µLm 0.739 mmol) in CH2Cl2 (2 mL) was stirred at 0 ºC for 15 
minutes, before a solution of acryloyl chloride (96%, 62 µL, 0.74 mmol) was added 
dropwise. The reaction mixture was stirred at 0 ºC for 1 h, then at rt for a further 2 h 
before being partitioned with aqueous NaHCO3 (10 mL) and CH2Cl2 (10 mL). The 
aqueous layer was extracted with CH2Cl2 (3 × 10 mL) and the combined organic layers 
were washed with H2O (10 mL), dried and concentrated in vacuo. Purification via 
flash column chromatography (40-60 °C petrol: EtOAc, 1:5) gave 159 (203 mg, 83%) 
as a colourless oil. 
δH (600 MHz, DMSO-d6) 1.39 (9H, s, 3×C(14)H2), 2.41 (2H, t, J 6.2, C(11)H2), 3.28 
(2H, q, J 5.8, C(4)H2), 3.44 (2H, t, J 5.7, C(5)H2), 3.46-3.53 (8H, m, 4×CH2), 3.58 
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(2H, t, J 6.3, C(10)H2), 5.56 (1H, dd, J 10.3, 2.3, C(1)HA), 6.07 (1H, dd, J 17.1, 2.2, 
C(1)HB), 6.24 (1H, dd, J 17.1, 10.3, C(2)H), 8.14 (1H, s, NH); δC (600 MHz, DMSO-
d6) 27.8 (C(14)H3), 35.9. 38.6 (C(11)H2, C(4)H2), 66.3 (C(10)H2), 69.1, 69.6, 69.7, 
69.7 (CH2), 79.8 (C(13)), 125.0 (C(1)H2), 131.8 (C(2)H), 164.7 (C(3)), 170.4 (C(12)); 
m/z (ES+) 332 (100%, [M+H]+), 354 (20%, [M+Na]+). 
3-oxo-7,10,13-trioxa-4-azahexadec-1-en-16-oic acid, 160. 
 
A reaction mixture of trifluoroacetic acid (5 mL, 43.8 mmol), and ester 159 (203 mg, 
0.613 mmol) in CH2Cl2 (10 mL) was stirred at rt for 1 h, before additional CH2Cl2 (50 
mL) was added and all solvents were removed in vacuo to give 160 (168 mg, 99%) as 
a colourless oil. 
δH (600 MHz, CDCl3) 2.63 (2H, t, J 6.0, C(11)H2), 3.54-3.58 (2H, m, C(4)H2), 3.62-
3.68 (10H, m, 5×CH2), 3.79 (2H, t, J 6.0 C(10)H2), 5.65 (1H, dd, J 10.2, 1.5, C(1)HA), 
6.19 (1H, dd, J 16.9, 10.2, C(2)H), 6.31 (1H, dd, J 16.9, 1.5, C(1)HB), 6.67 (1H, s, 
NH); δC (150 MHz, CDCl3) 35.0 (C(11)H2), 39.6 (C(4)H2), 66.5 (C(10)H2), 70.1 
(CH2), 70.3 (CH2), 70.4 (CH2), 70.7 (CH2), 126.9 (C(1)H2), 130.9 (C(2)H), 166.3 
(C(3)), 174.1 (C(12)); m/z (ES+) 276 (100%, [M+H]+). 
1-(4-((1-azido-13-oxo-3,6,9-trioxa-12-azahexadecan-16-yl)oxy)-5-methoxy-2-
nitrophenyl)ethyl 3-oxo-7,10,13-trioxa-4-azahexadec-1-en-16-oate, 161. 
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1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (93.7 mg, 0.489 mmol) and DMAP 
(8.0 mg, 0.07 mmol) were added to a solution of alcohol 158 (163 mg, 0.326 mmol) 
and acid 160 (90 mg, 0.326 mmol) in DMF (2 mL) at 0 ºC. The resulting mixture was 
stirred at rt for 18 h before being loaded onto a column. Purification via flash column 
chromatography (CH2Cl2:CH3OH, 100:2 to 100:15) yielded 161 (81.9 mg, 33%) as a 
yellow oil. 
δH (600 MHz, CD3OD) 1.62 (3H, d, J 6.4, C(14)H3), 2.11 (2H, quin, J 6.8, C(23)H2), 
2.41 (2H, t, J 7.5, C(24)H2), 2.63 (2H, t, J 6.0, C(4)H2), 3.34-3.38 (4H, m, 2×CH2), 
3.42 (2H, t, J 5.6, C(33)H2), 3.51-3.67 (22H, m, 11×CH2), 3.70-3.79 (2H, m, C(5)H2), 
3.96 (3H, s, C(18)H3), 4.08 (2H, t, J 6.8, C(22)H2), 5.64 (1H, dd, J 9.8, 2.6, C(1)HA), 
6.17-6.28 (2H, m, C(1)HB, C(2)H), 6.36 (1H, q, J 6.4, C(13)H), 7.14 (1H, s, CH), 7.59 
(1H, s, CH); δC (150 MHz, CD3OD) 22.1 (C(14)H3), 26.4 (CH2), 33.4 (CH2), 36.1 
(CH2), 51.7 (C(33)H2), 60.0 (C(18)H3), 67.6 (CH2), 69.7 (C(13)H), 70.4 (CH2), 71.1 
(CH2), 71.3 (CH2), 71.6 (CH2), 109.7 (CH), 109.9 (CH), 126.7 (C(1)H2), 132.0 
(C(2)H), 134.1 (C(15)), 141.3 (C(21)), 148.8 (C(19)), 155.5 (C(17)), 168.1 (C(3)), 
172.4 (C), 175.4 (C); νmax (oil) 3310, 3056, 2871, 2103, 1736. 1661.0; m/z (ES+) 779 
(100%, [M+Na]+); HRMS (ES+) C33H53N6O14
+ ([M+H]+) requires 757.3620, 
measured 757.3649. 
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4-(3-(4-((1-(16-(4-(4,17-Dioxo-3,7,10,13-tetraoxa-16-azanonadec-18-en-2-yl)-2-
methoxy-5-nitrophenoxy)-13-oxo-3,6,9-trioxa-12-azahexadecyl)-1H-1,2,3-
triazol-4-yl)methoxy)phenyl)-6-iminopyridazin-1(6H)-yl)butanoic acid, 163. 
 
To a mixture of alkyne 141 (38 mg, 0.107 mmol) and azide 161 (81 mg, 0.107 mmol) 
in H2O (0.1 mL) and DMF (0.1 mL) was added a solution of CuSO4.5H2O (26.7 mg, 
0.107 mmol) and THPTA (47 mg, 0.107 mmol) in degassed H2O (0.1 mL), followed 
by sodium ascorbate (64 mg, 0.107 mmol) in H2O (0.1 mL). The resulting solution 
was stirred at 50 ºC for 4 h, followed by rt for 16 h. The reaction solvent was removed 
in vacuo. Purification via flash column chromatography (CH2Cl2:CH3OH, 100:5 to 
50:50) gave 163 (28 mg, 24%) as a yellow oil. 
δH (600 MHz, CD3OD) 1.60 (3H, d, J 6.5, C(14)H3), 2.04-2.14 (4H, m, C(23)H2, 
C(2ʹ)H2), 2.38 (2H, t, J 7.5, C(24)H2), 2.63 (2H, t, J 5.8, C(4)H2), 3.34 (2H, t, J 5.6, 
CH2), 3.41 (2H, t, J 5.5, CH2), 3.49 (2H, t, J 5.5, CH2), 3.50-3.67 (22H, m, 11×CH2), 
3.69-3.80 (2H, m, C(5)H2), 3.89 (2H, t, J 5.1, C(3ʹ)H2), 3.93 (3H, s, C(18)H3), 4.02 
(2H, t, J 7.8, C(22)H2), 4.60 (2H, t, J 5.2, C(4ʹ)H2), 5.24 (2H, s, C(13ʹ)H2), 5.63 (1H, 
dd, J 9.7, 2.2, C(1)HA), 6.19 (1H, dd, J 17.1, 2.2, C(1)HB) 6.25 (1H, dd, J 17.1, 9.7, 
C(2)H), 6.34 (1H, q, J 6.4, C(13)H), 7.11 (1H, s, CH), 7.15 (2H, d, J 8.9, 2×C(11ʹ)H), 
7.51 (1H, s, CH), 7.62 (1H, d, J 9.4, C(7ʹ)H), 7.93 (2H, d, J 8.9, 2×C(10ʹ)H), 8.18 (1H, 
s, C(15ʹ)H), 8.25 (1H, d, J 9.4, C(6ʹ)H); δC (150 MHz, CD3OD) 22.1 (C(14)H3), 26.4 
(C(23)H2), 33.4 (C(24)H2), 36.0, (CH2), 40.4 (CH2), 40.4 (CH2), 51.5 (CH2), 57.0 
(C(18)H3), 62.5 (CH2), 67.6 (CH2), 69.6 (CH2), 69.7 (C(13)H), 70.3 (CH2), 70.5 
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(CH2), 70.6 (CH2), 71.2 (CH2), 71.3 (CH3), 71.4 (CH2), 71.4 (CH2), 71.5 (CH2), 109.7 
(CH), 109.9 (CH), 116.5 (C(11ʹ)H), 126.6 (C(7ʹ)H), 127.1 (C(1)H2), 129.4 (C(10ʹ)H), 
131.9 (C(2)H), 132.4 (C(6ʹ)H), 134.1 (C(15)), 141.2 (C(21)), 148.7 (C(19)), 153.8 (C) 
155.5 (C(17)), 162.1 (C), 168.2 (C(3)), 172.4 (C), 175.4 (C) {3 C signals unobserved}; 
νmax (oil) 3292, 2946, 2875, 2476, 2103, 1736, 1650, 1606; m/z (ES+) 1068 (100%, 
[M+H]+); HRMS (ES+) C50H70N9O17
+ ([M+H]+) requires 1068.4890, measured 
1068.4892. 
1-(4-Iodophenyl)-2-phenyldiazene, 166.125 
 
To a stirring solution of nitrosobenzene (200 mg, 1.87 mmol) in glacial acetic acid (12 
mL) was added 4-iodoaniline (341 mg, 1.56 mmol) in one portion. The reaction 
mixture was stirred at 40 °C for 12 h before being poured into H2O (40 mL). This 
aqueous solution was extracted with CH2Cl2 (3×40 mL), and the combined organic 
layers were washed with brine (50 mL), and dried and concentrated in vacuo. 
Purification via flash column chromatography (40-60°C petrol:Et2O, 200:1) gave 166 
(418 mg, 87%) as an orange solid. 
δH (600 MHz, CDCl3) 7.48-7.55 (3H, m, 2×m-PhH, p-PhH), 7.67 (2H, d, J 8.3, 
2×C(2)H), 7.93 (2H, d, J 8.7, 2×C(3)H), 7.93 (2H, d, J 7.2, 2×o-PhH); δC (150 MHz, 
CDCl3); 97.8 (C(1)), 123.1 (o-PhH), 124.6 (C(2)H), 129.3 (m-PhH), 131.5 (p-PhH), 
138.5 (C(3)H), 152.0 (C), 152.6 (C); m/z (ES+) 309 (100%, [M+H]+), 287 (75%), 268 
(70%). 
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1-Phenyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)hydrazine 
168, 4,4'-bis(phenyldiazenyl)-1,1'-biphenyl 169. 
 
A solution of 166 ((91 mg, 0.295 mmol) in toluene (5 mL) was added to a suspension 
of 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (127 μL, 0.45 mmol), Pd(PPh3)2Cl2 (4.1 
mg, 0.006 mmol) in dry triethylamine (123 μL, 0.885 mmol) and toluene (5 mL). The 
reaction mixture was heated to 80 °C for 2 h before EtOAc (20 mL) and brine (20 mL) 
were added. The organic layer was separated, dried and concentrated in vacuo. 
Purification via flash column chromatography (40-60 °C petrol: CH2Cl2, 3:2 to 0:1) 
yielded dimer 169 (8.5 mg, 4%). Further elution gave hydrazine 168 (53.0 mg, 58%), 
followed by azobenzene 167 (15.4 mg, 17%). 
Data for 169: δH (600 MHz, CDCl3) 7.47-7.55 (6H, m 6×CH), 7.64-7.68 (4H, m, 
4×CH), 7.79-7.83 (4H, m, 4×CH), 7.90-7.94 (4H, m, 4×CH); δC (150 MHz, CDCl3) 
123.1 (CH), 124.5 (CH), 129.3 (CH), 131.5 (CH), 132.5 (CH), {3 C signals 
unobserved}; νmax (solid) 3452, 3046 (C-H), 1680; mp 295-297 °C; m/z 362 (100%, 
[M+]). 
Data for 168: δH (600 MHz, CDCl3) 1.32 (12H, s, 4×C(1)H3), 5.67 (1H, s, NH), 5.76 
(1H, s, NH), 6.82-6.87 (5H, m, 2×o-PhH, p-PhH, 2×C(5)H), 7.22 (2H, t, J 7.5, 2×m-
PhH), 7.68 (2H, d, J 8.7, 2×C(4)H); δC (150 MHz, CDCl3) 25.0 (C(1)H3), 83.5 (C(2)), 
111.4, 112.5 (C(5)H, o-PhH), 120.2 (p-PhH), 129.5 (m-PhH), 136.5 (C(4)H), 148.6 
(C(3)), (C(6)), 151.6 (i-PhH); νmax (solid) 3042, 2978, 2929 (N-H, C-H), 1602, 1568, 
1501; mp 96-97 °C; m/z (ES+) 311 (100%, [M+H]+). 
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4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, 170.126 
 
A flame dried flask containing CsCO3 (595 mg, 1.83 mmol), bis(pinocolato)diboron 
(928 mg, 3.65 mmol), 4-iodoaniline (200 mg, 0.913 mmol) in CH3OH (10 mL) was 
stirred at reflux for 60 h, before being passed over a short plug of neutralised Al2O3 
(eluent Et2O). The resulting filtrate was concentrated in vacuo. Purification via flash 
column chromatography (CH2Cl2) gave 170 (95.8 mg, 48%) as a brown solid. 
δH (600 MHz, CDCl3) 1.32 (12H, s, 4×C(6)H3) 6.67 (2H, d, J 8.3, 2×C(2)H), 7.63 (2H, 
d, J 8.3, 2×C(3)H); δC (150 MHz, CDCl3) 25.0 (C(6)H3), 83.4 (C(5)), 114.2 (C(2)H), 
136.5 (C(3)H), 149.4 (C(4)), 149.4 (C(1)); m/z (ES+) 220 (100%, [M+H]+); HRMS 
(ES+) C12H19BNO2
+ ([M+H]+) requires 220.1511, measured 220.1362. 
1-phenyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)diazene, 
167.99 
 
To a stirring solution of nitrosobenzene (70.2 mg, 0.656 mmol) in glacial acetic acid 
(5 mL) was added 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 170 (95.8 
mg, 0.437 mmol). The reaction mixture was heated at 90 ºC for 3.5 h before being 
poured into H2O (10 mL). This aqueous solution was extracted with CH2Cl2 (5×20 
mL), and the combined organic layers were washed sequentially with saturated 
aqueous NaHCO3 (20 mL), H2O (20 mL) and brine (20 mL), and dried and 
concentrated in vacuo. Purification via flash column chromatography (CH2Cl2 : 
CH3OH, 100:0.5) yielded 167 (21.6 mg, 27%) as a brown solid. 
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δH (600 MHz, CDCl3); 1.38 (12H, s, 4×C(1)H3), 7.47-7.51 (1H, m, p-PhH), 7.53 (2H, 
t, J 7.5, 2×m-PhH), 7.91 (2H, d, J 8.7, 2×C(5)H), 7.92-7.98 (4H, m, 2×o-PhH, 
2×C(4)H); δC (150 MHz, CDCl3) 25.0 (C(1)H3), 84.2 (C(2)), 122.1 (C(5)H), 123.1 (o-
PhH), 129.2 (m-PhH), 131.3 (p-PhH), 135.8 (C(4)H), 152.8 (C), 153.4 (C), 154.4 (C); 
νmax (solid) 2980, 2923, 2852, 1602, 1503; mp (CH2Cl2) 95-97 °C; m/z (ES+) 309 
(100%, [M+H]+); HRMS (ES+) C18H22N2O2B
+ ([M+H]+) requires 309.1774, measured 
309.1777. 
(E)-1-Phenyl-2-(4-(trifluoro-l4-boranyl)phenyl)diazene, potassium salt, 171.99 
 
To a stirring suspension of nitrosobenzene (244 mg, 2.28 mmol) in glacial acetic acid 
(20 mL) was added 170 (500 mg, 2.28 mmol) and the reaction mixture was stirred at 
90 °C for 3.5 h. The reaction solvent was removed in vacuo until 10 mL remained. 
The resulting mixture was diluted with H2O (50 mL) and extracted with CH2Cl2 (3×50 
mL). The combined organic layers were washed sequentially with H2O (50 mL), 
saturated aqueous NaHCO3 (50 mL), then H2O (50 mL) and dried and concentrated in 
vacuo. To this crude mixture was added CH3CN (3 mL), H2O (0.3 mL), and KHF2 
(401.3 mg, 5.14 mmol), and the resulting solution was stirred at rt for 2.5 h. After this 
the reaction mixture was quenched with saturated aqueous NaHCO3 (1 mL) and the 
solvent removed in vacuo. The residue was cooled to 0 °C and 40-60 °C petrol (25 
mL) was added. The resulting suspension was then filtered through a short column of 
Celite®, and the precipitate at the top of the column was washed with petrol (25 mL) 
and the filtrate discarded. The precipitate was then dissolved in acetone (100 mL) and 
filtered through the column. This acetone filtrate was then concentrated in vacuo to 
give 171 (348 mg, 53%) as a white solid. 
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δH (600 MHz, acetone-d6) 7.50 (1H, t, J 7.5, p-PhH), 7.57 (2H, t, J 7.5, 2×m-PhH), 
7.70 (2H, d, J 8.3, 2×C(2)H), 7.74 (2H, d, J 8.3, 2×C(3)H), 7.90 (2H, m, 2×o-PhH); 
δC (150 MHz, acetone-d6) 120.9 (C(3)H), 122.3 (o-PhH), 129.1 (m-PhH), 130.3 (p-
PhH), 132.3 (C(2)H), 150.9 (C), 152.9 (C) {1 C signal unobserved}; νmax (solid) 3643, 
3040; mp 284-285 °C; m/z (ES-) 246 (100%, [M]), 248 (50%, [M-K+]-). 
(4-(Phenyldiazenyl)phenyl)boronic acid, 165.99 
 
Method A: A mixture of trifluoroborate salt 171 (50 mg, 0.174 mmol) and FeCl3.6H2O 
(52 mg, 0.191 mmol) in THF (5 mL) and H2O (5 mL) was stirred at rt for 2 h. The 
reaction mixture was filtered through basic alumina (THF) and concentrated in vacuo 
to give 165 as a white solid (26 mg, 66%). 
Method B: A solution of 1-phenyl-2-[(4-pinacolylborane)phenyl]diazene 167 (15.6 
mg, 0.05 mmol) and KHF2 (11.8 mg, 0.15 mmol) in H2O (0.1 mL) and CH3CN (1 mL) 
was stirred at rt for 3 h. Saturated aqueous NaHCO3 (1 mL) was added and the reaction 
was stirred at rt for 1 h before being partitioned between H2O (5 mL) and Et2O (10 
mL). The aqueous layer was extracted Et2O (8×25 mL), and the combined organic 
layers were dried and concentrated in vacuo to give 165 (8.4 mg, 58%) as a yellow 
solid.  
δH (600 MHz, acetone-d6) 7.57-7.60 (1H, m, p-PhH), 7.60-7.64 (2H, m, 2×m-PhH), 
7.92 (2H, d, J 8.3, 2×C(3)H), 7.97 (2H, d, J 7.2, 2×o-PhH), 8.09 (2H, d, J 8.3, 
2×C(2)H); δC (150 MHz, acetone-d6) 121.6 (C(3)H), 122.7 (o-PhH), 129.3 (m-PhH), 
131.4 (p-PhH), 135.1 (C(2)H), 152.7 (C), 153.7 (C) {1 C signal unobserved}; νmax 
(solid) 3390, 3045, 2919, 2850, 1600, 1502; mp degraded >100 ºC; m/z (ES+) 241 
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(95%, [11M+Na]+), 227 (100%, [10M+H]+); HRMS (ES+) C12H12N2O2B
+ ([10M+H]+) 
requires 226.1028, measured 226.1024. 
3-Amino-6-iodopyridazine, 172.121 
 
A reaction mixture of HI (57% aq, 4.00 mL, 7.72 mmol) and 3-amino-6-
chloropyridazine (500 mg, 3.86 mmol) was refluxed for 48 h. Once cooled to rt, 
EtOAc (1 mL) was added and the mixture sonicated for 3 min. The precipitate was 
filtered and washed with EtOAc (10 mL), before being redissolved in CH3OH (10 
mL). To this mixture was added NaOH (163 mg, 4.08 mmol), and the solution was 
stirred at reflux for 5 min. The solvent was concentrated in vacuo and the residue 
redissolved in H2O (5 mL). This was filtered after 15 min to give 172 (338 mg, 40%) 
as a cream solid. Further recrystalisation of the aqueous filtrate yielded 172 with 3-
amino-6-chloropyridazine 33 impurity. 
δH (600 MHz, DMSO-d6) 6.55 (1H, d, J 9.2, C(2)H), 6.55 (2H, s, NH2), 7.55 (1H, d, 
J 9.2, C(3)H); δC (150 MHz, DMSO-d6) 111.5 (C(4)), 116.4 (C(2)H), 137.1 (C(3)H), 
160.1 (C(1)); m/z (ES+) 222 (100%, [M+H]+); HRMS (ES+) C4H4N3I requires 
221.9528; measured 221.9530. 
6-(4-(Phenyldiazenyl)phenyl)pyridazin-3-amine, 164. 
 
To a microwave vial containing CH3CN (2.0 mL) and H2O (1.3 mL) was charged with 
171 (75 mg, 0.26 mmol), 3-amino-6-chloropyridazine 33 (30.6 mg, 0.237 mmol), 
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Pd(PPh3)2Cl2 (8.3 mg, 0.012 mmol) and K2CO3 (98.3 mg, 0.711 mmol) and the 
reaction was degassed, then irradiated for 15 min at 120 °C. The crude reaction 
mixture was concentrated in vacuo. Purification via flash column chromatography 
(40-60 °C petrol : EtOAc, 2:1 to 1:3) gave 164 (53.8 mg, 41%) as an orange solid. 
Product exists as ratio trans-164 : cis-164 of 0.28:1.00 under ambient light, NMR 
taken of a dark-adapted sample which shows peaks of thermodynamic trans-164 
isomer only. δH (600 MHz, CD3OD) 7.48 (1H, d, J 9.8, C(2)H), 7.53-7.60 (3H, m, p-
PhH, 2×m-PhH), 7.96 (2H, d, J 6.8, 2×o-PhH), 8.07 (2H, d, J 8.3, 2×C(7)H), 8.18 (2H, 
d, J 8.3, 2×C(6)H), 8.33 (1H, d, J 9.8, C(3)H); δC (150 MHz, CD3OD) 121.6 (CH), 
124.0 (CH), 124.5 (CH), 128.1 (C), 128.5 (CH), 130.0 (C), 130.4 (CH), 132.8 (CH), 
154.0 (C), 154.8 (C), 173.1 (C) {1 CH signal unobserved}; νmax (oil) 3351, 3305, 3224, 
3210, 3165, 1453, mp (CH3OH) 222-224 °C; m/z (ES
+) 276 (100%, [M+H]+); HRMS 
(ES+) C16H14N5
+ ([M+H]+) requires 276.1242, measured 276.1245. 
Allyl 4-(6-imino-3-(4-(phenyldiazenyl)phenyl)pyridazin-1(6H)-yl)butanoate, 174. 
 
A reaction mixture of 164 (14 mg, 0.051 mmol) and allyl 4-bromobutyrate (10.5 μL, 
0.051 mmol) in DMF (0.1 mL) was heated at 80 °C for 16 h. After this time EtOAc (5 
mL) was added and the reaction cooled to 0 °C. The resulting precipitate was filtered 
and washed with cold EtOAc (2 mL) to give 174 (14.9 mg, 73%) as a yellow solid. 
Product exists as ratio trans-174 : cis-174 of 0.30:1.00 under ambient light, NMR 
taken of dark-adapted sample which shows peaks of thermodynamic trans-174 isomer 
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only. δH (600 MHz, CD3OD) 2.30 (2H, quin, J 6.8, C(2ʹ)H2), 2.66 (2H, t, J 6.8, 
C(3ʹ)H2), 4.48-4.52 (4H, m, C(1ʹ)H2, C(5ʹ)H2), 5.16 (1H, dd, J 10.4, 1.5, C(7ʹ)HA), 
5.25 (1H, dd, J 17.3, 1.5, C(7ʹ)HB), 5.81-5.88 (1H, m, C(6ʹ)H), 7.54-7.60 (3H, m, p-
PhH, 2×m-PhH), 7.68 (1H, d, J 9.4, C(3)H), 7.95-7.98 (2H, m, 2×o-PhH), 8.08 (2H, d, 
J 8.3, 2×C(7)H), 8.20 (2H, d, J 8.3, 2×C(6)H), 8.43 (1H, d, J 9.4, C(2)H); δC (125 
MHz, CD3OD) 22.5 (CH2), 31.3 (CH2), 57.1 (CH2), 66.5 (CH2),118.6 (CH2), 124.1 
(CH), 124.5 (CH), 127.0 (CH), 128.8 (CH),130.4 (CH), 132.8 (CH), 133.0 (CH), 133.4 
(CH), 136.3 (C), 151.3 (C), 154.0 (C), 154.4 (C), 155.2 (C), 174.1 (C(4ʹ); νmax (solid) 
3319, 3040, 1735; mp (CH3OH) 169-170 °C; m/z (ES
+) 402 (100%, [M+H]+); HRMS 
(ES+) C23H24N5O2
 ([M+H]+) requires 402.1930, measured 402.1892. 
4-(6-Imino-3-(4-(phenyldiazenyl)phenyl)pyridazin-1(6H)-yl)butanoic acid {azo-
gabazine}, 163. 
 
 
A solution of NaOH (20 mg), 174 (14.9 mg, 0.037 mmol) in THF (1 mL) and H2O (1 
mL) was stirred at 50 °C for 3 h. The mixture was then cooled to 10 °C and washed 
with EtOAc (3 mL). The aqueous layer was acidified to pH 1 with 1 M aqueous HCl 
and stirred at rt for 1 h. The solvent was then concentrated in vacuo, and the residue 
triturated with H2O (2 mL) to yield 163 (12.3 mg, 80%) as a yellow solid. 
Product exists as ratio trans-163 : cis-163 of 0.33 : 1.00 under ambient light, NMR 
taken of dark-adapted sample which shows peaks of thermodynamic trans-163 isomer 
only. δH (600 MHz, CD3OD) 2.26 (2H, quin, J 6.9, C(2ʹ)H2), 2.59 (2H, t, J 6.9, 
C(3ʹ)H2), 4.50 (2H, t, J 7.1, C(1ʹ)H2), 7.50-7.60 (3H, m, p-PhH, 2×m-PhH), 7.70 (1H, 
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d, J 9.4, C(3)H), 7.96 (2H, d, J 7.5, 2×o-PhH), 8.07 (2H, d, J 7.9, 2×C(7)H), 8.21 (2H, 
d, J 8.3, 2×C(6)H), 8.42 (1H, d, J 9.4, C(2)H); δC (150 MHz, CD3OD) 22.6 (CH2), 
31.0 (CH2), 57.1 (CH2), 124.1 (CH), 124.5 (CH),126.9 (CH), 128.9 (CH),130.4 (CH), 
132.8 (CH), 133.0 (CH), 136.4 (C), 154.0 (C), 154.4 (C), 155.2 (C), 176.4 (C), 190.5 
(C); νmax (solid) 3039 (N-H, O-H, C-H), 1718; mp 242-246 °C; m/z (ES+) 362 (100%, 
[M+H]+); HRMS (ES+) C20H19N5O2
+ ([M]+) requires 362.1617; measured 362.1618. 
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